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A pilot mammographic breast cancer screening programme was established in 1991 for women 
aged fifty to sixty-four living in Otago and Southland. The pilot programme was evaluated to 
measure the acceptability, effectiveness, and economic efficiency of breast cancer screening in New 
Zealand. 
A series of targets related to the performance of the screening programme during its first screening 
round was used in this evaluation. The targets were derived from screening programmes that had 
been shown to reduce breast cancer mortality in randomised controlled trials. Methods were 
developed for measuring these targets in the Otago-Southland pilot programme and the evaluation 
largely consisted of monitoring these targets, together with carrying out surveys of women in the 
eligible population and their general practitioners. The results from the evaluation were reported to 
the programme staff at regular intervals and contributed to the design and management of the pilot 
programme. Information provided by this evaluation also contributed to the New Zealand 
government's decision in June 1995, to establish a national breast cancer screening programme 
which will be implemented over three years. 
The early results from the pilot programme were encouraging, with over ninety percent of women 
aged fifty to sixty-four in Otago and Southland having been identified so they could be invited to be 
screened. Seventy-four percent of the target population were screened in the first screening round. 
In the first eighteen months of the programme 7, 182 women were screened. Satisfaction with the 
screening programme was very hjgh, with njnety-four percent of screened women planning to 
continue in the programme. As a result of screening 832 women (11.6 percent of those screened) 
were referred to the assessment clinic. This referral rate did not meet the target that had been set, 
and as a result the specificity of the programme was low, at eighty-nine percent. Fortunately, 
despite the high referral rate, few women underwent surgical biopsies and the benign : malignant 





rate of 10.2 per thousand women screened. Sensitivity was excellent, at ninety-two percent. The 
economic analysis showed that breast cancer screening can be carried out in New Zealand at a 
similar cost to breast cancer screening programmes in other countries. 
The results of the evaluation suggest that the pilot programme will reduce breast cancer mortality, 
among eligible women, but methods to lower the referral rate and improve specificity should be 
sought. Arising from the evaluation of the pilot programme, several recommendations are made 





This thesis documents the evaluation of the effectiveness and acceptability of the Otago-Southland 
pilot programme, with a summary and discussion of the results of the evaluation, including the 
associated economic analysis of the pilot programme. The evaluation of the pilot programme was 
directed by Mark Elwood (Professor of Cancer Epidemiology, University of Otago) and was 
coordinated by the author. The evaluation team also included Sheila Williams (Biostatistician), 
Bronwen McNoe (Research Assistant), Nancy Devlin (Health Economics Consultant) and Arun 
Menon (Public Health Medicine Registrar). The author developed the targets for the evaluation 
and methods to measure the targets, and designed the surveys and questionnaires that were used in 
the evaluation. The author was also responsible for the day to day running of the evaluation until 
leaving New Zealand in January 1994 to take up a position in England. Where other members of 
the evaluation team carried out work that has· been discussed in the thesis, this has been 
acknowledged in the body of the text, or the work has been included as an appendix to the text. 
Structure of the thesis 
Chapter One is a review of relevant literature, with the published studies of mammographic breast 
cancer screening described in detail. This chapter presents the evidence about breast cancer 
screening and discusses the strengths and weaknesses of different study designs in assessing the 
efficacy of breast cancer screening. It also addresses the issue of the efficacy of screening 
according to age. Chapter Two covers the introduction of population-based breast cancer 
screening in New Zealand, including the epidemiology of breast cancer in New Zealand, factors 
leading up to the introduction of population-based screening, and the recommendations that were 
made about pilot programmes and their evaluation. This chapter also compares mammographic 






benefits of breast cancer screening are also addressed. Methods for evaluating breast cancer 
screening programmes are described in Chapter Three, with reasons given for the choice of the 
evaluation method that was used for the Otago-Southland pilot programme. Chapter Four gives a 
detailed description of the evaluation method including the derivation of the targets used. The 
methods and results of the evaluation of the first eighteen months of the Otago-Southland pilot 
programme are presented and discussed in Chapters Five and Six. Chapter Seven is a summary and 
discussion, including an analysis of the strengths and weaknesses of the evaluation method, the 
successes and failures of the pilot programme in terms of its effectiveness, acceptability, and 
economic efficiency, and the implications for a national breast cancer screening programme in New 
Zealand. 
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The Efficacy of Mammographic Screening 
Introduction 
The first mammography screening programme was set up in the United States in 1956, where 
1,312 asymptomatic women aged thirty-five and over volunteered to undergo six-monthly 
mammograms. The results were encouraging but their interpretation was limited because of the 
lack of an appropriate comparison group (Gershon-Cohen et al 1967). The first randomised 
controlled trial of mammographic screening for breast cancer was started in 1963 (Shapiro 1977). 
Since then the results from several randomised controlled trials and numerous other studies of 
breast cancer screening have been published. These trials are described below (sections L2 - 1.4). 
1.1 Evaluating the efficacy of breast cancer screening 
As with other types of screening, evaluation of the efficacy of breast cancer screening can be 
affected by bias (Miller 1978). The four types of bias which cause particular problems for 
evaluating screening are lead time bias, length bias, overdiagnosis bias, and selection bias: 
Lead time bias. 
The survival time for women with breast cancer is the time from diagnosis until death. In screened 
women the diagnosis is made earlier than it would have been in the absence of screening; this is 
known as the "lead time" obtained by screening. The true effect of screening on breast cancer 
mortality cannot be assessed merely by comparing survival times for screened with unscreened 






Breast tumours grow at different rates and therefore remain for differing periods in the 
presymptomatic screen-detectable phase. With each screening round the probability of detecting 
slow growing tumours is greater than the probability of detecting fast growing tumours, as slower 
growing tumours remain in the presymptomatic screen-detectable phase for longer. There will be 
fewer fast growing tumours in the screened compared with the unscreened group, and differences 
in outcome between groups may be partly due to this rather than to an effect of screening. Length 
bias is a greater problem with the first (prevalence) screen than with subsequent screens, since some 
of the tumours detected at the prevalence screen could have been in the pre-symptomatic screen-
detectable state for longer than the interval between screens. 
Overdiagnosis bias. 
Screening detects very early lesions and it is possible that some of these cancers would never affect 
a woman in her lifetime (with the woman remaining asymptomatic and dying from some cause 
other than breast cancer ). There is also the possibility that screening detects tumours that are not 
really malignant, but which are pathologically indistinguishable from early malignant breast cancers. 
Because these cancers are more likely to be found in a screened group than an unscreened group, 
comparisons of outcome could favour the screened group irrespective of any real effect of 
screening. 
Selection bias. 
Not all women who are invited, take part in screening. It may be that women who choose to take 
part have a different underlying risk of developing or dying from breast cancer. For instance 
women with a family history of breast cancer may decide to take part because they perceive 
themselves to be at higher risk. It is possible that this would be an even greater problem in 
screening programmes where women are not invited, but self-refer, since women who self-refer 
may differ more markedly in their risk of breast cancer. A particular problem with selection bias is 
that it can operate in two directions; if low-risk women are more likely to be screened, then breast 
cancer mortality is likely to be lower anyway in this group, and the effect of screening will be 
overestimated, whereas if high-risk women are more likely to be screened the effect of screening 







With each of these biases the problem lies in comparing dissimilar groups. If the groups are 
intrinsically different in time of diagnosis, type of cancer detected, and/or underlying risk of breast 
cancer, any difference in outcome between the groups cannot be attributed solely to screening. 
These biases can affect comparisons of tumour size, nodal involvement at diagnosis, and post-
diagnosis survival time. The first three biases will cause overestimation of the benefits of screening, 
while the fourth, selection bias, could result in either overestimation or underestimation of the effect 
of screening. 
The best information about the efficacy of breast cancer screerung comes from randomised 
controlled trials with breast cancer mortality as the outcome measure. This is because with such a 
study design the groups compared are similar ( due to randomisation) and the outcome measure 
(death from breast cancer) is independent of the time of diagnosis. To avoid selection bias the 
outcome for all the women in the intervention group is measured even though not all of these 
women will have accepted the offer of screening. This means that the efficacy of offering screening 
to a group of women is being measured rather than the efficacy of screening a group of women. 
Trials which are designed to measure the efficacy of screening enroll women who have already 
agreed to take part, and then randomly allocate them to be screened or not. This has not been a 
common approach in randomised controlled trials of breast cancer screening, with only two trials 
(the Canadian trials) designed in this way (section 1.2.6). 
1.2 Randomised controlled trials of breast cancer screening 
Several randomised controlled trials of mammographic screening have been carried out during the 
last thirty years. All of these trials used breast cancer mortality as the outcome measure. The trials 
are described in chronological order and the most recently published results from the trials are 
summarised in Table 1.1 
1.2.1 New York Health Insurance Plan Trial 
The Health Insurance Plan (HIP) trial was the first randomised controlled trial of mammographic 








1963 62,000 female members of the HIP medical insurance scheme aged forty to sixty-four years, 
who had not previously been diagnosed with breast cancer were individually randomised to either 
an intervention or a control group of 31,000 women each. The women in the intervention group 
were invited to be screened while the women in the control group received their usual medical care. 
The trial was designed to be able to detect at least a twenty percent decrease in breast cancer 
mortality. 
The first screening round began in 1963 and continued until June 1966. Annual rescreening ended 
in June 1970. In the intervention group sixty.,.:five percent attended for an initial screen and they 
were offered screening annually for the next three years. Of these women, eighty-eight percent had 
at least one subsequent screen. Screening consisted of two-view mammography, and a clinical 
examination carried out by a physician. The two screening modalities were carried out 
independently so that the unique contribution of each modality could be assessed. Women were 
referred for assessment to a "large number of hospitals in which surgery was performed" (Shapiro 
1977). All histology was reviewed by one pathologist who was blind to the intervention or control 
group status of the women. 
The methods of follow up used were identical for intervention and control group women. Follow 
up consisted of contacting the women (or their next of kin), searches of hospital insurance and 
death records, and surveys of all women in the trial whose status was unknown, at five year 
intervals. Death from breast cancer was defined as death with breast cancer as the underlying cause. 
Deaths without histological confirmation (clinical or autopsy evidence only) were included. 
By ten years after entry (about six years after screening ended) there were thirty percent fewer 
deaths from breast cancer in the intervention group than in the control group (RR 0.71, 95% CI 
0.56-0.89). The reduction in breast cancer mortality was confined to women who were aged fifty 
or more at the time of diagnosis. Eighteen years after the trial began (Shapiro 1994) the relative 
risk was 0.77 (95% CI 0.61-0.97). The amount of mammography, physical examination, or breast 
self-examination in either the intervention or control group after the end of the trial is unknown, and 




1.2.2 Kaiser-Permanente Trial 
In 1964 a randomised trial was set up to evaluate the effect of multiphasic health checks (Dales et 
al 1979). The study subjects were all men and women aged thirty-five to fifty-four who lived in the 
San Francisco Bay area and had been members of the Kaiser-Permanente Health Plan for at least 
two years. The subjects were randomly allocated to an intervention and a control group. The 
intervention group was offered health checks while the control group was not. One of the health 
checks offered was annual mammography for the next eleven years for women aged forty-eight and 
over. There were fewer than three thousand women in this category and three quarters of them 
were aged less than fifty when the study began. Breast cancer mortality was the same in the 
intervention and control groups after eleven years follow up, with fourteen deaths from breast 
cancer in each of the equal sized groups. 
1.2.3 Swedish Two-Counties Trial 
A randomised controlled trial of mammographic screening was started in Sweden in 1977 (Tabar 
- -- -- - -- -- -- - - - --
and Gad 1981, Tabar et al 1985, Tabar et al 1992, Tabar et al 1995). In this trial 162,981 women 
in the counties of Ostergotland and Kopparberg were randomly allocated to control or intervention 
groups. Randomisation occurred at community level ( according to area of residence) rather than 
by individual. Women in the control group received their usual medical care. Screening was by 
single-view mammography only, and was repeated about every twenty-four months for women 
aged forty to forty-nine and about every thirty-three months for women aged fifty or more at entry. 
Of the women who were invited to be screened, eighty-nine percent attended the first screening 
round. The participation rate in women aged over seventy-four was less than fifty percent and 
published reports from this trial are confined to women aged forty to seventy-four at 
randomisation. Women in the control group were offered screening in 1985 (once three screening 
rounds had been completed in women aged fifty and over at entry, and after four rounds in women 
aged less than fifty at entry). Thirteen percent of the women in the control group had a 
mammogram during the study period. It is not stated in any of the published reports that any 
particular surgical protocol was followed, only that "ductography, pneumocystography, cytologic 







According to published reports on this trial death from breast cancer was defined as due to breast 
cancer after review of clinical and pathological records. However this is inconsistent with a report 
from the Stockholm randomised controlled trial (Frisell et al 1991) where it was stated that death 
with breast cancer present at death was used as the end point in order to be consistent with the 
Two Counties trial. 
After seven years there were thirty-one percent fewer deaths from breast cancer in the intervention 
group (RR 0.69, 95% CI 0.51 to 0.92). The reduction in breast cancer mortality was seen in 
women aged fifty or more (RR 0.61, 95% CI 0.44 to 0.84) but not for women under fifty (RR 
1.26, 95% CI 0.56 to 2.84). The difference between intervention and control groups began to 
emerge after the fourth year of screening. By twelve years of follow up the overall result remained 
about the same (Tabar et al 1995), with a thirty percent reduction (RR 0.69, 95% CI 0.57 to 0.84) 
in breast cancer mortality in the women invited to screening, but in younger women by this time 
there was a non-significant reduction (RR 0.87, 95% CI 0.54 to 1.41 for women aged forty to 
forty-nine). There were differences in the results for the two counties (Tabar et al 1995), with 
Kopparberg county showing a greater reduction in breast cancermortal_ity (RR 0.60, 95% CI 0.46 
to 0.79) compared with Ostergotland county (RR 0.78, 95% CI 0.57 to 0.84), but these results are 
not significantly different (Breslow-Day test for homogeneity of effect, x2 = 2.38, p = 0.13). 
1.2.4 Malmo Trial 
A randomised controlled trial was also started in Malmo, Sweden in 1977 (Andersson et al 1988). 
The 42,000 women in Malmo aged forty-five to sixty-nine years were identified from the Malmo 
population registry and were individually randomised to intervention and control groups. Women 
who had been previously diagnosed with breast cancer were included in this trial but it was not 
reported whether such women were equally distributed between the intervention and control 
groups or by age. Staging was done according to the tumour diagnosed through screening, 
irrespective of the stage of any tumour previously diagnosed. Analyses which excluded women 





Women in the intervention group were offered screening by mammography only, approximately 
every twenty-one months. In the first two screening rounds women were offered two-view 
mammography. In subsequent screening rounds women were offered single-view or two-view 
mammography depending on their type of breast parenchyrnal pattern. At the first screen seventy-
four percent of women participated. Virtually all women who required treatment were treated at 
one hospital by a team specialising in breast diseases. The cause of death in patients with breast 
cancer was determined by an independent committee consisting of a pathologist and an oncologist 
who were blind to the intervention or control group status of the patients and who independently 
assessed the cause of death for all women who died after having been diagnosed with breast cancer. 
After ten years (five completed screening rounds) there was no significant difference in breast 
cancer mortality between the two groups (RR 0.96, 95% CI 0.68-1.35). There was a twenty-one 
percent reduction in breast cancer mortality among intervention group women aged fifty-five and 
over; this reduction was not significant (RR 0.79, 95% CI 0.51 to 1.24). There was a 
non-significant excess mortality of similar magnitude among intervention group women under fifty-
five (RR 1.29, 95% CI 0.74 to 2.25). By twelve years after the trial began (Shapiro 1994) there 
was a nineteen percent reduction in breast cancer mortality (RR 0.81, 95% CI 0.62 to 1.07). Nearly 
a quarter of the control women had a mammogram during the study period, and twenty percent of 
the control women who were diagnosed with breast cancer were diagnosed by mammography. 
1.2.5 Edinburgh Trial 
A randomised controlled trial of breast cancer screening was started in Edinburgh in 1979 (Roberts 
et al 1989). 45,130 women registered with eighty-four general practices in the city and aged forty-
five to sixty-four who had not previously been diagnosed with breast cancer were entered into the 
trial. Screening was by two-view mammography and clinical examination at the first round. After 
this women were invited to be screened annually with clinical examination alone, in years two, four, 
and six, and single-view mammography and clinical examination in years three, five, and seven. Of 
the women invited sixty-one percent attended the first screening round. Women diagnosed with 
breast cancer were seen at a surgical review clinic. Death from breast cancer was defined as death 










After seven years there was a non-significant seventeen percent reduction in breast cancer mortality 
among women offered screening (RR 0.83, 95% CI 0.58 to 1.18). This reduction was almost 
completely confined to women over fifty. In women aged fifty to sixty-four there was a 
non-significant reduction of twenty percent (RR 0.80, 95% CI 0.54 to 1.17). After ten years 
(Shapiro 1994) the reduction was sixteen percent (RR 0.84, 95% CI 0.63 to 1.12). 
1.2.6 Canadian Trials 
Two randomised controlled trials were started in Canada in 1980 (Miller et al 1992a, Miller at al 
1992b ). The women in the Canadian trials were volunteers who had no history of breast cancer 
and had not had a mammogram in the previous twelve months. These women were randomly 
allocated to control and intervention groups after having agreed to take part in the trial. Since all 
the women in the trial had agreed to take part in screening before they were allocated to either the 
intervention or control group, these trials were different from the other previously described trials; 
they investigated the effect of screening rather than the effect of an invitation to screening. 
Trial I (women aged fifty to fifty-nine years) 
The purpose of this trial was to measure the additional contribution of annual mammographic 
screening to screening by physical examination alone in women aged fifty to fifty-nine on entry. 
There were 39,405 women aged fifty to fifty-nine in this trial. All the women received an initial 
physical examination by a trained nurse-examiner or physician and were taught breast self 
examination. The women in the control group received annual physical examinations, while the 
intervention group received both annual physical examinations and annual two-view 
mammography. After eight years there was little difference in breast cancer mortality between 
groups (RR 0.97, 95% CI 0.62 to 1.52) . 
Trial II (women aged forty to forty-nine years) 
This trial was designed to find out whether annual screening with mammography and physical 
examination reduces mortality from breast cancer in women aged forty to forty-nine on entry. 
There were 50,430 women aged forty to forty-nine in this trial. All the women received an initial 






examination. They were then randomly allocated to a control group or an intervention group. The 
women in the intervention group were offered annual two-view mammography and physical 
examination while the women in the control group were not offered further screening but were 
followed up annually by mail. After eight years there were more deaths from breast cancer among 
the intervention group than the control group but this difference was not statistically significant (RR 
1.36, 95% CI 0.84 to 2.21). 
In both of these trials referral for surgical treatment was the responsibility of each woman's 
physician rather than the screening programme, so there was no standard surgical protocol for the 
trials. Whether death was a result of breast cancer was determined by a panel which was blind to 
the intervention or control group status of the women. The panel reviewed the death certificates 
and case notes for any woman whose death could have been from breast cancer. This included 
women whose death certificates mentioned cancer of the breast, liver, or colon, and women whose 
cause of death was unknown. 
There has been considerable controversy over the results of the Canadian trials and about the way 
the trials were conducted (Kopans 1990, Stacey-Clear et al 1992, Rasuli 1993, Rose 1993, 
Burhenne 1993, Miller 1993, Mettlin and Smart 1993, Baines 1994, Miller 1994, Tarone 1995). 
The trials were criticised for the quality of their mammography (Kopans 1990, Rasuli 1993, 
Burhenne 1993), although much work was done to monitor screening quality (Miller 1993, Baines 
1994). The randomisation process was also questioned, since there was a significant excess of 
women with advanced breast cancer at the intial screen in the intervention group of the Canada II 
trial (Tarone 1995), however the randomisation was very carefully carried out and demographic 
variables, and breast cancer risk factors were equally distributed across the two groups (Baines 
1994). Also there was no imbalance in advanced breast cancers at the initial screen in the fifty to 
fifty-nine age group in the Canada I trial, which used the same randomisation procedure (Mettlin 
and Smart 1993). It appears that the imbalance in women with advanced cancer occurred by 
chance (Mettlin and Smart 1993, Baines 1994) . 
One paper criticising the Canada II study was based on a comparison of survival times in women 
under fifty with breast cancer diagnosed by mammography compared with women whose cancers 





survival time in the women diagnosed by mammography, that the Canada II study must be flawed. 
However, lead time bias could explain some, if not all, of the difference in survival between the two 
groups in the study by Stacey-Clear et al. 
Probably the most important issue with respect to the Canadian trials is that the follow-up period 
was relatively short at the time the results were reported. Both trials could be affected by this. The 
Canada I trial differed from other trials in that it compared two screening programmes 
(mammography and physical examination compared with physical examination only) whereas other 
trials compared screening with no screening. It is likely that in this situation the difference between 
groups would be smaller, and could take longer to emerge (Baines 1994). The trial was designed 
to detect a forty percent reduction in breast cancer mortality. If the actual effect of adding 
mammography to physical examination is thirty percent or less, it will take longer follow-up, with 
more breast cancer deaths, to show a significant effect (Miller et al 1992). 
In the Canada II trial there were relatively few breast cancer deaths at the time of publication of the 
results, and the trial did not achieve its planned power (Baines 1994). The results of the Canada II 
trial are not inconsistent with other trials, as several of the other trials showed an initial non-
significant excess mortality in women under fifty in the first eight years of follow-up (Tabar et al 
1985, Tabar et al 1992, Andersson et al 1988, Frisell et al 1986). Further results from both trials 
will be published after longer follow-up (Miller et al 1992). 
1.2. 7 Stockholm Trial 
This randomised controlled trial started in Stockholm in Sweden in 1981 (Frisell et al 1986, Frisell 
et al 1991). 60,000 women aged forty to sixty-four were randomly allocated to an intervention 
group and a control group. No women were excluded from either the intervention or the control 
group. Screening was with single-view mammography and the screening interval was about 
twenty-eight months. At the first round eighty-one percent of invited women took part. After five 
years women in the control group were invited to take part in a single screening round. Once this 
screening round was completed no further diagnoses of cancer were included in the trial. The 
criteria for surgery were the same for women in the intervention and control groups. Death from 





After 7. 4 years follow up there was a non-significant twenty-nine percent reduction in breast cancer 
mortality in the women offered screening (RR 0.71, 95% CI 0.4 to 1.2). The mortality reduction in 
women over fifty was forty-three percent and was not significant (RR 0.57, 95% CI 0.3 to 1.1), 
while in women under fifty there was a non-significant nine percent increase in breast cancer 
mortality (RR 1.09, 95% CI 0.4 to 3.0). By eight years (Shapiro 1994) there was a twenty percent 
reduction in breast cancer mortality in the women offered screening (RR 0.80, 95% CI 0.53 to 
1.22). 
1.2.8 Gothenburg Trial 
This trial was started in 1982. The results from this trial have only been published as part of an 
overview of the Swedish randomised trials of breast cancer screening (Nystrom et al 1993). In the 
Gothenburg trial 49,533 women aged forty to fifty-nine were randomly allocated to intervention 
and control groups. Women aged forty to forty-nine were individually randomised while the 
women aged fifty to fifty-nine were randomised by cluster, according to day of birth. Screening 
was by two-view mammography at eighteen month intervals. Participation in the first screening 
round was eighty-four percent. Women in the control group were invited to take part in screening 
in 1987. There is no information published about any surgical protocol used in the Gothenburg trial. 
After seven years follow up there was a non-significant fourteen percent reduction in breast cancer 
mortality among the women offered screening (RR 0.86, 95% CI 0.54 to 1.37). There are no 
published results comparing women under fifty with women aged fifty years and over. 
1.2.9 Combined analyses of randomised controlled trials 
There have been several combined analyses of the randomised controlled trials of mammographic 
screening; meta-analyses based on the published results of all the trials (Elwood et al 1993), or of 
the trials and case-control studies (Kerlikowske et al 1995) and an overview ( combined analysis of 
the raw data) of all the Swedish trials (Nystrom et al 1993). Two meta-analyses focussing 
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1995). The first meta-analysis (Elwood et al 1993) showed a reduction in breast cancer mortality 
of thirty-four percent (RR 0.66, 95% CI 0.55 to 0.79) for women over fifty at entry, and no 
reduction in breast cancer mortality for younger women (RR 1.08, 95% CI 0.85 to 1.39). The 
second meta-analysis (Kerlikowske et al 1995) showed a twenty-six percent reduction (RR 0.74, 
95% CI 0.66 to 0.83) for women over fifty, and a non-significant seven percent reduction (RR 
0.93, 95% CI 0.76 to 1.13) for women under fifty. One meta-analysis of published data on 
screening in women under fifty (Glasziou et al 1995) found a non-significant reduction (RR 0.95, 
95% CI 0. 77 to 1.18), while the other (Smart et al 1995), which had a longer follow-up of between 
seven and eighteen years found a non-significant sixteen percent reduction for all the trials (RR 
0.84, 95% CI 0.69 to 1.02) but a significant twenty-four percent (RR 0.76, 95% CI 0.62 to 0.95) 
reduction if the Canadian trial was excluded. The meta-analysis by Smart et al includes data that 
has not yet been published, but was presented at conferences. It also combines trials at different 
lengths of follow up, which wrongly assumes a constant breast cancer mortality rate over time. 
The Swedish overview found a reduction in breast cancer mortality of twenty-nine percent (RR 
0.71, 95% CI 0.57 to 0.89) among women aged fifty to sixty-nine at entry and a non-significant 
thirteen percent reduction (RR 0.87, 95% CI 0.63 to 1.20) for women aged forty to forty-nine. 
Further information about differences in the efficacy of screening for women of different age groups 
is given in section 1.4. 
1.3 Non-randomised studies of breast cancer screening 
Several non-randomised studies of screening have also been carried out. These studies are more 
likely to be affected by the biases associated with the evaluation of screening ( section 1.1) and so 
are not as useful for measuring the true effect of marnmographic screening on breast cancer 
mortality. 
1.3.1 UK Trial of Early Detection of Breast Cancer 
The UK Trial of Early Detection of Breast Cancer (UKTEDBC) was a non-randomised 





Kingdom (UK Trial of Early Detection of Breast Cancer Group 1988a). Two districts (Edinburgh 
and Guildford) offered women mammographic screening, two (Huddersfield and Nottingham) 
offered women instruction in breast self-examination (BSE), and the other four (Dundee, Oxford, 
Southmead, and Stoke-on-Trent) were comparison districts. In Edinburgh women were randomly 
allocated to be offered screening or to receive their usual care; Edinburgh therefore conducted a 
randomised controlled trial (section 1.2.5) but also contributed to the non-randomised UK Trial of 
Early Detection of Breast Cancer. 
The UK.TED BC started in 1971 and 45,841 women between forty-five and sixty-four were offered 
mammographic screening in Guildford and Edinburgh. There were 127,117 women in the 
comparison districts. Screening was by two-view mammography (Edinburgh) or single-view 
mammography (Guildford) and clinical examination at the first round. Of the women invited sixty-
one percent in Edinburgh, and seventy-two percent in Guildford attended the first screening round. 
After this women were invited to be screened annually with clinical examination alone in years two, 
four, and six, and single-view mammography and clinical examination in years three, five, and 
seven. 
Death from breast cancer was defined as the death of any woman in the study where the death 
certificate gave breast cancer as the primary cause. (In the Edinburgh randomised controlled trial 
the definition of death from breast cancer included deaths where breast cancer was given as the 
primary or the secondary cause). There was a non-significant reduction of twenty percent (RR 
0.80, 95% CI 0.64 to 1.01) in the risk of dying from breast cancer among these women compared 
with women in the comparison population for whom no extra services were offered. 
In the reports from this trial (UK Trial of Early Detection of Breast Cancer Group 1988a, UK Trial 
of Early Detection of Breast Cancer Group 1988b) it is recognised that the results should be 
interpreted with greater caution than those from the randomised controlled trials. However some 
comparisons were made between the UKTEDBC results and those from previously published 
randomised controlled trials (HIP and Swedish Two-Counties). The reasons suggested for the 







women, low participation rates, self-selection of lower risk women for screening, and lower 
sensitivity of the screening test (UK Trial of Early Detection of Breast Cancer Group, 1988b ). 
There were also differences in treatment protocols between the districts (UK Trial of Early 
Detection of Breast Cancer Group, 1988b ). 
1.3.2 Breast Cancer Detection Demonstration Project 
The Breast Cancer Detection Demonstration Project (BCDDP) was set up in America in 1972 
(Seidman et al 1987). Its purpose was to show that breast cancer screening for women aged thirty-
five to seventy-four could be implemented on a large scale. The BCDDP was a demonstration 
project rather than a scientific study and it did not include a comparison group. The women who 
took part were screened with annual clinical examination, mammography, and in some centres 
thermography. The women were also taught breast self examination (BSE). The records for 
women who took part were centrally processed at a data management centre in Philadelphia. There 
was some controversy about the relevance of the BCDDP results and a working group was set up 
to review the BCDDP. This working group reported in 1979 (Working Group to Review the 
National Cancer Institute-American Cancer Society Breast Cancer Detection Demonstration 
Projects 1979) concluding that results from the BCDDP could not be used to provide evidence on 
the efficacy of screening because of the lack of a suitable comparison group. 
1.3.3 Case-control studies 
Several case-control studies have been carried out to measure the effectiveness of established breast 
cancer screening programmes. These studies reported a reduced risk of death from breast cancer 
for women who had taken part in screening (Verbeek et al 1984, Verbeek et al 1985, Collette et al 
1984, Collette et al 1992, Palli et al 1986, Palli et al 1989). In these studies the cases were women 
eligible for screening who had died from breast cancer after their first screening invitation. The 
control women were age-matched women who were eligible for screening. The screening history 
for both cases and controls was taken up to and including the date of diagnosis of the case. The 
results from these case-control studies are summarised in Table 1.2. 
15 
TABLE 1.2 




Age group Ratio 





0.48 Women diagnosed All women invited, who 
' 35-65 (0.33-1.0) after their had not died from breast f 
A..:~ 1975 first invitation cancer at the time when 
\ and who died the case died ( five age-




Utrecht I 0.30 Women whose Utrecht women of the 
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1.3.4 Case-control analysis of Guildford data 
Two case-control studies have been carried out related to one of the screening districts (Guildford) 
and a comparison district (Stoke-on-Trent) from the UKTEDBC (Moss et al 1992). The first 
study (study A) estimated the risk of death from breast cancer in women in the screening district 
relative to the control district, where screening had not been offered, and the second (study B) 
estimated the relative risk for women who had ever been screened compared with women who had 
never been screened, in the screening district alone. Study B was carried out to assess the extent of 
selection bias in a case-control study carried out among women who had been offered screening. 
The results of this study, and the effect of selection bias on case-control analyses of breast cancer 
screening are discussed in Chapter Three (section 3.1.3). The relative risk in study A was 0.76 
(95% CI 0.54 to 1.08), suggesting a twenty-four percent reduction in breast cancer mortality in the 
screening district compared with the comparison district. The women in the study were aged forty-
five to sixty-four. The results for women under fifty were not examined separately. 
1.3.5 Case-control studies and the efficacy of breast cancer screening 
Case-control studies cannot measure the efficacy of screening very accurately because of the 
likelihood of selection bias. The studies may overestimate or underestimate the effect of screening, 
depending on the direction of selection bias. The studies are consistent however in finding a 
reduction in breast cancer mortality for women over fifty. The two studies which included women 
under fifty were unable to demonstrate a significant protective effect of screening for women under 
fifty. 
1.4 Breast cancer screening and age 
Even in the earliest randomised controlled trials of breast cancer screening it was noticed that the 
reduction in breast cancer mortality was largely confined to women who were over fifty at entry 




Canada II trial, none of the trials was designed to look at the issue of screening for women under 
fifty, so the numbers of women aged less than fifty in the trials were small. Whether it is reasonable 
to analyse sub-groups within the trials has been questioned (Kopans 1994), but there is significant 
heterogeneity between the results for older and younger women in the trials (Elwood et al 1993), 
suggesting that it is legitimate to analyse the results in the two age groups separately. The one trial 
that was designed to look at the question of screening for women under fifty, the Canada II trial, 
(section 1.2.6) found no evidence ofbenefit. 
Meta-analyses have been carried out (section 1.2.9) showing that breast cancer screening for 
women over fifty results in about a thirty-four percent reduction in breast cancer mortality. For 
women under fifty there is no good evidence of benefit. Since the first meta-analysis (Elwood et al 
1993) was published several others have been unable to demonstrate any benefit of screening for 
women under fifty. An overview of the Swedish randomised controlled trials (Nystrom et al 1993) 
found a non-significant thirteen percent reduction in mortality for women under fifty, but a recent 
analysis estimated that about seventy percent of this mortality reduction was likely to be due to 
screening in these women after they had reached the age of fifty (de Koning et al 1995a). This 
issue also affects the interpretation of the meta-analysis carried out by Smart et al since it included 
results of trials after long follow-up periods of ten years or more. There is a trial under way in the 
UK to investigate this issue, but the results will not be available for several years. In this trial 
women are randomised to be offered screening from the age of forty and then to enter the national 
screening programme at fifty, or to enter the national screening programme at fifty with no prior 
offer of screening. The trial will investigate whether there is any additional benefit of screening 
women from forty to forty-nine in addition to screening from fifty to sixty.:.four (Murphy and 
Odartchenko 1993). 
Tables 1.3 and 1.4 compare the results from the randomised controlled trials at seven years 
follow-up, according to the age at entry of the women screened. The Canadian trials (section 
1.2.6) were not included since they differed from the other trials in assessing the efficacy of 
screening, rather than the efficacy of offering screening. The Gothenburg trial (section 1.2.8) is not 
included because the results from this trial have not been published ( except as part of the overview 
of Swedish trials). Unfortunately none of these trials was specifically designed to provide 
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TABLE 1.3 
Results of Randomised Controlled Trials by Age: 
Younger Women 
Trial Age group Person-years of follow up Breast cancer deaths 
Intervention Control Intervention Control 
HIP 40-49 93,878 94,714 30 39 
,1-
Malmo 45-54 55,145 55,938 17 13 
S2C 40-49 136,459 107,836 26 18 
'·{, 
' 
Edinburgh 45-49 40,851 40,009 13 13 
Stockholm 40-49 99,155 54,446 16 8 
t) 
TOTAL 425,488 352,943 102 91 
\ 
















' Source: Elwood JM, Cox B, Richardson AK. The effectiveness of breast cancer screening in young women. Online J 










Results of Randomised Controlled Trials by Age: 
Older Women 
Trial Age grozp Person-years of follow up Breast cancer deaths 
Intervention Control Intervention Control 
HIP 50-64 112,898 115,024 39 66 
Malmo 55-69 88,278 88,221 27 25 
S2C 50-69 315,262 223,523 75 86 
Edinburgh 50-64 117,095 107,845 55 63 
Stockholm 50-64 171,092 92,927 23 22 
TOTAL 804,625 627,540 219 262 
















Source: Elwood JM, Cox B, Richardson AK The effectiveness of breast cancer screening in young women. Online J 











information on the efficacy of screening for women at different ages, and the small numbers of 
women involved together with a lower risk of breast cancer in the younger age group mean that 
only large differences in mortality would have been statistically significant. But there is significant 
heterogeneity between the results shown in Tables 1.4 and 1.5 for the younger and older groups 
(Breslow-Day test of homogeneity of effect x2 = 4.34, df= 1, p = 0.04), and although the individual 
trials had inadequate power to detect small reductions in mortality for younger women the meta-
analysis by Elwood et al had adequate statistical power to detect a twenty percent reduction in 
mortality in the younger group. None of the combined analyses found convincing evidence of a 
reduction in breast cancer mortality resulting from screening women under fifty, but they were 
consistent in finding that screening reduced mortality by about a third for women over fifty. 
The difference in outcome for the two age-groups may be related to the performance of the 
screening test. It is clear from the Swedish Two-Counties trial (Tabar et al 1992) that 
mammography produces different results in the two age-groups (Table 1.5). In Table 1.5 "sojourn 
time" refers to the amount of time that a cancer remains pre-clinical but screen-detectable (this can 
also be interpreted as the mean lead-time gained by screening), and "predictive value" refers to the 
percentage of breast cancers diagnosed in the prevalence screen that would later have come to 
diagnosis in the absence of screening. A low predictive value suggests overdiagnosis due to 
screening, and this was found particularly in women under fifty. The differences for younger 
women seen in Table 1.5 may also be related to their pre-menopausal status. Most women aged 
less than fifty are premenopausal and therefore have more glandular tissue in their breasts. This 
tends to make their breast tissue denser, so that mammography may be less sensitive (Tabar et al 
1995). 
Some authors have been reluctant to accept that screening could be less effective for women under 
fifty (Kopans 1994). It has been suggested, on the basis of the shorter mean sojourn time for 
women under fifty, that the screening test should be carried out more frequently in younger women, 
and recommendations of annual mammography for women aged forty to forty-nine have been 
made (Kopans 1994, Tabar et al 1995). However, if the results from the trials are applied to the 
actual situation that would result from offering annual screening to women under fifty, it is clear 
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TABLE 1.5 
Measures of effectiveness of screening by age in the Swedish Two-Counties trial 
Age group 




lOOOwoman- 1.05 1.87 2.50 2.99 
years 
Prevalence in 




prevalence to 1.99 2.50 3.52 4.06 
incidence 
Incidence in 
\ \ year after , 
,( screen(% of 
expected) 
Year 1 46 10 17 8 
·t 
) 
/ Year2 53 28 27 44 
Sensitivity 60% 86% 86% 95% 86% 
''\ Mean sojourn 
time 1.25 3.03 3.89 3.41 3.47 
"Predictive 
value" 38% 100% 95% 80% 97% 
.( 
* combined 
Source: Elwood JM, Cox B, Richardson AK. The effectiveness of breast cancer screening in young women. Online J 










Comparing the first year of screening for 10,000 women aged 40-49 
with 10,000 women aged 50-64 
Age group 
Screening interval (years) 
Number of women screened 
per year 
Number referred per year 
Number of biopsies per year 
Women diagnosed with breast 
cancer each year as a result of 
screerung 
Benign : malignant biopsy ratio 
Percentage of the cancers expected 
in the next year that were detected 
early by screening 
Evidence that screening 



















Source of data for this table : Day NE, Chamberlain J. Screening for breast cancer: workshop report. Eur J Cancer 







that not only are the benefits of screening not proven for this group, but the risks of false positive 
and false negative tests are greater (Table 1.6). Because mammography is less sensitive in younger 
women, there will be more false negative tests than in women over fifty. There are also more false 
positive tests in younger women, and the benign to malignant biopsy ratio is higher than in women 
over fifty. All of these risks are compounded by the fact that the women would be screened twice 
as often as women over fifty (who are offered screening every two years). Finally, and most 
importantly, these risks are not balanced by any evidence of benefit in women under fifty. The risks 
and benefits of screening are discussed further in Chapter Two. 
1.5 Summary 
There have been many studies of the efficacy of mammographic screening for breast cancer. The 
most useful studies are the randomised controlled trials because their results are least likely to have 
been affected by bias or confounding. The non-randomised studies, while requiring more cautious 
interpretation, have been useful in supplementing the results from the randomised controlled trials 
and have been used to explore the practical aspects of population-based screening. Together, the 
results show that under the best conditions, mammographic screening for breast cancer can reduce 
breast cancer mortality in women over fifty years by about a third. At present there is not good 







The Establishment of Population-Based Breast Cancer Screening in New Zealand 
Introduction 
This chapter examines the context in which population-based breast cancer screening 
programmes were introduced in New Zealand. The epidemiology of breast cancer in New 
Zealand, and the way data on breast cancer incidence are collected are described in section 
2.1. The likely effect of breast cancer screening is compared with other possible strategies 
to reduce breast cancer mortality in section 2.2. The risks and benefits of breast cancer 
screening are investigated, and the characteristics of an organised screening programme are 
described in section 2.3. Population-based screening is discussed in section 2.4 and the 
factors leading up to the introduction of population-based breast cancer screening in New 
Zealand, and the establishment of the pilot programme and its evaluation are outlined in 
section 2.5. 
2.1 Breast cancer in New Zealand 
New Zealand has a population of about three and a half million people. Eighty percent of 
the population are of European descent, ten percent are Maori (New Zealand Health 
Information Service 1993). Breast cancer is an important cause of morbidity and mortality 
in New Zealand. It is the most common cause of death from cancer in women and causes 
eighteen percent of all female deaths from cancer and five percent of all female deaths. In 
1991 the age-standardised incidence rate (standardised to Segi's world population) for 
New Zealand women was 74.3 per hundred thousand per year. Breast cancer incidence 
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rates for Maori and non-Maori women are similar (New Zealand Health Information 
Service 1994). The incidence of breast cancer increases with age, and in New Zealand 
seventy percent of breast cancer registrations are in women over fifty years old (Table 2.1). 
From 1980 to 1991 there was a ten percent increase in breast cancer registrations but the 
breast cancer mortality rate remained unchanged over this time at about twenty-six deaths 
per hundred thousand per year (New Zealand Health Information Service 1994). Mortality 
rates for Maori women were lower than for non-Maori women, at about twenty-two per 
hundred thousand per year. Each year about fifteen hundred New Zealand women are 
diagnosed with breast cancer and about six hundred women die from it (New Zealand 
Health Information Service 1994). 
Information about cancer incidence and mortality in New Zealand is collected by the New 
Zealand Cancer Register. This Register was established in 1948 within the National Health 
Statistics Centre of the Department of Health. Initially the Register consisted of 
information about people treated for cancer in public hospitals only. Information on 
cancers of all sites was initially collected, but in 1958 because of resource constraints, 
registration of skin cancers (apart from malignant melanoma) was discontinued. In 1972 
cancer registration was extended to private hospitals. The Cancer Registry also received 
notice of all deaths occurring in New Zealand every year and used this information to 
update its records and create new records if necessary. Collection of data for the Cancer 
Register was carried out routinely by hospital coders in public hospitals, but in private 
hospitals it was the responsibility of the medical practitioner treating the patient, and was 
not compulsory. This led to problems with under-reporting of cancers where people were 
treated outside the public hospital system, and concern that the proportion of all cancers 
registered by the Cancer Registry had varied over time (Cox et al 1989). In 1988 a 
working group recommended that legislation should be enacted to make it compulsory for 
all pathology laboratories (both public and private) to supply a copy of any pathology 
report with the diagnosis of cancer and related conditions to the New Zealand Cancer 
Registry (Cancer Registration Working Group, 1988). It was hoped that this would 
increase coverage, and also provide legal protection for medical practitioners who were 
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TABLE2.l 
Breast cancer registrations and deaths in New Zealand women 
Age group Number of Age-specific rate Number of Age-specific 
registrations in (per 100,000) deaths in 1990 mortality rate 
1991 (per 100,000) 




20-24 2 1.5 
25-29 16 11.5 2 1.4 
30-34 39 28.2 11 7.9 
35-39 85 68.1 22 17.9 
40-44 158 132.8 37 32.4 
45-49 159 170.5 57 62.9 
50-54 172 215.4 45 57.6 
55-59 153 223.0 66 94.6 
\L 
60-64 171 243.7 79 112.6 . , 
65-69 174 261.7 73 112.2 
70-74 161 288.6 71 132.8 
75-79 119 264.4 69 153.8 
80-84 101 339.3 53 180.0 
1 85+ 84 382.9 50 237.8 
j Total 1594 635 
Sources: New Zealand Health Infonnation Service. Cancer: new registrations and deaths 1991. Wellington: 
Ministry of Health, 1994. 
. r 
New Zealand Health Information Service. Mortality and demographic data 1990. Wellington: 







reluctant to notify the registry because of concerns about patient confidentiality. Little 
progress was made however, and by 1989 private medical practitioners in Auckland, New 
Zealand's largest city, had refused to register their patients, and data collection at the 
registry had fallen several years behind (Skegg 1989). It was suggested that if this 
downward trend continued the Cancer Register would no longer be accurate enough to be 
used to evaluate cancer control initiatives such as cervical and breast cancer screening 
(Skegg 1989). 
In 1991 a review committee was set up (Cancer Registry Working Group 1991) which 
reiterated the need for legislation to make registration compulsory, since the existing system 
could miss people who were treated only at outpatient clinics or at private hospitals, and 
also suggested a minimum delay of eighteen months between collection of data and its 
publication by the registry. Later the chair of the review committee reported on progress 
since the review, a bill having been introduced in Parliament in mid-1992 to make cancer 
registration compulsory (Elwood 1992). This legislation, the Cancer Registration Act, was 
passed in 1993 to take effect from 1 July 1994. It is believed that cancer registrations for 
the period 1980 to 1991 represented at least ninety-five percent of all tumours (National 
Health Statistics Centre 1989, New Zealand Health Information Service 1994). 
From 1979 to 1988, when there was little use of mammography for screening in New 
Zealand, the stage distribution of breast cancer at diagnosis (New Zealand Cancer Registry 
1990) for women aged fifty to sixty-four was as shown in Table 2.2. As would be expected 
in the absence of widespread screening, there was very little ductal carcinoma in situ 
(DCIS) diagnosed, fifty-one percent of women were diagnosed with localised breast 
cancer, thirty-seven percent with regional or node involvement, and only eight percent of 
women had distant metastases at the time of diagnosis. The stage at diagnosis was not 
stated for three percent. 
It is interesting to compare the stage-distribution at diagnosis for New Zealand women in 
the absence of screening with the control groups in randomised controlled trials of 












Stage distribution of breast cancer diagnosed in New Zealand 
women aged fifty to sixty-four in ten years from 1979 to 1988 
in situ localised regional or node distant 
disease involvement metastases 
42 2,289 1,677 368 




Source: New Zealand Cancer Registry computer tape. Breast cancer registrations 1979-88. Wellington, 
1990. 
Stage-distribution data: Dr J Elisabeth Wells, Department of Public Health and General Practice. 















The percentage of women diagnosed with localised disease in New Zealand prior to the 
introduction of screening was higher than in the control group in the Health Insurance Plan 
(HIP) trial where forty-six percent of control women had node negative tumours, but close 
to that for control group women in the Swedish Two-Counties trial, where fifty-four 
percent of women had node-negative tumours (Shapiro et al 1988, Tabar et al 1992). The 
Swedish Two-Counties trial showed a significant reduction in breast cancer mortality when 
screening was offered to a population where, in the absence of screening, there was a 
similar stage-distribution at diagnosis to that of New Zealand women in the absence of 
screening. This suggests that screening in New Zealand has the potential (assuming a 
screening programme of equivalent quality) to have a similar impact to the Swedish Two-
Counties trial. The issue of stage-distribution at diagnosis in the absence of screening and 
its likely effect on the effectiveness of screening are discussed in more detail in Chapter 
Three (section 3.6.3). There are large inter-country differences in breast cancer incidence 
(Table 2.3), with rates in the highest risk countries being five times the rates in countries 
with the lowest risk (Parkin et al 1992). New Zealand has among the highest breast cancer 
incidence and mortality rates in the world (Parkin et al 1992, Boring et al 1993). The inter-
country differences in breast cancer incidence are further discussed under prospects for the 
primary prevention of breast cancer in section 2.2.1. 
2.2 Comparing strategies to reduce breast cancer mortality in New Zealand. 
Breast cancer is a major health problem in New Zealand and it is important to find ways to 
reduce its impact on New Zealand women. This section focuses on breast cancer mortality. 
There are three preventive strategies which could reduce breast cancer mortality. They are 
removal of or protection from the cause(s) of breast cancer (primary prevention), early 
detection by screening (secondary prevention) and improvements in treatment (tertiary 
prevention). In this section the three strategies are compared. The comparison is restricted 



















Breast cancer incidence and mortality in New Zealand 
compared with other countries 
Country Age standardised Age standardised 
breast cancer incidence breast cancer mortality 
per 100,000 * per 100,000 # 
New Zealand 74.3 26.8 
USA 89.2 white 22.4 
65.0 black 
Canada 71.1 24.2 
Denmark 68.6 28.3 
Sweden 62.5 17.4 
Australia 59.0 20.6 
England 56.0 29.3 
Finland 52.5 17.3 
Hong Kong 32.3 8.4 
Japan 25.0 6.0 
China 21.5 4.7 
* Standardised to Segi's world population 
Source: Parkin DM, Muir CS, Whelan SL et al (eds). Cancer incidence in five continents volume 6. 
IARC Scientific Publications No. 120. Lyon: International Agency for Research on Cancer, 1992. 
# Standardised to WHO world standard population 











2.2.1 Primary prevention 
The ideal strategy would be to prevent breast cancer from occurring (primary prevention). 
Since the cause of breast cancer is unknown, complete prevention of the disease is not 
possible. Despite this, it might seem that there is some potential to reduce breast cancer 
incidence as migrant studies suggest that the differences in breast cancer incidence between 
countries are due to environmental rather than genetic factors (Buell 1973, Shimizu et al 
1991, Kelsey and Hom-Ross 1993, Zeigler et al 1993). If all the environmental factors 
were identified and if they were all modifiable, it would be possible to reduce breast cancer 
incidence everywhere to the level found in low incidence countries. But it is clear that all 
the factors that contribute to inter-country differences have not been identified, as these 
international differences cannot be explained on the basis of differences in known risk 
factors between countries (Thomas 1991, Thomas 1993). 
Even with respect to the recognised risk factors primary prevention is a distant goal; most 
of the women who develop breast cancer could not have been previously identified as being 
at higher risk of the disease (Love 1995). Also many of the recognised risk factors are not 
easily modifiable; for instance family history, age at menarche, and age at menopause (Bush 
and Helzlsouer 1993, Brinton 1994). Others such as age at first pregnancy or the number 
of children that a woman has are usually determined by considerations other than the wish 
to reduce risk of breast cancer. Dietary modifications are a possibility but studies 
investigating the risk associated with a high fat diet or with alcohol have been inconclusive 
(Brinton 1994, Lund 1994, Toniolo et al 1994). Two large cohort studies (Willett et al 
1987, Jones et al 1987) failed to show an association between high fat intake and breast 
cancer risk. A randomised controlled trial to investigate the effect of a low fat diet on 
breast cancer incidence is presently underway in Canada (Love 1995), and a similar trial, 
the Women's Health Initiative Dietary Modification Trial, is underway in the United States 
(Henderson 1995) but the results will not be available for several years. A high level of 
physical activity may slightly reduce the risk of breast cancer (Brinton, 1994). Genetic 
testing for women with a strong family history is now a possibility. Some women with a 
strong family history and a very high risk of breast cancer can be offered genetic testing to 
see whether they are at risk (Vogelstein and Kinzler 1994 ); some of these women opt for 













is very much less. Genetic testing has the potential to prevent about two percent of women 
from developing breast cancer (Easton et al 1993, Easton et al 1994) although this would 
be likely to affect women younger than fifty since familial breast cancer tends to occur 
earlier than sporadic breast cancer. Chemoprevention is another possible means of 
prevention and a trial is presently under way to find out whether tamoxifen taken regularly 
can reduce the incidence of breast cancer among high risk women aged thirty-five and over 
(Bush and Helzlsouer 1993). The results from this trial will not be available until 1997. 
Estimates of the possible reduction in breast cancer that could be achieved by modifications 
in lifestyle have been made, with the highest estimate being forty-five percent (Miller 1992) 
but incorporated in this estimate was the effect of diet, in particular dietary fat, which was 
estimated by Miller to be about twenty-seven percent but it may be much less (Lund, 1994, 
Toniolo et al, 1994). It is now widely accepted that primary prevention of breast cancer is 
not yet feasible because most of the established risk factors do not increase risk greatly, and 
most are not modifiable (Kelsey 1993, Brinton 1994, Love 1995). Another important 
feature of primary prevention as a strategy to reduce breast cancer mortality in women over 
fifty is that it appears that the risk of breast cancer may be determined early in life 
(Bjamason 1974, de Waard 1991, Ekbom et al 1992, Kelsey and Hom-Ross 1993) so 
even if primary prevention were possible, it could take several decades to have any effect. 
2.2.2 Screening 
The efficacy of screening for breast cancer has been discussed in Chapter One. The aim of 
screening is to detect disease at an earlier stage when treatment may be more successful. 
Randomised controlled trials of breast cancer screening using mammography have provided 
clear evidence that screening can reduce breast cancer mortality by about thirty percent in a 
population of women over fifty who are offered screening. In New Zealand in 1984, before 
there was much use of mammography for screening, 195 women aged from fifty-five to 
sixty-nine died from breast cancer. From the results of the randomised controlled trials 
screening has the potential to reduce this by thirty percent (about fifty-eight women). The 
thirty percent reduction has been applied to the fifty-five to sixty-nine age group since 
33 
'\ 
'' . ' 
. i 
I 
breast screening has a delayed effect on mortality, beginning about five years after entry to 
screening (Rutqvist et al 1990). 
2.2.3 Treatment 
The third strategy would be to improve the treatment of breast cancer (tertiary prevention). 
This strategy is worthwhile, but so far the gains from treatment of breast cancer have been 
relatively small. A systematic overview of the treatment of early breast cancer (stage one 
and two) showed that appropriate treatment (with tamoxifen and adjuvant chemotherapy 
compared with treatments that did not include tamoxifen and adjuvant chemotherapy) 
improved five-year survival from about sixty-five percent to seventy-two percent for 
women aged over fifty (Early Breast Cancer Triallists' Collaborative Group 1990). In 1984 
(before the introduction of widespread mammography) there were 433 women aged 
between fifty and sixty-four diagnosed with breast cancer in New Zealand (National Health 
Statistics Centre, 1989). The distribution of stage at diagnosis for fifty to sixty-four year old 
women in the ten years from 1979 to 1988 is shown in Table 2.2 ( section 2.1 ). Up to 
eighty-eight percent of women aged fifty to sixty-four were diagnosed with "early breast 
cancer''. This equates to 381 women diagnosed with "early breast cancer'' from the total of 
433 women diagnosed with breast cancer in New Zealand in 1984. From the overview of 
treatment of early breast cancer (Early Breast Cancer Triallists' Collaborative Group 1990), 
treatment including tamoxifen and adjuvant chemotherapy can improve the five year 
survival of women over fifty by up to nine percent, compared with treatment that does not 
include tarnoxifen and adjuvant chemotherapy. It is likely that some of the 381 women 
aged fifty to sixty-four diagnosed with early breast cancer would have received treatment 
with tarnoxifen and adjuvant chemotherapy (Mason et al 1994), so adding a nine percent 
improvement in five year survival (from about sixty-five percent without tarnoxifen and 
adjuvant chemotherapy to seventy-two percent with), is probably an overestimate, but 
means that after five years, of the 381 women, the number surviving would rise from 248 
(sixty-five percent) to 274 (seventy-two percent), and so up to twenty-six extra women 
would be alive five years after diagnosis. 
Fot women with more advanced breast cancer five year surviyal is lower and the results of 




overview has not been done. As a way of estimating the maximum effect that could be 
obtained from optimal treatment, a nine percent increase in five year survival from sixty-five 
percent to seventy-two percent can be applied to all 433 women aged fifty to sixty-four 
who were diagnosed with breast cancer. The number of women surviving five years would 
then rise from 281 to 311, or thirty extra women. This is an overestimate of the true 
potential of treatment, since the actual five year survival for women with advanced disease 
is lower than for women with early breast cancer. 
Table 2.4 shows the number of deaths that could be prevented in New Zealand in a year by 
secondary prevention (mammographic screening), and tertiary prevention ( ensuring the 
optimum treatment) for women who had been diagnosed with breast cancer when they 
were between fifty and sixty-four years old. To make this comparison the number of deaths 
that could be prevented by each of these strategies in a year has been calculated for women 
aged fifty-five to sixty-nine as the effects of both treatment and screening on breast cancer 
mortality are delayed. The comparison shows that mammographic screening has the 
greatest potential for reducing breast cancer mortality. Employing both strategies would 
have the greatest impact on breast cancer mortality. 
2.3 Breast cancer screening: risks and benefits 
For women over fifty mammographic screening is the most effective way to reduce breast 
cancer mortality. Even though its impact is relatively small (potentially preventing the 
deaths of fifty-eight of the six hundred women who die from breast cancer in New Zealand 
every year) it is the most effective of the three strategies to reduce breast cancer mortality. 
Obviously if an effective method of primary prevention, or a cure for breast cancer could be 
found there would be no need for screening. In the meantime it has the greatest potential to 
reduce breast cancer mortality in New Zealand women aged fifty and over. But breast 
.. cancer screening has risks as well as benefits .. These risks and benefits are outlined in Table 
2.5 (adapted from Chamberlain 1984). The benefits associated with screening will be 
examined first, in section 2.3.1, and then the risks of screening will be discussed in section 
2.3.2. 
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A comparison of the maximum numbers of breast cancer deaths that could be 
prevented each year in New Zealand, using different preventive strategies to reduce 
breast cancer mortality for women aged 50-64 at diagnosis. 
Strategy 
Number of breast 
cancer deaths that 














* this annual reduction in mortality would not begin until about five years after the introduction of the 
preventive strategy, as the effects of both treatment and screening on breast cancer mortality are delayed 
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2.3.1 Benefits of breast cancer screening 
The benefits of breast cancer screening depend upon the age-range of the women to whom 
it is offered. There is evidence that screening can reduce breast cancer mortality for women 
over fifty but no clear evidence for women under fifty (Chapter One, section 1.4). This is 
important, as there must be clear evidence of benefit before screening is offered: 
We believe that there is an ethical difference between everyday medical practice and 
screening. If a patient asks a medical practitioner for help, the doctor does the best he [or 
she] can. He [or she] is not responsible for defects in medical knowledge. If, however, 
the practitioner initiates screening procedures he [or she] is in a very different situation. 
He [or she] should, in our view, have conclusive evidence that screening can alter the 
natural history of the disease in a significant proportion of those screened. (Cochrane and 
Holland 1971). 
Screening should not be offered to women under fifty, as there is no clear evidence of 
benefit. Although mammography can detect breast cancer in younger women it is not clear 
that doing this actually reduces breast cancer mortality (Chapter One, section 1.4). For 
women over fifty there is evidence of benefit from screening. It is clear from the literature 
that breast cancer screening can reduce breast cancer mortality by about a third in a 
population of women aged fifty and over who are offered screening. The benefit is greater 
than this for women who take part in screening. Although the reduction in breast cancer 
mortality is about a third in the randomised controlled trials, this includes women who were 
offered screening but did not take part, and is therefore a diluted estimate of the effect of 
screening. For women who take part in screening the benefit has been estimated at forty to 
fifty percent (Day and Chamberlain 1988, Day 1991). So for every hundred women who 
are diagnosed with breast cancer in a screening programme about forty to fifty will have 
increased survival as a result. Some of these women will survive many years longer than 
they would have otherwise and some may be cured (Joensuu and Toikkanen 1995). 
But it is important to note that this benefit is available only to the women who are 
diagnosed with breast cancer, and these women are quite a small proportion of the 
population offered screening. The risk of dying from breast cancer in the next twenty years 






Benefits and risks of breast cancer screening 
Bene.fits 
Improved prognosis for some 
women diagnosed by screening 
Less radical treatment which 
cures some women with early 
breast cancer 
Resource savings 
Reassurance for those with 
negative test results 
Risks 
Longer morbidity for women 
whose prognosis is unaltered 
Over-treatment of questionable 
abnormalities 
Resource costs 
False reassurance for women with 
false negative results 
Anxiety and sometimes morbidity 
for women with false positive 
results 
Hazard of screening test 
Source: adapted from Chamberlain JM. Which prescriptive screening programmes are worthwhile? J Epid 
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Taking part in a breast cancer screening programme could, at the most, halve this risk (to 
one chance in a hundred). Although this absolute effect of screening is rather small, it is 
nevertheless the largest reduction in the risk of dying from breast cancer that is available to 
women aged fifty to sixty-four at present. 
Another benefit of screening is the possibility of less radical treatment for women whose 
cancers are detected early, and it has been shown that the introduction of a breast cancer 
screening programme results in less invasive treatment of breast cancer (Moody et al 1994, 
de Koning et al 1990). Less invasive treatment is also associated with less psychological 
morbidity (Schain et al 1994). 
There are economic issues that must also be considered. Is the cost of providing a 
screening programme excessive in relation to the benefit that it can produce? This also 
depends on the population being considered. Where women under fifty are included, the 
costs are extremely high (Carter et al 1993, Wright and Mueller 1995). But analyses of 
breast cancer screening programmes for women over fifty have found that the cost per year 
of life saved is not excessive, being within the realms of other interventions already 
provided by the health service (Forrest 1987, de Koning et al 1991, Hall et al 1992, Carter 
et al 1993). The costs of screening will differ depending on the country in which the 
programme is carried out, the structure of the health service, and the acceptance of 
screening in the eligible population. Some of the costs of setting up and running a 
screening programme may be offset later by a reduction in the costs of treating women with 
advanced breast cancer. In Sweden after five years of breast cancer screening it became 
cheaper to continue the screening programme than to discontinue it because the 
programme resulted in fewer women needing treatment for advanced disease (Tabar 1987). 
The economic aspects of breast cancer screening are discussed in detail in Chapter Seven. 
The final benefit attributed to screening is reassurance for women with negative tests . 
Whether this can legitimately be claimed as a benefit is uncertain, since an invitation to 
screening may engender anxiety which is later relieved by a negative test ( a net zero 
benefit). But some women are anxious about breast cancer even in the absence of a 
screening programme, and these women may feel less anxious after a negative test. It is 








develop in the interval after a negative screen, and women should be aware of this so they 
do not delay seeking advice if they develop breast symptoms after a negative screen. 
Given that screening should only be offered to women aged fifty and over it is important to 
determine whether the benefits available for women aged over fifty outweigh the possible 
risks associated with screening. As outlined above, the proportion of screened women who 
could benefit from screening is low, since most women do not develop breast cancer. In 
the Swedish Two-Counties study nineteen deaths from breast cancer were averted for 
every ten thousand women aged fifty to sixty-four screened (Chen et al 1995). Since 
many women are screened for every woman who benefits it is extremely important to 
minimise the risk of harm from being screened. 
2.3.2 Risks of breast cancer screening 
No screening test is perfect, and although most women will be correctly identified as having 
breast cancer or not, some women will have false positive or false negative tests. The 
women who have false negative tests may be wrongly reassured so that they present later 
than they would have otherwise. There is very little information on this, except that the 
number of women experiencing false negative tests is low ( as would be expected, since the 
incidence of breast cancer is relatively low), at about five per ten thousand women screened 
(Shapiro et al 1982, Tabar et al 1985, Roberts et al 1989, Frisell et al 1991). It is possible 
to calculate the false negative rate for a given screening programme by subtracting the 
sensitivity for that programme from one. It is not certain how many women with false 
negative screening tests delay seeking advice, nor what effect such delay has. 
The women who have false positive tests undergo unnecessary investigations with 
associated anxiety. It has been shown that women who have had routine breast cancer 
screening examinations do not experience increased psychiatric morbidity (Dean et al 1986, 
Ellman et al 1989, Baines et al 1990). But women requiring further assessment have 
significantly higher anxiety scores than do those attending for routine screening (Lerman et 
al 1991, Ellman et al 1989 Gram et al 1990). There is conflicting information on the 








women with false positive results (Ellman et al 1989, Gram et al 1990), while another 
study found that women who had false positive tests were more anxious about breast 
cancer afterwards (Bull and Campbell 1991 ). As well as the likelihood of increased anxiety 
women with false positive tests suffer unnecessary investigations with associated morbidity. 
Obviously it is very important to keep this risk as low as possible in a screening 
programme. 
But it is also important to recognise that some of the risks associated with screening are not 
new; women experience similar risks in the absence of a screening programme. Even 
without a screening programme many women are concerned about breast cancer and visit 
their general practitioners because of breast problems. In the Netherlands, without mass 
screening, nine percent of women aged over forty visited their general practitioners for 
breast assessment in the course of a year ( de Koning et al 1990). Some of the women who 
visit their general practitioners are then referred on for further assessment. These women 
may have discovered a breast lump themselves, the general practitioner may have 
discovered a problem at routine breast examination, or they may be asymptomatic women 
who have had mammography in the absence of organised screening. Women who undergo 
assessment at surgical outpatients clinics, but who do not have breast cancer have been 
described as "the worried well" (Gravelle et al 1982) and in a study carried out in England 
before the introduction of the national breast cancer screening programme 4. 7 percent of 
women aged forty and over fell into the "worried well" category in a year (Gravelle et al 
1982). 
These women experience the anxiety and morbidity resulting from unnecessary 
investigations in just the same way that women in the "false positive" group in a screening 
programme do, and the number of such women is not inconsiderable. Table 2.6 compares 
biopsy rates per thousand women before and after the introduction of a breast cancer 
screening programme in Australia (Hall et al 1992, Salkeld and Gerard 1994). It is clear 













Comparison of assessment and biopsy rates before and after the introduction of a 



















Sources: Hall J, Gerard K, Salkeld G, Richardson J. A cost utility analysis of breast cancer screening in 
Australia. Soc Sci Med 1992; 34: 993-1004 . 
Salkeld G, Gerard K. Will early detection ofbreast cancer reduce the costs of treatment? Aust J 













for assessment and the biopsy rate increased by fifty percent. But for the extra five biopsies 
per thousand women an extra three women were diagnosed with breast cancer. So for 
each woman diagnosed with breast cancer the number undergoing unnecessary biopsies 
was lower in an organised screening programme than without a screening programme. 
Once the screening programme is established, the likelihood of false positive results and 
unnecessary biopsies falls. The first (prevalence) round of a screening programme results in 
more women being referred for assessment than the second and subsequent rounds because 
in the later rounds most of the women taking part have already been screened two years 
earlier (in an earlier round), and their previous films are available for comparison. The later 
rounds will largely detect cancers that have arisen since the previous screen. In the first 
screen there will be a higher prevalence of cancers, because some cancers may be detected 
at this screen that would have been detectable earlier, had there been a previous screen. In 
the Netherlands ( de Koning et al 1990, de Koning et al 1995b) the biopsy rate in the 
second screening round was actually less than the biopsy rate before the breast screening 
programme was introduced (Table 2.7). 
It is possible that radiation exposure during mammography could increase the risk of breast 
cancer; it is known that radiation exposure associated with the atomic bombs in Japan, and 
repeated x-ray treatment of women with tuberculosis increased breast cancer risk (Boice 
and Monson 1977, Tokunaga et al 1982, Adami et al 1990). But the level of radiation 
' associated with mammography is much less. For a woman undergoing regular 
mammograms in a breast cancer screening programme the radiation risk is very small, and 
has been estimated at less than a hundredth of a woman's underlying risk of developing 
breast cancer (Gohagan et al 1986). Another risk of screening is discomfort associated 
with the screening test. Investigations of the level of this risk show that most women find 
mammography uncomfortable rather than painful (Stomper et al 1988, Jackson et al 1988, 
Wolosin 1989, Rutter et al 1992). This issue is examined further in Chapter Six, along with 
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Biopsy and breast cancer detection rates in the second round of screening compared 
with the rates before the introduction of screening in the Netherlands. 


















Sources: de Koning HJ, van Oortmarssen GJ, van Ineveld BM, van der Maas PJ. Breast cancer screening: 
its impact on clinical medicine. Br J Cancer 1990: 61: 292-7. 
de Koning HJ, Fracheboud J, Boer R, et al. Nation-wide breast cancer screening in the 








2.3.3 Summary of benefits and risks 
There is good evidence that screening can reduce mortality from breast cancer by about a 
third in women aged fifty and over. The evidence for women under fifty is not clear. In the 
absence of this evidence it would be unethical to offer screening to women under fifty. For 
women over fifty for whom a benefit has been shown, the risks of screening must also be 
considered. Screening is not unique in having risks, as most treatments have risks or side-
effects, but the risks associated with screening can affect a larger number of women, since 
compared with treatment, screening is offered to a much larger group. The aim for any 
screening programme should be to keep the risks as low as possible without losing the 
benefits of screening. The best way to minimise risks and ensure that screening can reduce 
breast cancer mortality is to offer screening in a coordinated fashion, so that each stage of 
the screening process is of high quality. It is possible for a well-organised screening 
programme to reduce some of the risks associated with the investigation of breast 
problems, that would have occurred in the absence of screening (Table 2.5). The essential 
characteristics of an organised screening programme have been described for cervical 
screening programmes (Hakama et al 1985). These characteristics can be adapted for a 
breast cancer screening programme, since similar considerations apply. Table 2.8 shows 
the essential characteristics of an organised breast cancer screening programme (modified 
from Hakama et al 1985). 
The essential characteristics of a properly organised programme enhance the possibility of 
benefit while reducing the risks associated with screening. The first three characteristics 
relate to identifying and inviting eligible women. The possible impact of a programme is 
greatest if all eligible women are invited to be screened. No matter how good a programme 
is, its impact will be poor if many of the eligible women do not receive invitations. An 
organised screening programme will have a policy on the appropriate age-range for 
screening, whereas in the absence of an organised programme women (for instance those 
aged less than fifty) may be screened inappropriately. The fourth and fifth characteristics 
relate to the facilities for screening, assessment and treatment. In particular, adequate 
facilities for assessment and treatment are essential, especially in the first screening round 
where the assessment and biopsy rates are higher than in subsequent rounds. If assessment 
facilities are inadequate women with positive tests will have to go on a waiting list. This 
45 
I l ., 
1 .'! 
\ ···. , 
.\ 
TABLE2.8 
Essential f ea tu res of an organised breast cancer screening programme: 
The target population has been identified 
The individual women are identifiable 
Measures are available to guarantee high coverage and attendance, such as a personal letter 
of invitation 
There are adequate facilities for carrying out the screening test 
Adequate facilities exist for diagnosis and for appropriate treatment 
There is a carefully designed and agreed referral system so that women are followed up 
appropriately 
There is an organised quality control system 
Source: modified from Hakama M, Chamberlain J, Day NE, Miller AB, Prorok PC. Evaluation of 






delay increases anxiety (Fentiman 1988, Marteau 1990, Smith et al 1991). The sixth 
essential for organised breast cancer screening is adequate follow up and coordination 
between those offering the screening test and those carrying out assessments. Without 
good coordination there is the risk that women with positive tests will not be followed up 
and referred for assessment. Organised screening programmes have specialist assessment 
clinics, which can reduce biopsy rates. In the Netherlands the biopsy rate after the 
introduction of an organised programme was less than the biopsy rate before the breast 
screening programme was introduced ( de Koning et al 1990, de Koning et al 1995b). 
With properly organised screening there is also less potential for waste. In the United 
States there are already more mammography machines than would be required to screen 
every woman in the United States according to the national screening guidelines. This 
means that many mammography facilities are under-utilised, and calls into question whether 
the staff taking and reading the films have adequate throughput to maintain their skills 
(Skolnick 1994). Lastly, it is also easier to build evaluation and quality control into 
organised screening programmes, so that the risks and benefits of screening can be 
monitored. Organised screening programmes, where women are identified and invited to 
take part tend to be offered to all women in a defined population. This type of screening 
has been described as "population-based". Population-based screening will be discussed in 
the next section, with respect to the introduction of population-based screening in New 
Zealand. 
2.4 Population-based screening 
Population-based screerung or mass screerung 1s screerung "pertaining to a general 
population defined by geopolitical boundaries, with this population being the denominator 
and/or the sampling frame" (Last, 1988). Screening is offered to all eligible people within a 
defined population. Eligibility may be determined by certain characteristics such as gender, 
and age, but everyone in the eligible population will then be offered screening. Ten 
principles of screening were developed by the World Health Organisation as guidelines to 
help determine whether population-based screening for a particular disease would be 





of the population and the disease but also to the provision of an organised screening 
programme (as outlined in section 2.3.3). The ten principles of screening are listed in Table 
2.9. 
According to these principles, population-based breast cancer screening for women aged 
fifty to sixty-four was found to be an appropriate public health strategy for Britain (Breast 
Cancer Screening Working Group, 1987). But in making this assessment the British 
working group had information from the screening programmes that had been set up as 
part of the United Kingdom Trial of Early Detection of Breast Cancer. Although many of 
the British findings apply equally to New Zealand, the acceptability and the effectiveness of 
breast cancer screening, and its costs (principles six, seven, nine and ten) could not be 
addressed in New Zealand without first collecting local information. 
2.5 The introduction of breast cancer screening in New Zealand 
By 1987 the results from randomised controlled trials of breast screening were well known, 
many countries had local or regional population-based breast cancer screening programmes 
and Sweden, Finland and Iceland were developing national programmes. The British 
government had set up a working group to investigate the prospects for breast cancer 
screening (Breast Cancer Screening Working Group, 1987), had accepted its 
recommendations, and was planning to set up a national programme which would offer 
single-view mammography every three years to women aged fifty to sixty-four. At this 
time there were no population-based breast cancer screening programmes in New Zealand, 
although there were a few private radiology clinics offering screening mammography . 
In response to these developments a working group was set up by the Cancer Society and 
the Department of Health to make recommendations about mammographic screening in 
,~ 
New Zealand. The working group chaired by Professor David Skegg, reported in 1988 









Principles of screening 
1. The condition should pose an important health problem 
2. The natural history of the disease should be well understood 
3. There should be a recognisable early stage 






treatment started at a later stage 
There should be a suitable test 
The test should be acceptable to the population 
There should be adequate facilities for the diagnosis and treatment of abnormalities 
detected 
Screening should be repeated at intervals determined by the natural history of the 
disease 
The chance of physical or psychological harm to those screened should be less than 
the chance of benefit 
10. The cost of a screening programme should be balanced against the benefit it 
provides 
Source: Wilson JMG, JW1gner G. Principles and practice of screening for disease. WHO Public Health 





morbidity and mortality the group decided that breast screening was the most effective 
strategy available at the time. But the working group recognised that there were problems 
with introducing population-based screening in New Zealand. At the time of the report 
there were not enough skilled people in the country to organise and carry out a national 
screening programme. Neither were there adequate systems for inviting and recalling 
women. 
We therefore recommend that decisions about routine screening should be postponed 
until at least two pilot studies have been completed. The purpose of these studies would 
not be to assess the efficacy of mammographic screening, which has already been 
established overseas. The purpose would be to determine whether screening can be 
introduced in New Zealand in a way that is effective (in temlS of medical outcome), 
efficient (from an economic viewpoint), and acceptable to women. 
(Skegg et al 1988) 
Several recommendations about pilot programmes were made by the working group (Table 
2.10) .. The Ministry of Health agreed to fund two pilot progranunes according to the 
guidelines suggested in the Skegg report. The Cancer Society of New Zealand agreed to 
fund independent evaluations of the pilot programmes which would provide information 
about the acceptability, effectiveness, and economic efficiency of population-based 
mammographic screening in New Zealand. The Health Research Council of New Zealand 
provided scientific assessment of the proposals for. pilot programmes together with their 
associated evaluation protocols, which were submitted from different areas in New 
Zealand. In December 1989, after the proposals submitted from various regions in New 
Zealand had been assessed, the proposal for a mammographic screening programme in 
Otago and Southland was accepted. 
Otago and Southland are the southernmost regions in the South Island of New Zealand and 
their combined population is about 270,000 people. There are two main centres; Dunedin 
with a population of about 100,000 and Invercargill with a population of about 55,000. 
Large parts of Otago and Southland are rural. The population density of Otago and 
Southland is low by international standards, ranging from about 376 per square kilometre in 










Recommendations for pilot programmes in New Zealand 
1. the eligible age-range should be 50-64 
2. screening should be offered every two years 
3. ways to achieve high participation should be explored 
4. only dedicated mammography equipment should be used 
5. screening should be by two-view mammography 
6. the possibility of preliminary reading by non-radiologists should be investigated 
7. the results of screening should be sent to women and their general practitioners, 
and any further assessment should be carried out at specialist assessment clinics 
8. there should be adequate training for the staff of the pilot programmes 
9. each pilot programme should be directed by one person, with managerial skills and 
knowledge of population-based screening 
10. the pilot programmes should be carefully monitored 
11. a cost-benefit analysis of the pilot programmes should be carried out 
12. the acceptability of screening should be assessed 
Source: Skegg DCG, Paul C, Benson-Cooper D, et al. Mammographic screening for breast cancer: 







In the proposed programme women aged fifty to sixty-four and living in Otago and 
Southland were to be invited for screening with two-view mammography every two years. 
Three screening units were subsequently established; two fixed units based at Dunedin and 
Invercargill, and a mobile unit which travelled to rural areas. Assessment clinics were set up 
at Dunedin and Invercargill. The associated evaluation was designed to ensure that the 
programme would benefit the women who took part (since the benefit to risk ratio is 
highest in a well-organised and monitored programme), and to provide information about 
the acceptability, effectiveness, and economic efficiency of population-based 
mammographic screening in New Zealand. Screening at the fixed units in Dunedin and 
lnvercargill started in September 1991. Shortly after this a second pilot programme was 
started in Waikato, to offer two yearly two-view mammography to women aged fifty to 
sixty-four, and to provide similar information about acceptability, effectiveness, and 
economic efficiency, and in particular to address the acceptability of breast cancer screening 
for Maori women (two percent of the eligible women in Otago and Southland were Maori 
whereas sixteen percent of the eligible women in Waikato were Maori). 
2.6 Summary 
This chapter has described the situation leading up to the introduction of population-based 
breast cancer screening in the form of pilot programmes in New Zealand. The evaluation 
of the Otago and Southland pilot programme was carried out in accordance with . the 
recommendations of the Skegg report (Skegg et al 1988), focussing on the acceptability, 
effectiveness, and economic efficiency of the pilot programme. Methods for evaluating 
pilot programmes are discussed in Chapter Three and Chapter Four describes the 
development of the evaluation protocol for the Otago and Southland pilot programme. 
The methods and results from the evaluation of the Otago and Southland pilot programme 
are reported in Chapters Five (the effectiveness of the pilot programme) and Six (the 
acceptability of the pilot programme), and these results, together with the results from the 
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CHAPTER THREE 
Deciding on the Evaluation Method 
Introduction 
The evaluation of the Otago and Southland pilot programme was carried out in accordance with 
the reconunendations of the Skegg report (Skegg et al 1988), focussing on the acceptability, 
effectiveness, and economic efficiency of the pilot programme. The purpose of the evaluation was 
to find out whether population based breast cancer screening could be carried out in New Zealand 
in a way that would be effective, acceptable, and economically efficient. The results from the 
evaluation had to be available within a short time so that they could be used to help make decisions 
about a national breast cancer screening programme in New Zealand. 
In this chapter techniques and methods for evaluating pilot progranunes are discussed in section 
3.1. The evaluation methods considered were experimental or quasi-experimental methods (a 
randomised controlled trial or a non-randomised comparison study), a case-control study, or the 
goal-attainment method of evaluation (evaluation using pre-set goals). In section 3.2 the methods 
are compared in terms of their ability to meet the requirements for the evaluation of the Otago and 
Southland pilot programme. Some key results from the randomised controlled trials of breast 
cancer screening are examined in section 3.3 to determine which of the trials should be used to 









Evaluation is the process that attempts to detennine as systematically and objectively as possible the 
relevance, effectiveness, and impact of activities in the light of their objectives (Last 1988). A key 
concept in evaluation is that the activities being evaluated are compared against some standard of 
acceptability (Downie et al 1991). 
Three approaches to the evaluation of medical care have been defined (Donabedian 1966); 
evaluation of outcomes, evaluation of processes, and evaluation of the settings in which medical 
care takes place. These can be linked to three commonly used evaluation methods; the 
experimental paradigm, which measures outputs, the goal attainment model, which focuses on 
processes, and the elucidation model which examine settings (Robinson 1984, Turner et al 1992). 
The experimental approach measures outcomes. This approach to evaluation has been the 
traditional approach and usually involved classical experimental design (for instance a randomised 
controlled trial) or a quasi-experimental design with a comparison group but without 
randomisation. The goal attainment model involves measuring the extent to which a programme 
attains goals which have been specified before the start of the programme. It is sometimes difficult 
to develop measurable goals for evaluation, and elucidation models of evaluation do not necessarily 
involve specific goals, but describe the way a programme is carried out. 
There were several possible methods of evaluating the pilot breast cancer screening programme. 
These methods are discussed in this chapter. The possibilities included experimental or quasi-
experimental methods (a randomised controlled trial, or a non-randomised comparison study), or a 
case-control study, and the goal-attainment method (evaluation using pre-set goals). The 
elucidation method was not considered, for two reasons. First, the focus of the elucidation method 
is not on measurement (Robinson 1984), but the evaluation was required to "monitor the process 
and outcome of mammography'' including "the ratio of benign to malignant biopsies and 
assessment of the cancer detection rate" (Skegg et al 1988). Secondly, a major criticism of the 
elucidation method is that this approach rarely allows generalisation, (Robinson 1984), but one of 
the main purposes of the evaluation of the Otago and Southland programme was to collect 








evaluation methods considered, with its strengths and limitations is discussed as an option for 
evaluating the Otago and Southland pilot programme. 
3.1.1 Experimental method 
The classical experimental method for evaluating breast cancer screening is a randomised controlled 
trial, with breast cancer mortality as the outcome measure. But the purpose of evaluating the pilot 
programme was not to find out whether screening could reduce mortality from breast cancer. This 
had already been shown in several randomised controlled trials (Chapter One). Rather, the purpose 
of the evaluation of the Otago and Southland pilot programme was to provide information about 
the acceptability, effectiveness, and economic efficiency of population based mammographic 
screening in New Zealand. The evaluation had to provide rapid results based on relatively small 
numbers of women. A randomised controlled trial would have been inappropriate in this context for 
two reasons. First, the efficacy of breast cancer screening had already been demonstrated. 
Secondly, the number of women and the period of follow up required would make it impossible to 
use this method of evaluation, given the size of the eligible population and the time available for 
evaluating the Otago and Southland pilot programme. 
3.1.2 Quasi-experimental methods 
It would have been possible to evaluate the pilot programme by comparing breast cancer mortality 
in the pilot area with a comparison area. But there are problems with this approach. Firstly any 
differences in breast cancer mortality between the two areas could be due to factors other than the 
presence or absence of the screening programme. Such factors might include differences in access 
to health care and the availability of appropriate treatment, and differences in the underlying risk of 
breast cancer in the two areas. This was addressed in reports from the UK.TEDBC (United 
Kingdom Trial of Early Detection of Breast Cancer group 1988a, United Kingdom Trial of Early 
Detection of Breast Cancer Group 1988b ). The authors of those reports stated that their results 
should be interpreted with greater caution than results from randomised controlled trials because 
the comparison was non-randomised, and this meant "it was not possible to adjust for all the factors 
other than the early detection interventions which may have contributed to differences in breast 






numbers of women and several years of follow up in order to detect changes in breast cancer 
mortality that could be attributable to screening. The time available for the evaluation of the Otago 
and Southland pilot programme was too short to allow this approach. 
3.1.3 Case-control study 
Several case-control studies have been carried out to try to measure the effectiveness of established 
breast cancer screening programmes. These case-control studies, summarised in Chapter One, 
reported a reduced risk of death from breast cancer for women who had taken part in screening 
(Verbeek et al 1984, Verbeek et al 1985, Collette et al 1984, Collette et al 1992, Palli et al 1986, 
Palli et al 1989). 
A case-control study might appear to be a better method for evaluating the pilot programme than 
the options discussed previously, since it could be carried out with smaller numbers and over a 
shorter time period. But there are limitations of using a case-control study as an evaluation 
method. The first limitation is selection bias. The women who take part in screening may have a 
different risk of developing or dying from breast cancer, compared with the women who do not 
take part. If women who are at low risk of dying from breast cancer are more likely to participate 
in screening, a case-control study would overestimate the protective effect of screening. (If 
high-risk women were less likely to accept screening then the controls would have had a greater 
exposure to screening even if screening actually had no effect on breast cancer mortality). 
In the HIP study, women at higher risk took part in screening (Shapiro 1977, Shapiro et al 1982) 
while in the Swedish and UK randomised trials women at lower risk took part (Tabar et al 1985, 
Andersson et al 1988, Roberts et al 1989). A case-control study of the women offered screening 
in the HIP study using a sample of invited women as controls has been shown to underestimate the 
benefit of screening because of this self-selection of high-risk women (Freidman and Dubin 1991). 
It is impossible to adjust for this except in the context of a randomised controlled trial where there 
is a control group to compare with the non-attenders. In the HIP study the reason for the lower 
incidence of breast cancer among non-attenders could not be explained by differences in known risk 
factors such as age, parity, and history of benign breast disease between the attenders and the non-




completely, even by adjusting for known risk factors, in a case-control study of breast cancer 
screenmg. 
The effect of selection bias in case-control studies has also been demonstrated in two case-control 
analyses carried out within the UKTEDBC study (Moss 1991, Moss et al 1992). The UKTEDBC 
study was a non-randomised study which compared breast cancer mortality in districts where 
women had been offered mammography with breast cancer mortality in comparison districts where 
screening had not been offered ( section 1.3 .1 ). In the first case-control analysis carried out by 
Moss et al, the cases and controls were taken from two combined districts ( a screening district and 
a comparison district). In the second case-control analysis the cases and controls were taken from 
the screening district only. The first analysis estimated the risk of death from breast cancer in 
women in the screening district relative to the control district ( analogous to estimating the risk of 
death from breast cancer in the intervention group compared with the control group in a 
randomised controlled trial of breast cancer screening). The second analysis estimated the relative 
risk for women who had at some time been screened compared with women who had never been 
screened in the screening district alone. The second study was carried out to assess the extent of 
selection bias in a case-control study carried out in a population where all the women had been 
offered screening. The relative risk in the first study was 0.76 (95% CI 0.54-1.08), suggesting a 
twenty-four percent reduction in breast cancer mortality in the screening district compared with the 
comparison district. The relative risk in the second study was 0.51 (95% CI 0.27-0.98). 
A cohort analysis of breast cancer incidence and mortality in the two districts was carried out which 
produced a relative risk of breast cancer death for the screening district compared with the 
comparison district of0.79. The incidence of breast cancer in the comparison district was the same 
as that in non-attenders, but breast cancer mortality was higher in the non-attenders, suggesting that 
women at higher risk of dying from breast cancer had been less likely to take part in screening. The 
authors concluded that a case-control study carried out within a population that had been offered 
screening gave a biased estimate of the overall benefit of screening to the population. 
The study by Moss et al suggested that, in order to reduce the effect of selection bias in a case-
control study, it would be necessary to include information from a comparison district where 




experimental approach (section 3.1.2) by the problem that differences in breast cancer mortality 
between the two districts could be due to factors other than the presence or absence of the 
screenmg programme. 
The second major limitation is that, although a case-control study could be carried out over a 
shorter time period than either a randomised controlled trial or a non-randomised trial of breast 
cancer screening, the time required would still have been considerable. Because breast cancer 
screening takes about five years to reduce breast cancer mortality (Rutqvist et al 1990), a case-
control study to evaluate the effectiveness of the pilot programme could not be carried out earlier 
than five years from the start of the programme. 
3.1.4 Goal-attainment method 
Once randomised controlled trials had shown that breast cancer screening was efficacious the 
possibility arose that new programmes could be evaluated by comparing them with the screening 
programmes that were studied in the randomised controlled trials. 
Another approach to assessment is to examine the process of care itself rather than its outcomes. 
This is justified by the assumption that one is interested not in the power of medical technology to 
achieve results, but in whether what is now known to be "good" medical care has been applied. 
Judgements are based on considerations such as the appropriateness, completeness and redundancy 
of information obtained through clinical history, physical examination and diagnostic tests; 
justification of diagnosis and therapy; technical competence in the perfonnance of diagnostic and 
therapeutic procedures including surgery; evidence of preventive management in health and 
illness; coordination and continuity of care; acceptability of care to the recipient and so on. This 
approach requires that a great deal of attention be given to specifying the relevant dimensions, 
values and standards to be used in assessment The estimates of quality that one obtains are less 
stable and less final than those that derive from the measurement of outcomes. They may, 
however, be more relevant to the question at hand: whether medicine is properly practiced. 
(Donabedian 1966). 
It was suggested that early characteristics of programmes such as sensitivity and specificity, stage 
distribution, and detection rates could be used as surrogate endpoints for reduced breast cancer 
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be used to set goals for the evaluation of a pilot programme. The advantages of a goal-attainment 
evaluation of the pilot programme are outlined below: 
( 1) breast cancer screening could be offered with adequate monitoring to ensure that the benefits 
demonstrated in randomised controlled trials were delivered by the pilot programme. Screening is 
unlike other medical interventions because it is offered to people who are well, with the 
understanding that they will benefit from taking part. This meant that breast cancer screening 
should not have been offered to women unless the programme was organised and evaluated in such 
a way that the benefits could be attained. The effectiveness of screening could be evaluated against 
a standard devised from the results of programmes that had been shown to reduce breast cancer 
mortality. 
(2) the quality of the programme could be monitored so that the risks associated with screening 
could be minimised. This included ensuring that women received their results rapidly, and 
investigating ways to reduce the number of women recalled unnecessarily, thus minimising the 
anxiety related to positive tests. 
(3) the choice of characteristics to be monitored could be tailored to the particular requirements of 
the evaluation of the pilot programme. For instance aspects other than the likely effect on mortality 
could be measured, and compared with the results from existing programmes. Such aspects 
required in the evaluation of the Otago and Southland pilot programme included information on the 
acceptability and the economic efficiency of the programme. 
( 4) the results from this method of evaluation were available rapidly and did not require years of 
follow up. This also meant that if corrective action is needed it could take place early in the 
operation of the pilot programme. 
59 
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3.2 Comparing the possible methods of evaluation 
Randomised controlled trials are essential for assessing the efficacy of screening. Once efficacy had 
been demonstrated it was inappropriate and also impractical, because of the numbers of women and 
the time required, to use this method to evaluate the effectiveness of pilot programmes. A 
non-randomised comparison was also rejected because factors other than the effect of the screening 
programme could affect the results. Also this approach could not provide rapid results. A 
case-control study was not used because of the potential for selection bias. This could not be 
adjusted for easily in a case-control study because it is impossible to measure the direction or 
magnitude of selection bias except in a randomised controlled trial. Unless the study included 
women who had been offered screening and women who had not been offered screening ( eg: an 
appropriate comparison district as well as the screening district) selection bias would have been a 
problem. Also a case-control study could not show any effect on breast cancer mortality earlier 
than about five years from the start of the programme, since it takes this long before a reduction in 
breast cancer mortality is detectable (Rutqvist et al 1990). A goal-attainment evaluation using 
surrogate endpoints appeared to be the most practical and appropriate method for evaluating pilot 
programmes. Because of this, and recognising the limitations of other approaches, the evaluation 
of the Otago and Southland pilot programme used goals based on surrogate endpoints to predict 
the effect of the pilot programme on breast cancer mortality among eligible women. The evaluation 
also included the collection of information on acceptability and economic issues to supplement the 
goal-attainment method. Targets were selected based on the programmes which had been shown to 
be efficacious (programmes which had been evaluated in randomised controlled trials). The trials 
were examined in detail (section 3.6) to select goals (targets) that would suit the particular aims of 
the evaluation of the Otago and Southland pilot programme. 
3.3 Comparing the randomised controlled trials of breast cancer screening. Which trials 
should be used for the development of targets? 
Breast cancer screening programmes that were part of randomised controlled trials of screening 
could provide very useful information for designing an evaluation using surrogate markers. Once a 




that programme could be used as a gold standard for other programmes. But it was essential that 
the programmes were sufficiently alike in their design and execution for it to be realistic to compare 
them in order to develop targets for the pilot programme. The randomised trials were examined in 
detail to find out whether it would be appropriate to include them all in developing targets for the 
evaluation, whether any adjustments needed to be made when comparing the trials, and whether 
more emphasis should have been placed on the results from some trials than others. 
Table 3 .1 gives some characteristics of the randomised controlled trials. The Canadian trial is not 
included in this table because this trial differed from the others in its design which was to test the 
efficacy of screening rather than the efficacy of the offer of screening. 
3.3.1 Exclusion criteria in the trials 
There were differences in the exclusion criteria used in the randomised controlled trials. In the 
Swedish Two-Counties trial the total population of women aged forty and over was entered into 
the trial and no exclusions were documented, but most analyses have been restricted to women 
with breast cancer diagnosed after the date of randomisation. In the Malmo trial women with 
previously diagnosed breast cancer were included and staging was carried out according to the 
stage of the cancer diagnosed during the trial, irrespective of any previous diagnosis of breast 
cancer. In the Stockholm trial women with breast cancer diagnosed after randomisation but before 
screening were analysed separately. No information is given about women with breast cancer 
diagnosed prior to randomisation. In the Swedish overview all women with breast cancer 
diagnosed before the date of randomisation were excluded. 
Women who already have breast cancer may have a different prognosis from other women who 
take part in screening. Provided randomisation has evenly distributed these women between study 
and control groups, including or excluding them should not affect the results. In the Malmo study 
women with previously diagnosed breast cancer were included but separate analyses which 




Summary of Randomised controlled trials 
Trial HIP S2C MAL EDB STK 
Year started 1963 1977 1976 1979 1981 
J: 
Randomisation Individual Cluster Individual Cluster Day of birth 
\ 
Age range 40-64 40-74 45-69 45-64 40-64 
-'c. Study group 31000 77000 21000 23000 40000 
\ 
Control group 31000 56000 21000 23000 20000 
q 




c' interval (months) 12 24- 36* 21 12 28 
1st screen 
sensitivity (%) 82 96 78 92 86 
,',I,) 
1st round 
i participation (%) 65 89 74 61 81 











Years of follow up 


















































3.3.2 Definition of mortality outcomes in the trials 
Different end points for breast cancer mortality were used in the randomised controlled trials (Table 
3.2). Some trials defined death from breast cancer as "death with breast cancer as the primary 
cause given on the death certificate" while others used less rigorous definitions such as "death with 
breast cancer as the underlying cause" or "death with breast cancer present at death". If death with 
breast cancer present at death is used as the definition, many more women could be included (for 
instance women who died in motor vehicle accidents or women who died prematurely from other 
diseases although they had also been diagnosed with breast cancer). The deaths of these women 
would not have been influenced by screening, but there could be more such women in the 
intervention group because screening diagnosed breast cancer earlier; (women in the control group 
who died from other causes may also have had breast cancer but not had it diagnosed because they 
had not been screened). Also if the less rigorous definition is used it is likely that larger numbers of 
women would be classified as having died from breast cancer. This could result, given the same 
number of subjects, in these trials producing results at a greater level of significance than if the more 
rigorous definition had been used. This problem was addressed in the Swedish overview (Nystrom 
et al 1993) and in a later paper (Nystrom et al 1995), where an independent review committee 
carried out a blinded assessment of mortality. Two definitions were used; "breast cancer present at 
death" and "breast cancer as the underlying cause of death". The results for "breast cancer as the 
primary cause of death" are not reported. Predictably, use of "breast cancer present at death" 
produced more deaths but the relative risks and ninety-five percent confidence intervals were 
similar with a relative risk of 0.78 (95% CI 0.68 to 0.89) for "breast cancer present at death" and 
0.77 (95% CI 0.67 to 0.88) for "breast cancer as the underlying cause of death" (Nystrom et al 
1993). 
3.3.3 Comparing the HIP trial with subsequent randomised trials of breast cancer screening 
The HIP trial differs from subsequent trials of breast cancer screening, in particular in its results for 
women under fifty. It is recognised that the quality of mammography in the early 1960's in the HIP 
trial was probably not as good as that in later trials (Smart 1994); but despite this the reduction in 
mortality found in the HIP trial was as good as or better than that found in the other trials. A 
possible explanation for this is that, in the absence of screening, the clinical diagnosis of breast 






This could mean that even inferior mammography would be capable of detecting cancer much 
earlier than it was generally detected during the 1960's. There is evidence for this, since the 
distribution of stage at diagnosis changed markedly from 1940 to 1979. By the 1970's a higher 
percentage of breast cancers was detected in a localised stage even though mammography was not 
widely available. Table 3 .3 shows the changing percentage of breast cancers registered in a 
localised stage with the Connecticut Cancer Registry from 1940 to 1979 (Roush et al 1987). 
It is consistent with this explanation that although the age-adjusted incidence of breast cancer has 
increased by fifty percent from 1965 to 1975 in America, the age-adjusted mortality has remained 
almost unchanged since 1960 (Fox 1979). Age-specific mortality rates for fifty to sixty-nine year 
old women have remained constant and those for forty to forty-nine year old women have declined 
since the mid-1960's even though the age-specific incidence increased during this time (Devesa et 
al 1987, Avila and Walker 1987) . 
The stage distribution at diagnosis reported for control women in the HlP study is similar to that 
for control women in later trials, although forty-six percent of control women in the HlP trial had 
node negative tumours compared with fifty-four percent of control women in the Swedish Two-
Counties trial (Shapiro et al 1988, Tabar et al 1992). Larger differences might have been expected, 
but the validity of such comparisons has been questioned because of changes in stage classification 
and also because staging in the HlP study was based on retrospective analysis of hospital records 
which is known to be inaccurate (Forrest 1990). Also it has been pointed out by Peto and Easton 
(Peto and Easton 1989) that diagnostic improvements tend to alter staging over time, so that a 
tumour diagnosed twenty years ago might be allocated a higher stage if it were diagnosed now, 
because it is easier to detect smaller tumours and micrometastases. So the tumours diagnosed in the 
HIP study could have been more advanced even though the reported stage distribution is similar to 













Mortality end-points used in the randomised controlled trials 
Endpoint 
death with breast cancer 
as the primary cause of death 
death with breast cancer 
as the underlying cause of death 
death with breast cancer 








Percentage of Cancers in Localised Stage 
Connecticut Cancer Registry, 1940 to 1979 
1940-49 1950-59 1960-69 
37.7 41.8 48.6 




Source: Roush GC, Holford TR Schymura MJ, White C. Cancer risk and incidence trends: the Connecticut 




A similar explanation has been given for the low mortality from breast cancer among Swedish 
women compared with other women in Europe. Although the age adjusted breast cancer incidence 
in Sweden is similar to that in Denmark, the Netherlands, and the UK (about sixty per hundred 
thousand per year) mortality is considerably lower (seventeen per hundred thousand per year 
compared with about twenty-eight per hundred thousand per year). The stage-distribution of 
breast cancer at diagnosis is different in Sweden, where women seem to present earlier and there 
are fewer women diagnosed with stage three and stage four cancers (Gad et al 1984). 
Later detection of breast cancer in the United States at the time of the HIP trial may have affected 
the results for women under fifty in particular. No randomised trial of breast cancer screening has 
provided convincing evidence that screening is beneficial for women under fifty. The HIP trial is 
the only one to have shown an effect even approaching the magnitude of that seen for women over 
fifty. But in the HIP trial, the effect of screening on breast cancer mortality in women under fifty 
may have been mostly due to clinical examination (table 3.4). This effect would not be seen in later 
trials if breast cancer was by this time being diagnosed earlier ( either due to greater awareness 
leading to earlier presentation or to better diagnosis) even in unscreened women. Table 3.4 shows 
the mode of detection of histologically confirmed cancers in the HIP trial (Shapiro et al 1988) 
compared with the mode of detection for cancers in the Edinburgh and Guildford screening 
programmes shown in Table 3.5 (UK Trial of Early Detection of Breast Cancer Group 1988b). It 
is clear that the proportion of breast cancers detected by mammography had increased in the later 
programmes compared with the HIP trial. 
The only trial to have shown an appreciable effect on breast cancer mortality for women under 50 is 
the HIP trial. However the HIP trial was carried out a decade earlier than subsequent trials. The 
HIP results may be due to the relatively delayed diagnosis of breast cancer that was occurring in the 
United States in the 1960's (Table 3.3), so that the lead time achieved by screening younger 
women was sufficient to make an impact on mortality. Earlier diagnosis since then may mean that 
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TABLE 3.4 
Health Insurance Plan trial histologically confirmed breast cancers 
Modality of detection (percent) 
Age at entry Number of Clinical Mammography Clinical and 
breast cancers only only Mammography 
40-49 40.0 57.5 25.0 17.5 
50-59 67.0 40.3 38.8 20.9 
60-64 25.0 36.0 32.0 32.0 
Source: Shapiro S, Venet W, Stra'C P, Venet L. Periodic screening for breast cancer: the health Insurance Plan 






UK Screening Programme First screen (mammography and clinical examination) 
Modality of detection (percent) 
Centre Number of Clinical Mammography Clinical and 
breast cancers only only Mammography 
Edinburgh 81.0 6.0 32.0 62.0 
Guildford 99.0 7.0 27.0 63.0 
Source: UK trial of early <letection of breast cancer group. Progress report of the UK trial of early detection of breast 
cancer. In: Day NE, Miller AB, (eds) Screening for breast cancer. Toronto: International Union Against 








3.3.4 The effect of self-selection for screening on comparisons of randomised controlled trials 
A randomised controlled trial with breast cancer mortality as the outcome measure is the best way 
to measure the efficacy of breast cancer screening, because the results will not be affected by bias. 
However when randomised controlled trials are compared with one another (for instance when 
setting targets for screening programmes), bias can be introduced. For example, in the Health 
Insurance Plan (HIP) trial the incidence of breast cancer in unscreened study group women was 
1.45 per thousand, while in control group women it was 1.87 per thousand (Shapiro 1977, Shapiro 
et al 1982). It has been suggested that women with a higher risk of cancer tended to self-select 
themselves for screening (Shapiro 1977, Shapiro et al 1982). A trial where the screened women 
have a higher underlying risk of breast cancer is likely to detect more early cancers and produce a 
greater mortality reduction than a trial which had a similar participation rate but no self-selection of 
high-risk women. Self-selection of high risk women did not occur in the other randomised trials of 
breast cancer screening, in fact in some of the trials the opposite occurred and there was self-
selection of low-risk women (Shapiro 1977, Shapiro et al 1982, United Kingdom Trial of Early 
Detection of Breast Cancer Group 1988a, Roberts et al 1989, Frisell et al 1986, Frisell et al 1991, 
Andersson et al 1988). This means that comparisons of the trials will be misleading because other 
trials with similar participation rates could not expect to match the results of the HIP trial unless 
they too had self-selection of high risk women as attenders. For instance the Edinburgh trial 
(Roberts et al 1989), with similar participation, sensitivity, and underlying breast cancer incidence 
showed self-selection that was in the opposite direction to the HIP trial (the non-attenders in the 
Edinburgh trial were at higher risk of breast cancer), and this may be one of the reasons that the 
Edinburgh trial did not achieve a comparable reduction in breast cancer mortality. 
Before comparing randomised controlled trials of breast cancer screening it would be useful to be 
able to adjust for differences in self-selection between the trials. An "adjusted participation rate" 
(the expected participation rate in the absence of self-selection) should be used. A method of 
calculating an adjusted participation rate was developed by the author and is described below. 
By comparing breast cancer mortality in the non-attenders and the controls the expected breast 
cancer mortality in screened women (in the absence of screening) can be calculated. In the absence 











been similar in the two groups. Since breast cancer mortality in the control group and in non-
attenders is known, it is possible to calculate what the breast cancer mortality would have been 
among attenders, in the absence of screening. 
If there is no self-selection m(na) = m(ctl) where m = breast cancer 
mortality 
na = non-attender 
ctl = control group 
If there is self-selection of 
high-risk women, then m(na) < m(ctl) 
If there is self-selection of 
low-risk women, then m(na) > m(ctl) 
If there had been no screening programme, the expected breast cancer mortality in the intervention 
group would have been the same as in the control group ( since the groups were produced by 
randomisation). If m( ctl) is the number of deaths per thousand control group women, then the 
expected number of deaths from breast cancer among a thousand intervention group women (in the 
absence of screening) should be the same as in a thousand control group women. 
m( ctl) = ~(int) where int = intervention 
group 
~ = expected mortality 
The intervention group is comprised of women who attended screening and women who did not, 
so the number of deaths in the intervention group is the sum of breast cancer deaths in attenders 
plus non-attenders: 
~(int)= G(a) + m(na) 








h}(int) cannot be observed, but can be estimated from m(ctl).· 
~(int) = m( ctl) 
Since allocation to the groups was at random, m(ctl) and ~(int) are the same: 
A 
m(ctl) = m(a) + m(na) 
and therefore the expected number deaths among the attenders (in the absence of screening) is: 
I\ 
m(a) = m(ctl) - m(na) 
The participation rate, adjusted for selection, is then: 
A m(a) x 100% 
m(ctl) 1 
For example, in the HIP trial the cumulative mortality rate (deaths per thousand women entered) 
was 2.7 in non-attenders and 4.3 in controls. Thirty-five percent of women in the intervention 
group did not attend screening. There was self-selection of high-risk women for screening in the 
HIP trial, since m( na) < m( ctl). 
For every two thousand women entered in the HIP trial there were a thousand women in the 
control group with 4.3 breast cancer deaths, and a thousand women in the intervention group, of 






The expected number of breast cancer deaths per thousand among attenders (in the absence of 
screening) was: 
I\ 
m(ctl) - m(na). m(a) = 
= 4.3 -0.95 
= 3.35 
The adjusted participation rate is: 
A 
100% m(a) X 
m(ctl) 1 
3.35 X 100% 
4.3 1 
= 78% 
It is clear that women at higher risk of dying from breast cancer were more likely to attend 
screening, since the thirty-five percent who did not attend screening experienced only twenty-two 
percent of the expected breast cancer deaths in the intervention group. In the absence of screening, 
seventy-eight percent of the deaths would have occurred among the other sixty-five percent of the 
intervention group. 
In the example from the HIP trial, because of the self-selection of women with a higher underlying 
risk of death from breast cancer, it is likely that the HIP screening programme would have had a 
higher breast cancer detection rate than programmes which had similar participation rates but no 
self-selection of high-risk women. The HIP results are equivalent to what would be expected if the 
screening programme had a seventy-eight participation rate but no self-selection of high-risk 
women, so the "adjusted participation rate" for the HIP trial is seventy-eight percent. Table 3.6 
shows adjusted participation rates for other breast cancer screening trials, calculated by the same 
method. Multiplying the participation rate by the sensitivity for each programme gives the 
"maximum breast cancer detection" which is the maximum percentage of cancers in the eligible 











Adjustment for self-selection in randomised controlled trials 
Cumulative breast cancer mortality 


























Maximum breast cancer detection for each trial 
Adjusted Max.imum Breast 
Participation sensitivity* Cancer Detection 
Trial: 
HIP 78% 82% 64% 
STK 77% 86% 66% 
S2C 77% 96% 74% 
EDB 55% 92% 51% 
MAL 53% 78% 41% 
* Sensitivity is defined as screen-detected cancers divided by the sum of screen-detected cancers plus interval 




defined as screen-detected cancers divided by the sum of screen-detected cancers plus interval 
cancers in the twelve months after screening. The maximum breast cancer detection should 
correlate with the mortality reduction achieved by the programme. The maximum breast cancer 
detection calculated using the adjusted rather than the unadjusted participation rate, correlates more 
closely with the reduction in breast cancer mortality for each trial (Table 3.8). 
When usmg the results from randomised trials to set targets for breast cancer screening 
programmes it is important to use an adjusted participation rate because otherwise it could seem 
(from the unadjusted HIP results) that a thirty percent reduction in breast cancer mortality in the 
eligible population is obtainable even if only sixty-five percent of the population participate in 
screening. In fact this would only be the case if self-selection of high risk women occurred in all 
screening programmes and it is clear from other programmes that this is not so. 
3.4 Summary 
The published literature about mammographic breast cancer screening has been reviewed in 
Chapter One, and the background to and requirements for the evaluation of the Otago and 
Southland pilot programme were described in Chapter Two. Possible methods of evaluating a pilot 
programme have been discussed in this chapter. The randomised controlled trials have also been 
compared in detail in this chapter to establish whether it is appropriate to consider all the trials 
when developing targets for the pilot programme, whether any adjustments should be made when 
comparing the trials, and whether more emphasis should be placed on the results from some trials 
than others. 
Although the trials differed in their endpoints for breast cancer mortality and in the criteria for 
excluding women, adjusting for the differences does not affect the results appreciably. This 
suggests that despite differences in endpoints and exclusion criteria the various trials can be 
compared and may be used to develop targets for the pilot programme. It is likely that in the HIP 
trial the time of diagnosis of breast cancer was brought forward relative to the usual time of 
diagnosis in the United States in the 1960's, which was probably later than the usual time of 




































the HIP trial, and also explains some of the differences between the HIP and the other trials. 
Because of this, less emphasis should be placed on the HIP trial relative to the later trials, especially 
when developing targets for the pilot screening programme. 
When setting a target for participation based on the trials it was important to adjust for the self-
selection that occurred among the participants in all the trials, so that the target for participation in 
the pilot programme was not inadvertently set too low. It was recognised that self-selection could 
occur in the pilot programme, and that it would not be measurable, but by recognising this 
possibility, and considering the lowest and highest levels of participation found in the trials, an 
appropriate target was set that would still allow for some self-selection in either direction. 
Chapter Four describes the derivation of appropriate targets for the evaluation of the Otago and 
Southland pilot programme. The targets based on the randomised controlled trials of breast cancer 
screening were chosen to provide a standard against which the performance of the Otago and 
Southland pilot programme could be evaluated. The targets related to the three key areas of 
effectiveness, acceptability, and economic efficiency that had been specified for the evaluation 
(Skegg et al 1988) and these targets are described in Chapter Four, with an explanation for the 
choice of each target. 
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CHAPTER FOUR 
The Derivation of Targets for the Evaluation 
Introduction 
The Otago and Southland pilot breast cancer screening programme was established in 1991 
(Elwood et al 1991 ). In this programme two-view mammography is offered every two years to an 
eligible population of about nineteen thousand women aged between fifty and sixty-four and living 
in Otago and Southland. The programme has two fixed screening centres at Dunedin and 
Invercargill hospitals, a mobile screening unit that travels to rural areas, and two specialist 
assessment clinics ( at Dunedin and Invercargill) for women who are referred for further 
investigations after being screened. 
An evaluation of the pilot programme was designed as recommended by the Skegg report (Skegg 
et al 1988) to provide information about the acceptability, effectiveness, and economic efficiency of 
breast cancer screening in New Zealand. The evaluation measured the performance of the pilot 
programme against targets based on the results of successful programmes. The results from the 
evaluation were regularly reported to the programme staff, and were used in the implementation 
and management of the pilot programme. The evaluation was designed to provide information 
about the acceptability, effectiveness, and economic efficiency of population-based breast cancer 
screening in New Zealand as specified in the Skegg report (Skegg et al 1988). The evaluation 
protocol was approved by both the Otago Area Health Board and Southland Area Health Board 
ethics committees. 
To try to measure the effect of the pilot programme on breast cancer mortality directly would have 
taken many years and would have been hampered by small numbers and the lack of a suitable 
comparison group, as discussed in Chapter Three. Instead it was decided that surrogate measures 







evaluation was designed to compare early characteristics of the pilot programme with those of 
established programmes which had been shown to reduce breast cancer mortality. Results from 
five randomised controlled trials of screening (Shapiro 1977, Shapiro et al 1982, Tabar and Gad 
1981, Tabar et al 1985, Andersson et al 1988, Roberts et al 1989, Frisell et al 1986, Rutqvist et al 
1990) were used in this comparison. The Swedish Two-Counties and Health Insurance Plan trials 
showed significant reductions in breast cancer mortality, while the other three trials showed smaller, 
non-significant reductions. The aim was for the pilot programme to share the early characteristics 
of the programmes which had been shown (in randomised controlled trials) to reduce breast cancer 
mortality in the longer term. 
Information that could be used for quality control was also collected. For instance although the 
specificity of the screening test would not directly affect breast cancer mortality, a small drop in 
specificity would adversely affect a large number of women (section 4.1.2). At worst, it would be 
possible for a programme with extremely low specificity to be effective in reducing breast cancer 
mortality but be unsustainable because of the cost to women and to the programme, of unnecessary 
investigations. 
The evaluation method used targets based on relevant characteristics of the prevalence screen of 
programmes that had been shown to be effective and efficient in the longer term. Both quality 
control and the effect of the programme on breast cancer mortality were addressed. If the pilot 
programme met the targets it would be assumed to be operating as well as successful programmes 
were at the same stage. Targets were developed for the first screening round (prevalence screen) 
of the pilot programme (the development of targets for subsequent screening rounds is discussed in 
Chapter Seven). The targets are described within the three specified evaluation areas of 
effectiveness, acceptability, and economic efficiency: 
Effectiveness 
The development of targets to measure the effectiveness of the pilot programme is described in 
section 4. 1. The effectiveness targets included targets for the identification and invitation of eligible 
women (section 4.1.1 ), screen sensitivity and specificity (section 4.1.2), the referral rate and the 
benign to malignant biopsy rate ( section 4 .1.3 ), and the ratio of cancers detected at the prevalence 





programme and published data on tumour size, grade, and stage of prevalence screen cancers were 
also made. The results of the evaluation of the effectiveness of the pilot programme are described 
in Chapter Five. 
Acceptability 
Methods for evaluating the acceptability of screening were also developed (section 4.2). A target 
participation rate (section 4.2.1) was used to assess the acceptability of screening. Several surveys 
were conducted to measure acceptability (section 4.2.2), including a pre-screening survey, and 
surveys of women who took part in screening, and who attended the assessment clinics. Women 
who declined an invitation to take part in the programme were also surveyed. These surveys are 
described briefly in this chapter and in detail in Chapter Six. 
Economic efficiency 
There were two issues to be addressed in the economic evaluation; first whether the pilot 
programme could provide screening in a way that would not be "wasteful of scarce resources" 
(Skegg et al 1988), and second to be able to extrapolate from the pilot programmes so that an 
estimate of the cost of a national breast cancer screening programme could be made. The 
evaluation of the economic efficiency of the pilot programme is described and the results discussed 
in detail in Chapter Seven. 
The methods of data collection used in the evaluation are described briefly in section 4.4. More 
detailed methodology is given in Chapters Five and Six. The relevant characteristics of the 
reference breast cancer screening programmes are shown in Table 4.1 with the targets set for the 
pilot programme. The reasons for choosing these targets for the pilot programme are discussed in 
detail below (sections 4.1 to 4.3). 
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4.1 Measuring the effectiveness of the pilot programme 
4.1.1 Identification of eligible women 
The aim of a screening programme is to reduce the impact of breast cancer on the eligible 
population. To achieve this as many eligible women as possible must be identified and invited to 
take part in the programme. In the Health Insurance Plan (HIP) trial all eligible women could be 
identified from the HIP insurance records (Shapiro 1977, Shapiro et al 1982). In Sweden and the 
Netherlands eligible women were identified from population registers which were extremely 
accurate (Tabar and Gad 1981, Tabar et al 1985, Andersson et al 1988). In Edinburgh eligible 
women were identified through general practice registers, but these were found to be inaccurate 
with the eligible population overestimated despite some eligible women not being included (Roberts 
et al 1989, Bowling and Jacobsen 1989). 
In New Zealand the electoral roll is the closest approximation to a population register. It is 
compulsory for all New Zealand citizens to register on the electoral roll once they reach the age of 
eighteen. Maori have the option of registering on either the general electoral roll or the Maori 
electoral roll. In 1991 it became possible to obtain lists of voters within certain age-groups from 
the electoral roll centre, for health-related purposes. The actual ages or dates of birth of voters are 
not released, but a lists of names of voters within designated age-ranges can be obtained for each 
electorate. The electoral roll centre does not separate voters according to gender, so any lists 
obtained include males and females. The electoral roll is estimated to have only about ninety-three 
percent coverage (Department of Statistics 1984) which means that not all eligible women could be 
identified and invited to be screened using this source alone. Some women who are not on the 
electoral roll could be identified and invited through general practice age-sex registers. The target 
set for the pilot programme was to identify at least ninety percent of the eligible women. The target 
was to be measured by comparing the number of eligible women in the census with the number 
who could be identified, with names and addresses, using a combination of the electoral roll and 
general practice age-sex registers. 
The participation rate was defined as the proportion of invited women who were screened as a 
result of the invitation. In order to approach or exceed the lowest recorded participation rate for 







Characteristics of the first screening round of established mammographic screening 
programmes and targets for the pilot programme 
Characteristic Programme 
to be evaluated 
HIP S2C STK MAL EDB 
Identification of eligible 
women 100% 100% 100% 100% 90% 
Participation * 78% 77% 77% 53% 55% 
Coverage 78% 77% 77% 53% 50% 
Sensitivity# 82% 96% 86% 78% 92% 
Specificity 96% 95% 97% 97% 
Referral rate 5% 5% 1.5% 1.7% 3% 
Biopsy rate 3% 1.5% 1.2% 1.0% 
Benign : malignant ratio 4: 1 2: 1 1 : 2 0.7: 1 2: 1 
Reduction in mortality 29% 31% 24% 4% 20% 
Screen prevalence / expected 
incidence 1.3 3.2 2.0 2.0 3.8 
* Randomised controlled trial results adjusted for selection effect (Chapter Three, section 3.6.3) 





















percent or higher in the first screening round. 
The participation rate is linked to the identification of eligible women, in that the two combined 
produce the coverage of the eligible population. With over ninety percent identification of eligible 
women a participation rate of seventy-eight percent would result in more than seventy percent 
coverage (seventy percent of women in the target population being screened). Both the H1P and 
Swedish Two-Counties programmes had over seventy percent coverage, but they had been able to 
identify and invite one hundred percent of their target population, whereas the pilot programme 
would not be able to do this. A target of seventy percent coverage was chosen because this seemed 
the highest possible coverage that could realistically be achieved in a programme that lacked a fully-
inclusive population register. 
4.1.2 The screening test 
It was important for the radiologists in the pilot programme to match the standard of film reading 
achieved in successful programmes. It was thought that films from established screening 
programmes (where the outcome from each film is known) could be used as a "gold standard" if 
such films could be obtained. In the Otago and Southland pilot programme each. woman's films 
were read by two radiologists. The radiologists divided the screened women into two categories 
on the basis of their screening films; those who required further investigation, and those who did 
not. It was decided to assess inter- and intra-rater reliability using coefficient kappa to measure 
agreement. This had rarely been done in breast cancer screening programmes; in the few studies on 
inter-rater reliability for mammography, radiologists achieved kappa scores of 0.8 for agreement 
on the classification of parenchymal pattern (Boyd et al 1986). Reported kappa scores for 
recommendation for further action were not as high (up to 0.6) however these had been based on 
four possible recommendations rather than two where it may be possible to achieve greater 
agreement (Boyd et al 1982, Boyd et al 1986, Jannarone et al 1987). It is important for inter-rater 
reliability to be high, but this must be combined with high sensitivity and specificity. High inter-
rater reliability would be irrelevant if the sensitivity were low ( all this would mean is that both 
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Repeat mammograms 
Poor technical quality of some films could hamper their interpretation. It was important to maintain 
good technical quality so that women were not recalled unnecessarily (Breast Cancer Screening 
Working Group 1987). It is possible to keep the number of mammograms that have to be 
repeated for technical reasons alone as low as 0.4 percent (Sickles et al 1987). Technical quality 
assurance for the Otago and Southland pilot programme was the responsibility of the Otago 
University Departments of Radiology and Medical Physics. From the time that the evaluation 
protocol was first developed, a medical physicist was involved so that information about technical 
quality was part of the feedback given to the programme staff The number of extra films taken, 
and the number of women recalled for technical reasons were recorded in the evaluation, as an 
indication of the technical quality of mammography in the pilot programme. The aim was to 
maintain the number of women referred for technical reasons toward the lower end of the range 
reported for other screening programmes. Technical recall rates in other breast cancer screening 
programmes ranged from 0.4% in the United States (Sickles et al 1987) to 3.8% in Australia 
(Rickard et al 1991). 
Specificity 
It is difficult to measure sensitivity and specificity during the first screening round because some 
false negative results cannot be identified until the second round. However it was possible to 
estimate sensitivity and specificity in the shorter term for the evaluation. Specificity is the 
proportion of women without disease who are correctly identified as negative by the screening test. 
If a test has high specificity it means that only a very small proportion of women have false positive 
tests. Achieving high specificity is important in quality control in order to minimise the number of 
women undergoing unnecessary investigations as a result of false positive tests. Specificity can be 
estimated early in the screening process. It is possible to estimate specificity before the second 
screening round by dividing all negative tests (including false negatives) by the sum of all negatives 
and false positives (Miller 1985, Morrison 1985). This is an adequate estimate of specificity 
(although false negatives have been included in the numerator and the denominator) because the 
number of false negatives is very small in relation to the number of true negatives. 
The target set for specificity in the screening programme was based on results from the randomised 
controlled trials of screening (Table 4.1) and European screening programmes. All had specificities 
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of ninety-five percent (Breast Cancer Screening Working Group 1987, Gad et al 1984) or greater. 
The target for specificity in the pilot programme was therefore set at ninety-five percent. 
High sensitivity is more important than high specificity in reducing breast cancer mortality, since 
sensitivity is the ability of the test to correctly identify women with breast cancer. A small drop in 
specificity would not influence mortality greatly but would cause a considerable number of women 
to undergo unnecessary investigations. High sensitivity is sometimes achieved at the expense of 
specificity, since lowering the threshold of suspicion in order to miss very few women with breast 
cancer usually means that the number of false positive tests increases, and specificity drops. This 
trade-off, and the importance of reducing breast cancer mortality were acknowledged when the 
evaluation was planned; the target for specificity was set at the lower end of the range published for 
successful breast cancer screening programmes (Table 4.1). 
Sensitivity 
It was important to estimate sensitivity because this could be used to help predict the effect of the 
programme on breast cancer mortality. Sensitivity has been measured in screening programmes in 
three different ways. The three methods for estimating sensitivity in breast cancer screening 
programmes are described below: 
Method One defines sensitivity as screen-detected cancers divided by the sum of screen-detected 
cancers plus interval cancers in the following twelve months. The disadvantages of this method are 
(i) it includes cancers that were not detectable at screening (but also excludes slow-growing cancers 
that were detectable at screening but were not detected clinically within twelve months), (ii) it may 
include non-progressive cancers in the numerator, thus overestimating sensitivity, and (iii) it 
overestimates sensitivity for all programmes except those with a one-year screening interval. 
Method Two estimates sensitivity by the formula 1 - PI1 where PI1 is the proportional incidence of 
interval cancers (Day 1985). In the year after screening, screened women should have a reduced 
incidence of breast cancer compared with the incidence that would have been expected in the 
absence of screening. This happens if screening has successfully detected breast cancer early (if it 
has detected cancers that would otherwise have appeared later). One way of estimating this is to 
compare the number of interval cancers to the number of cancers diagnosed over the same period 
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in a control group. In a randomised controlled trial a control group is available, but in other 
situations an historical comparison group can be used provided there is no evidence of a change in 
the underlying incidence of breast cancer over the time of the study. If the number of interval 
cancers is low compared with the expected incidence of cancer it suggests that the screening test is 
picking up many of the breast cancers that would otherwise have arisen in the following year. 
Subtracting the proportional incidence from one gives an estimate of the sensitivity of the screening 
test; if the proportional incidence is five percent it suggests that ninety-five percent of cancers were 
detected early by screening. Calculating the expected breast cancer incidence in the screened group 
in the absence of screening (Day et al 1989) is straightforward: 
The incidence rate in the total population, It = Pia + ( 1-P)Ina where the P is the participation rate, 
Ia is the incidence rate in attenders 
Ina is the incidence rate in non-
attenders. 
The expected incidence in the screened group, in the absence of screening, is therefore: 
Ia = !1 - (1-P)Ina 
p 
It is the incidence in the control group (in a randomised controlled trial) or in an historical 
companson group. 
The advantage of this method is that it relates interval cancers to the number of cancers that would 
have been expected to develop in the screened women in the absence of screening (the expected 
number of cancers is estimated from the incidence in a control group or an historical comparison 
group), and comparisons between programmes are therefore not affected by differences in 
prevalence, nor by selection bias. Overdiagnosis bias is avoided because non-progressive cancers 
are not included in the estimation of sensitivity (since the calculation is based on a comparison of 
interval cancers with expected cancers). 
Method Three defines sensitivity as screen-detected cancers divided by the sum of screen-detected 
cancers plus cancers missed at screening. This method involves re-reading the previous films for all 
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women diagnosed with breast cancer in the interval between screens and at re-screening (used in 
Malmo and Canada). This method cannot be used before the second screening round. 
The important issue for the evaluation was not necessarily which method is better at estimating the 
sensitivity of the screening test, but which could be used to produce reliable early targets for 
evaluating the programme. Method Three is not useful before the second screening round. 
Methods One and Two can be used during the first screening round. Method One requires 
information about cancers detected by screening, and interval cancers. This information is relatively 
easy to obtain because screened women are usually followed up. Method Two requires 
information about interval cancers and also cancer incidence in an unscreened group (historical, or 
women not yet invited for screening) and cancer incidence in women who do not participate in the 
screening programme. Method Two should give the most accurate estimate of sensitivity but 
Method One has the advantage of being easily calculated early in the programme. Although 
Method One overestimates sensitivity it can be used as an interim target. Targets for sensitivity 
estimated by both methods are given in Table 4.2. 
To reduce breast cancer mortality in the eligible population a screening programme must be able to 
(a) identify a high proportion of the women with early breast cancer, and (b) include enough 
women for the group as a whole to benefit. The product of sensitivity multiplied by coverage is the 
maximum percentage of breast cancers that can be detected in a population-based screening 
programme (Table 4.3). The lilP trial had a sensitivity of eighty-two percent with sixty-five 
percent coverage ( equivalent to seventy-eight percent coverage without self-selection). Both 
sensitivity and coverage were considerably higher than this in the other trials except Malmo and 
Edinburgh. The target set for sensitivity in the Otago and Southland pilot programme was eighty-
five percent sensitivity (Method One) and the target set for coverage of the eligible population was 
seventy percent (section 4.1.1 ). The eighty-five percent target for sensitivity was chosen because it 
was comparable with sensitivity in the randomised controlled trials, and because together with 
seventy percent coverage of the eligible population it would give the programme a maximum breast 
cancer detection rate of sixty percent ( eighty-five percent sensitivity multiplied by seventy percent 











































(I. C. = interval cancers within twelve months from screening) 
























Sensitivity and coverage in screening programmes 
Coverage of Test 
Eligible Population Sensitivity 
Trial 
HIP 78% 82% 
STK 77% 86% 
S2C 77% 96% 
EDB 50% 92% 
MAL 53% 78% 
* Participation adjusted for selection (Chapter Three, section 3.6.3) 
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4.1.3 Referral for assessment 
The number of women referred will be influenced by the sensitivity and specificity of the screening 
test. If referral rates are low it may be that the test accurately distinguishes between women who 
require further assessment and those who do not, but alternatively it could mean that the sensitivity 
of the test is low and that women who require further assessment have not been referred. Referral 
rates in successful programmes have been five percent or less. In the Swedish Two-Counties trial 
there was a five percent referral rate in the first screening round which decreased to 2. 5 percent in 
later rounds. However the Swedish programme had a two-stage referral process where some 
women were recalled for more detailed mammograms, and only those with persistent abnormalities 
were then referred for assessment (Gad et al 1984). It is not clear from published reports how 
many of the other programmes had similar two-stage referral procedures. In the HIP study the 
referral rate was five percent but this was averaged across screening rounds. The rate in the first 
round was probably higher than five percent, since referral rates are usually higher in the first than 
in subsequent screening rounds (Kopans and Swann 1988). In the pilot programme it was decided 
that all symptomatic women should be referred irrespective of the results of their mammograms. 
Because the referral rate in the Swedish Two-Counties trial was five percent in the first screening 
round after detailed mammography, and possibly higher in the first round in the HIP trial, and 
because the pilot programme also had a policy of automatically referring all symptomatic women, 
the target for the first round of the pilot programme was set at between five and ten percent, but 
with the expectation that it would decline in subsequent screening rounds. The purpose of further 
assessment is to distinguish between women who require biopsies and those who do not. Because 
having a biopsy is likely to cause women anxiety and since many biopsies resulting from screening 
require hook-wire localisation and a general anaesthetic, it is important to minimise the number of 
unnecessary biopsies. Provided test sensitivity and specificity are adequate, the biopsy rate and 
benign to malignant ratio indicate how well the assessment process identifies women who require 
biopsies. Successful screening programmes in Europe have had benign to malignant biopsy ratios 
between 1.7 : 1 and 3 : 1 (Breast Cancer Screening Working Group 1987). The ratio is usually 
higher during the establishment of screening programmes (Kopans and Swann 1988, Stockdale et 
al 1988). In recognition of this the target for the Otago and Southland pilot programme was set at 




4.1.4 Breast cancer detection 
Some measures of clinical outcome are important predictors of the programme's effect on breast 
cancer mortality. Day et al ( 1989) suggested, based on the results from the Swedish Two-Counties 
trial, that the prevalence of breast cancer at the first screening round should be at least three times 
the expected incidence of breast cancer in the absence of a screening programme, since taken 
together with the incidence of interval cancers, this gives an indication of the ability of the screening 
programme to detect cancers early. The stage-distribution of cancers detected by screening can be 
recorded for comparison with the stage-distribution seen before the introduction of screening. The 
stage-distribution of screen-detected cancers was suggested as a surrogate endpoint for reduced 
mortality because it appeared to explain almost all the reduction that occurred in the Swedish Two-
Counties trial (Dufly et al 1991, Tabar et al 1992). The problem with using stage-distribution as a 
surrogate measure is that length and overdiagnosis biases would tend to shift the stage-distribution 
of screen-detected cancers towards the earlier stages, and it would be possible for a shift in stage 
distribution to occur due to the lead-time resulting from screening, without a concomitant reduction 
in mortality. In fact stage-distribution did not appear to explain the reduced mortality in the United 
Kingdom trial of early detection of breast cancer (Moss et al 1994). To avoid the problem of bias 
affecting stage-distribution, the absolute rate of advanced breast cancer can be assessed after about 
the third year of screening, as this is an indicator of the mortality rate expected in future years (Day 
et al 1989). Stage-distribution can only be used as an approximate indicator of the likely effect of 
the programme, and must be combined with other surrogate endpoints, especially in the prevalence 
screen, when it is more likely to be affected by length bias (Dufly et al 1991). Because stage-
distribution and the absolute rate of advanced cancers are both better used in the incidence screen, 
they have not been included as targets for the evaluation of the first round of the pilot programme . 
4.2 Measuring the acceptability of the pilot programme 
4.2.1 Participation in screening 
The lowest participation rate for a successful programme was sixty-five percent in the HIP trial. 
Because all the women in the trial were identified from the HIP insurance records this represented 
sixty-five percent of all the eligible women. However in the HIP trial women with a higher risk of 




means that the HIP screening programme detected more women with breast cancer than would be 
expected from a sixty-five percent participation rate. In other programmes the selection effect was 
different, but it is possible to adjust participation to take account of this as described in Chapter 
Three, section 3.6.3 (Tables 3.6 to 3.8). In order to approach or exceed the lowest recorded 
participation rate for successful programmes, the pilot programme has a target participation rate of 
seventy-eight percent or higher in the first screening round. With the identification of ninety 
percent of eligible women using the electoral roll, the screening programme would have a coverage 
of seventy percent of the target population and thus seventy percent of the target population would 
be screened. Supplementing the electoral roll with general practice age-sex registers would be 
likely to improve identification of eligible women. 
4.2.2 Surveys of the acceptability of screening 
Several surveys to find out about the acceptability of screening were carried out. The first was a 
pre-screening survey which was conducted before the introduction of the screening programme, in 
order to identify characteristics of eligible women, and of a screening programme, that would be 
likely to affect participation. Surveys of screened women and women who attended the assessment 
clinics were also carried out. The purpose of these surveys was to find out about satisfaction with 
the service, to provide feedback for programme sta.B:: to obtain an indication of future participation, 
and to collect information about costs to women which would be used in the economic analysis of 
the pilot programme. A survey of non-attenders was carried out to discover whether there were 
aspects of the screening programme that could be changed to encourage these women to attend, 
and improve participation. These surveys are described in detail in Chapter Six. 
4.3 The economic evaluation of the pilot programme 
The economic evaluation of the Otago and Southland pilot programme was coordinated by Dr 
Nancy Devlin, a health economist who acted as a consultant for the evaluation of the pilot 
programme (Devlin NJ et al 1993). The objective of the economic evaluation was to determine 
whether screening could be introduced in New Zealand "in a way that is effective from an 




programme (and, by extrapolation, a national programme) would be a worthwhile use of health 
resources, and how it compared with alternative uses of those resources. Information was 
collected about the costs associated with the pilot programme, including the costs of running the 
programme, and costs to women taking part (collected in the surveys of screened women). With 
this information estimates were made of the· cost per woman screened and the cost per cancer 
detected in the first round of screening. 
These estimates were compared with those from existing breast cancer screening programmes to 
establish whether the pilot programme screened women and detected breast cancer for similar 
costs. After several years it will also be possible to estimate the cost per year of life saved, based on 
the number and stage distribution of cancers detected in the pilot programme, and on predictions of 
resulting life years gained. The predictions will be based on other programmes where it was 
possible to measure life years gained by comparing the group offered screening with a control 
group, with a follow up period of many years. The results from the economic evaluation of the 
pilot programme are presented as Appendix Two, and summarised and discussed in Chapter 
Seven. 
4.4 Data collection for the evaluation 
The collection of data for the evaluation is discussed in detail in Chapters Five and Six. A 
description of the data collection systems that were implemented at the start of the evaluation is 
given here. 
Initially it was hoped that the pilot breast cancer screening programme would have a stand-alone 
computer system, adapted from the computer system of an established screening programme. This 
was not possible because of Dunedin Hospital's requirement for the pilot programme to use its 
existing radiology computer system. This computer system had been designed for booking 
appointments, generating letters, and recording all investigations and results. Some adaptations 
were made to the system to allow for instance, results from double reading of mammograms, and 




Because of the number of women who would be talcing part in the screening programme, it was 
decided that as much data as possible for the evaluation should come directly from the pilot 
programme's computer system, rather than having separate data collection systems for the 
evaluation. It was also thought that this would be more accurate, since all the information about 
screened women would be automatically entered into the pilot programme's computer system. 
Each woman who attended the screening programme was allocated a national master patient index 
(NNIPI) number as a unique identifier, so that her records could be matched with Dunedin Hospital 
records. At the commencement of the pilot programme Southland Hospital intended to change to 
the NMPI system, but this did not eventuate. The Southland women were identified using 
Southland hospital identification numbers instead. 
The evaluation team specified the routinely collected data they would require, and a programme 
was written by the computer consultants who were modifying the Dunedin Hospital radiology 
software, so that this information could be downloaded regularly to the evaluation database. The 
information that was requested by the evaluation team is given as Appendix Three, and included 
personal information such as a unique identifying number (the National Master Patient Index or 
NMPI number), the woman's date of birth, ethnic group, a domicile code, the method of identifying 
that woman ( eg: electoral roll, general practice register, self-referred), and her eligibility for 
screening. For each screening visit information about the ~ethod of invitation, the screening centre 
(Dunedin, Invercargill, or mobile), the time and date of the appointment, the number of films ( and 
reason for any extra films), the result of the screen and the date the result was produced, results of 
assessment (if applicable), and the final result (whether or not the women was diagnosed with 
breast cancer) was to be downloaded. The information for each screen was flagged with the 
screen number and the identification number so that a woman's entire screening history could be 
linked with her personal information into one file which was identified by the NMPI number. 
This information was downloaded at regular intervals and then analysed using SPSS-X (Statistical 
Package for Social Sciences 1990) .. A separate programme was written to convert film reading 
results into a separate ASCII file. The information from these files was then used to evaluate the 
screening and assessment phases of the programme, including film reading, referral rate, biopsy 
rate, benign : malignant biopsy ratio, and breast cancer detection rate. Initially the download was 








because the Waikato programme used a different computer system this did not eventuate, and so 
separate analyses were carried out for each pilot programme: 
Quality control measures were undertaken, to ensure the validity of data that had been downloaded 
from the screening programme computer system for the evaluation of the Otago and Southland 
Pilot Breast Cancer Screening Programme: 
At regular intervals Sheila Williams produced a printout of the National Master Patient Index 
(NMPI) numbers for those records where the dates on the download from the screening 
programme computer system were in question, or where there was missing data. Examples of 
inconsistent dates included where the woman's date ofbirth was inconsistent with the age-range for 
the screening programme, or where dates for screening and assessment appointments, and results 
were out of sequence. Using the NMPI numbers from the printout to identify each record, Ann 
Richardson manually searched the records at the screening centres (this involved trips to 
Invercargill for Southland records), to extract the correct information. The correct data was then 
entered on the screening programme computer system. Sheila Williams then produced another 
printout from the next download, to check that the previous inconsistencies had been rectified. 
Women who had biopsies were identified in the evaluation download. The screening programme 
also kept a manual record of women who had had biopsies ( a file containing copies of the histology 
reports for screened women was kept at the screening centre). At regular intervals a printout from 
the evaluation download was compared with the manual biopsy records at the screening centre. 
Any discrepancies were followed up by obtaining the woman's screening records. Where 
necessary, corrections were made to the data that had been entered on the screening programme 
computer system (and thus to the evaluation download). The need for such corrections was 
extremely rare. 
Women diagnosed with breast cancer through the screening programme were identified from the 
evaluation download. This information was then checked against two separate sources. Firstly it 
was checked against the biopsy file held in the screening centre which contained copies of all 
histology reports for women who had been referred for a biopsy as a result of screening, to ensure 




correctly identified on the evaluation download. Where there were inconsistencies, the NMPI 
number was used to find the woman's records to check, and where necessary, correct the 
infonnation on the computer system. Secondly, infonnation on women diagnosed with breast 
cancer was checked against the pathology records from all the pathology laboratories in Otago and 
Southland. There were four such laboratories; two private and two hospital pathology laboratories 
in Dunedin and Invercargill. Obtaining this information was important, both to validate the data on 
the evaluation download, but also to identify women with interval cancers. In Dunedin information 
about breast histology in all women aged fifty and over was collected from the Dunedin Hospital 
Pathology Department computer system, and the NMPI number was used to detennine whether 
the women were diagnosed as a result of screening or not. Infonnation on breast histology for 
Southland women was produced from the Southland Hospital pathology computer system. The 
Southland Area Health Board did not adopt the NMPI system which meant that printouts with 
patient numbers could not be used to identify screened women. Whenever a woman over fifty was 
diagnosed with breast cancer through the Southland Hospital Pathology Department a copy of 
histology report was routinely sent to the evaluation coordinator, and for the private pathology 
laboratories (where smaller numbers were involved) the evaluation coordinator requested copies of 
the fonns at regular intervals. In each case the histology form had the woman's name blanked out. 
Date of birth was used to look for possible matches with the screening register, and where there 
were matches and the name was required, the woman's surgeon asked her permission to release her 
name for the evaluation. This provided a method of identifying women with breast cancer 
diagnosed outside the programme, yet still maintaining confidentiality between the pathologist and 
the patient. The methods used to collect data from the pathology laboratories are also described in 
detail in Chapter Five, section 5.4. 
Data that could not be collected routinely was collected manually or in the fonn of surveys. Before 
the screening programme began a survey of general practitioners in Otago and Southland was 
carried out to discover what infonnation practitioners needed about the pilot programme, and to 
find out how many general practitioners had age-sex registers, and whether they would be prepared 
to help with identifying and inviting eligible women (Chapter Five, section 5.1.2). A pre-screening 
survey was carried out to find out about women's attitudes towards breast cancer screening and to 
identify factors that could influence participation (Chapter Six, section 6.1). Surveys of women 





of the screening programme (Chapter Six, sections 6.3 and 6.4), and a survey of women who 
declined an invitation to screening was carried out to investigate reasons for non-participation 
(Chapter Six, section 6.5). 
Some of the data that should have been available from the evaluation download were not available. 
The reasons for this failure of the download, the alternative methods used to collect the data, and 
the ramifications of problems with data collection are discussed in Chapters Five to Seven. 
4.5 Summary 
Comparing interim measures with the results of established programmes has now become an 
accepted way of evaluating screening programmes. Day et al (1989) suggested a method for 
evaluating screening programmes which compared early parameters of new programmes with those 
of established programmes that have been successful in the longer term. Their method deals with 
the projected effect of the programme on breast cancer mortality and focuses on participation and 
test sensitivity in particular. However evaluation must also include quality control. Verbeek et al 
(1991) described a method of short-term quality control that addresses some aspects of quality 
control in the evaluation of screening. 
The evaluation method presented here uses short-term targets and addresses both quality control 
and the effect of the programme on breast cancer mortality. These targets were derived from the 
published results of randomised controlled trials of mammographic screening and together 
represent the minimum required for a pilot programme to be operating effectively. The results are 
fed back to the pilot programmes so that they can monitor their progress and so that corrective 
action can be taken if necessary (Table 4.4). Failure to reach one of the targets may be 
compensated for by far exceeding another relevant target. For example, a programme that is 
slightly below the target set for sensitivity but which attracts very high participation rates may still 














Biopsy rate and 
benign:malignant ratio 
TABLE 4.4 
Action on failure to reach evaluation targets 
Remedial action: 
Supplement electoral roll with information from GP age-sex 
registers. 
Survey non-participants to identify aspects of the programme that 
have deterred them from participating. 
Increase publicity and education about screening. 
Is technical quality adequate? 
Film reader training. 
Reassess recall criteria. 
Are sensitivity and specificity adequate? 
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The results of the evaluation of the Otago and Southland pilot programme are described and 
discussed in Chapters Five and Six. The effectiveness of the pilot programme is covered in Chapter 
Five and the acceptability of the programme is discussed in Chapter Six. The implications of these 
results including the economic efficiency of the pilot programme, are discussed, and 
recommendations arising from these results are made in Chapter Seven. 
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The Effectiveness of the Pilot Programme 
Introduction 
The methods and results of the evaluation of the effectiveness of the pilot breast cancer screening 
programme are presented and discussed in this chapter. The evaluation of the effectiveness of the 
pilot programme has been divided into three areas (the identification and invitation of eligible 
women, the screening test, and referral for further assessment), and the performance of the pilot 
programme has been compared against the targets for effectiveness that were described in Chapter 
Four. The identification and invitation of eligible women to take part in the pilot programme are 
described in section 5 .1, including the establishment of the screening register ( sections 5 .1.1 and 
5.1.2), and the investigation of invitation methods (section 5.1.3). The quality of mammography in 
the pilot programme is examined in section 5.2, including technical quality (section 5.2.1) and 
radiological interpretation (section 5.2.2). Referral for further assessment is covered in section 5.3 
which includes infonnation on the referral rate, the biopsy rate, and the benign : malignant biopsy 
ratio. Breast cancer diagnosis in the pilot programme is discussed in section 5.4 including breast 
cancer incidence in women aged fifty to sixty-four in Otago and Southland before the pilot 
programme (section 5.4.1), breast cancer detection by screening (section 5.4.2), interval cancers 
(section 5.4.3), the diagnosis of breast cancer outside the screening programme (section 5.4.4), the 
sensitivity and specificity of screening (section 5.4.5), the stage-distribution, size and grade of 
breast cancers detected in the screening programme (section 5.4.6), and the assessment of 
overdiagnosis in screening programmes (section 5.4.7). The results of the evaluation of the 
effectiveness of the pilot programme are summarised in section 5.5. 
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5.1 Identifying and inviting eligible women 
The aim of a screening programme is to reduce the impact of breast cancer on the eligible 
population. To achieve this as many eligible women as possible must be identified and invited to 
take part in the programme. Several studies were carried out as part of the evaluation, to 
determine the best ways to identify eligible women (sections 5.1.1 and 5.1.2) and invite these 
women to take part in the pilot programme (section 5.1.3). 
5.1.1 Establishing the screening register 
It was important that all women aged fifty to sixty-four and living in Otago and Southland could be 
identified and invited to take part in the pilot programme so that the benefits from screening would 
be available to the entire eligible population (Chapter Four, section 4.2.1). 
Methods 
The names, addresses, and mesh block numbers of people aged fifty to sixty-four and registered as 
electors in the Otago, Dunedin North, Dunedin West, St Kilda, Wallace, Clutha, Awarua, and 
Invercargill electorates, and those on the Southern Maori roll corresponding to these electorates 
were obtained from the electoral roll centre (Chapter Four, section 4.1.1). Together these 
electorates matched the boundaries for the Otago and Southland Area Health Boards, which were 
the designated boundaries for the screening programme. These boundaries were also similar to the 
Otago and Southland statistical areas, used by the Department of Statistics for grouping census 
data by area. 
The first names of the electors were used to select all females aged fifty to sixty-four. Mesh block 
numbers were used to group the women into Dunedin, Invercargill, and mobile screening areas. (A 
mesh block is the smallest geographical unit for which data is collected by the Department of 
Statistics. Mesh blocks are used to define electoral boundaries and they can be aggregated to form 
larger geographical units such as Statistical Area Units.) The number of fifty to sixty-four year old 
women identified through the electoral roll was compared with the census number of fifty to sixty-
four year old women living in Otago and Southland at the time that the programme started to find 
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Results 
For Otago and Southland at the time that the screening programme started in 1991 there were 
17,145 women aged fifty to sixty-four on the electoral roll. This compared with 18,555 women 
aged fifty to sixty-four and living in Otago and Southland at the 1991 census (ninety-two percent 
identification of fifty to sixty-four year old women). Therefore the target of identifying at least 
ninety percent of women aged fifty to sixty-four living in Otago and Southland was met by using 
the electoral roll alone. But the electoral roll rapidly becomes out of date (since people change 
address in between updates of the roll) so new information has to be obtained whenever the 
electoral roll is updated . 
The electoral roll was one source of the names and addresses of women aged fifty to sixty-four and 
living in Otago and Southland. There was an eight percent discrepancy between the census and 
electoral roll figures. The reasons that some women might not appear on the electoral roll despite 
being included in census figures include not having registered as an elector, changing address or 
dying since the census, or being committed to a psycruatric institution or prison. As an alternative 
to a population register, the electoral roll, with ninety-two percent identification of women in the 
eligible age-range seems reasonable. In Edinburgh the general practice registers that were used to 
identify women for the screening programme correctly identified ninety percent of women in the 
eligible age-range (Roberts et al 1989). 
The other source of names and addresses of eligible women was general practice age-sex registers. 
It was hoped that these registers could be used to supplement the information from the electoral 
roll. The advantages of using general practice age-sex registers to invite women for screening were 
that general practitioners could be involved with the pilot programme from the time the invitations 
were sent out, women who were not on the electoral roll could be identified, and ineligible women 
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5.1.2 Survey of general practitioners in Otago and Southland 
A survey of all the general practitioners in Otago and Southland was carried out before the 
programme started, to discover what information practitioners needed about the pilot programme, 
and to find out how many general practitioners had age-sex registers, and whether they would be 
prepared to help with identifying and inviting eligible women. 
Methods 
The 159 general practitioners registered with the Medical Council as in practice in Otago and 
Southland were sent questionnaires (Appendix Four). Reminder letters and then telephone calls 
were used to follow up non-respondents. The general practitioners were asked whether they knew 
about the planned screening programme, what their policy for recommending mammographic 
screening was, whether they would encourage eligible women to take part in screening, and 
whether they needed any information before recommending screening to women in their practices. 
They were also asked whether their practices had age-sex registers, whether they could produce a 
list of women aged fifty to sixty-four, and whether they would be prepared to sign letters inviting 
eligible women in the practice to be screened. 
Results 
Of the 159 questionnaires sent out, five were returned because the practice no longer existed, three 
because the doctor was no longer in practice, and one because the doctor had died. Of the 150 
remaining general practitioners 141 (ninety-four percent) took part in the survey, five refused to 
complete the questionnaire, three could not be contacted by telephone, and one was away on leave. 
Most general practitioners in Otago and Southland were aware of the planned pilot programme; 
140 answered this question and 107 (seventy-six percent) already knew about the programme. 
Most practitioners had a policy of recommending mammography to certain groups of women in 
their practices (Table 5.1). Of the respondents 129 (ninety-one percent) said that they would 
encourage women to take part in the screening programme. A further six percent said they would 
do so provided general practitioners were involved in the programme. One hundred and one 
general practitioners (sixty-seven percent) were willing and able to produce lists of the women in 
their practices to supplement the screening register. Of 119 practitioners who answered the 











Recommendations for mammography in Otago and Southland general practices in 1991 
(before the start of the pilot programme) 
Recommendation Number Percent 
No policy 7 5 
Recommended only if risk factor or patient 
request 43 30 
Recommended to women over 40 45 32 
Recommended to women over 50 46 33 






The general practitioners identified in the survey were approached by the screening programme 
manager. General practice age-sex registers were the initial source used when the invitations were 
sent out. Screening programme staff also helped to compile lists for practices which did not have 
age-sex registers. The response from the general practitioners was better than had been expected 
from the survey, with only two practices declining to provide lists of the names and addresses of the 
women aged fifty to sixty-four in their practices. 
Each woman identified from a general practice list was checked off on the electoral roll, and 
women who had not been identified through the general practice registers were sent invitations 
later. Once the means of identifying and inviting eligible women had been developed, an 
investigation of the best method for inviting the women was carried out. 
5.1.3 Determining the best invitation method 
The method of inviting women to screening has been shown to affect participation. It had 
previously been shown that personal invitations result in higher participation in screening 
programmes than invitations which are not personalised, and that invitations with a specified 
appointment time result in higher participation than invitations which require women to make their 
own appointments (Hobbs 1986, Williams and Vessey 1990, Turnbull et al 1991). As part of the 
evaluation of the effectiveness of the pilot programme two randomised controlled trials were 
designed to find out the most effective ways of using personal invitations to invite women to take 
part in screening (Richardson et al 1994). The first randomised controlled trial investigated the 
effect of general practitioner endorsement of an invitation to screening, and the second investigated 
the effect of postal reminders compared with telephone reminders. Each invitation included a 
specified appointment time. 
Trial to investigate the effect of general practitioner endorsement of screening invitations 
A randomised controlled trial was carried out to investigate whether supporting letters from general 
practitioners accompanying the invitations from the screening centre affected participation in a 




All women aged fifty to sixty-four whose names were on the age-sex register of a large urban 
Health Centre with a practice population of 15,500 and who were eligible for screening (482 
women) were randomly allocated either to receive a letter from their general practitioners with their 
screening invitations or not. The general practitioners at the health centre provided personally 
signed form letters on the practice letterhead. If there was no reply within two weeks of the 
invitation being sent, a postal reminder (not signed by the general practitioner) was sent from the 
screening centre. Once all the appointment dates had passed the two groups were compared to see 
whether they had differed in the need for reminders and in the final participation rate. The trial was 
designed to have eighty percent power to detect a difference in participation of fifteen percent at 
0.05 significance, assuming a participation rate of fifty percent in the comparison group (Machin 
and Campbell 1987). 
Results 
Invitations were sent to 482 women, 248 with accompanying letters from their general practitioners 
and 234 without. Randomisation produced similar groups with respect to age. Also a similar 
percentage of each group was ineligible for screening (Table 5.2). A greater proportion of women 
who had not received letters replied specifically declining the invitation to be screened (fifteen 
percent compared with eight percent of those who had received letters). This difference was 
statistically significant (p = 0.03, difference 6.5 percent, 95% CI 0.8 to 12.2). 
Excluding women who were ineligible or could not be contacted because they were no longer at 
that address left 203 women who had been sent letters with their invitations and 192 women who 
had not. Of these women fifty-six percent of those who were sent letters participated as a result of 
the first invitation compared with forty-three percent of those who were not sent letters. This 
difference was significant (p = 0.01, difference 13 percent, 95% CI 3.2 to 22.7). 
Including those who had required reminders, participation among eligible women who had received 
letters was seventy-one percent compared with sixty-two percent among women who did not 
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In this trial, as with progranunes in other countries, personal endorsement of invitations by general 
practitioners increased participation (Irwig et al 1990, Williams and Vessey 1989, Dorsch et al 
1991, Hurley et al 1992). Including those who had required reminders, participation among 
eligible women who had received letters was seventy-one percent compared with sixty-two percent 
among women who did not receive letters from their general practitioners (p = 0.059). This 
participation rate was slightly higher than in a similar study carried out in Australia, where 68.6 
percent participation was achieved (Dorsch et al 1991). The women in the local trial had consulted 
their general practitioners within the previous two years and their names were therefore on the 
practice register. Participation may be different among women who do not regularly attend a 
general practitioner and are not on a general practice register. 
Only forty-three percent of the women in the trial were screened as a result of an unaccompanied 
invitation without a reminder. This level of participation would be unsatisfactory for a population 
based screening progranune as the benefits of screening would be available to fewer than half of the 
eligible women. The cost effectiveness of the progranune would also be lowered, as the major 
costs in screening are salaries and equipment, while the cost of consumables (such as film and 
chemicals) is low. The cost per woman screened drops as the number of women participating 
increases (Sickles et al 1986, McLelland 1987, UK Trial of Early Detection of Breast Cancer 
Group 1988). 
It is clear that reminders are very important in increasing participation. Apart from the effect on 
participation rates there are other advantages to general practitioner involvement in breast cancer 
screerung progranunes. Such advantages include avoidance of inappropriate invitations (for 
instance to women who are already being followed up after a diagnosis of breast cancer). Also, 
women can discuss the invitation and the screening progranune with their general practitioners, 
who will know when women in their practices are being invited and can provide support for 
women who require further assessment and investigation as part of the programme. Although the 
system of invitations used in this trial was time-consuming for the general practitioners involved, it 
contributed to updating the practice register and was seen as a good exercise in quality assurance 
for the practice. 
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Trial to compare postal reminders with telephone reminders 
This trial compared the effect of postal reminders with that of telephoned reminders for women 
who did not respond to an initial invitation to participate in a breast cancer screening programme. 
Methods 
The names of 641 consecutive women who had not replied within two weeks to an initial invitation 
were collected. Women with telephone numbers were randomly allocated to receive either a postal 
reminder or a telephoned reminder. The telephone calls were made up to three times at different 
times of the day. The 146 women without telephone numbers formed a third group and were sent 
a postal reminder. The trial was designed to have eighty percent power to detect a difference in 
participation of fifteen percent at 0.05 significance, assuming a participation rate of fifty percent in 
the comparison group (Machin and Campbell 1987). 
Results 
Of 641 women who had not replied to a postal invitation, 495 had telephone numbers and were 
randomly allocated to receive either a telephoned reminder or a postal reminder. There were 146 
women without telephone numbers. These women formed a separate group and all were sent 
postal reminders. 
Table 5.3 shows the results of telephoned reminders compared with postal reminders. There were 
248 women randomised to receive telephoned reminders. Of this group 118 were screened (forty-
eight percent). Thirteen women said that they would like later appointments but did not specify a 
time. None of these women had been screened by the end of the study period and they have been 
included with the non-participants. 
Of the 247 women who were sent postal reminders 121 women were screened (forty-nine percent). 
There was no significant difference in participation between the intervention and control groups (p 
= 0.8, difference 1.4 percent, 95% CI -10.2 to 7.4). Of the 146 women who did not have 
telephone numbers and so could not be randomly allocated to either group only forty women 
(twenty-seven percent) were screened. Twenty percent of the invitations in this group were 
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TABLE 5.3 
Comparison of telephoned with postal reminders 
Women who did not 





reminder 248 247 reminder 
Not screened: 
No reply 49 57 
Declined 33 35 
Ineligible 15 17 
Did not attend appointment 33 17 





In this trial a telephone reminder and a postal reminder were equally effective for women who did 
not respond to an initial invitation. Neither method resulted in a large number of missed 
appointments, but thirty-three (thirteen percent) of those who received telephone reminders missed 
their appointments compared with seventeen (seven percent) of those who received postal 
reminders (x2 = 5.6 p < 0.05). There were thirteen women among those telephoned who said that 
they wished to be screened later but who did not specify a time. None of these women had been 
screened by the end of the study period. It is sometimes difficult to refuse a telephoned reminder 
and it may be that these women did not wish to be screened. If this is so, telephone reminders may 
be undesirable. 
As the reminder methods are equally effective, whichever best suited the administrative 
arrangements of the screening programme could be used. An advantage of postal reminders is that 
some are returned marked "wrong address". As there is then no possibility of the appointment 
being used it can be allocated to another woman straight away. Telephone reminders may be more 
time-consuming than postal reminders ( especially if several calls have to be made in order to 
contact some women) and they have been found to cost more than postal reminders (Hurley et al 
1992). But it is easier to organise an appointment at relatively short notice by telephone. This 
provides the programme with greater flexibility in scheduling appointments (for instance gaps in the 
screening schedule due to cancellations can be filled at short notice). 
In Australia the effectiveness, costs, and cost-effectiveness of various strategies for recruiting 
women to be screened were considered (Hurley et al 1992). This was a non-randomised trial, 
where recruitment strategies were compared in an Australian pilot programme. The strategies 
included three public recruitment strategies (local newspaper articles, community promotion, and 
promotion to physicians), and five personal recruitment strategies (invitation letters with or without 
specified appointment times, either alone or with a follow-up letter, or telephone call to non-
attenders ). Personal recruitment strategies were more cost-effective than public strategies, at less 
than half the cost per woman screened of public recruitment strategies. Postal reminders were 







As a result of the two trials the Otago and Southland pilot programme is now using general 
practitioner letters with all invitations where possible, and postal reminders are sent to women who 
do not reply to the initial invitation. 
5.2 The screening test 
There are two particularly important aspects to quality assurance of mammography; the technical 
quality of the mammograms (section 5.2.1), and the quality of their radiological interpretation 
(section 5.2.2). In the Otago and Southland programme technical quality was the responsibility of 
a medical physicist. However some information, such as the number of extra films taken and the 
percentage of screened women who had to be recalled because of technical problems, was 
collected as part of the evaluation, as an indicator of the technical quality of the mammograms 
taken in the pilot programme. Other factors which affect the technical quality of mammograms 
include the calibration and maintenance of the mammography machine, positioning and 
compression when taking the mammograms, and film processing. These factors were monitored 
separately by the pilot programme radiographers and the medical physicist. 
5.2.1 Technical quality 
Because the programme used two-view mammography, the expected number of films was four per 
woman (two views for each breast). Information about the number of films taken at each screen 
was collected. Any more than four films per screen were regarded as 'extra films'. The reasons for 
extra films were categorised as 'technical', 'large breasts', and 'other'. The number of women 
recalled for assessment because of technical problems with the screening films (technical recalls) 
was also recorded. 
Over the first eighteen months of screening ten percent of women had more than four films taken 
( at the time of screening) to complete the mammogram adequately. Thirty percent of these women 
had extra films taken for other than technical reasons, the most common reason being that the 
woman had large breasts. For women screened at the fixed screening centres, extra films required 
for technical reasons could be taken at the same visit, since each woman's films were checked 
before she left the screening centre. For women screened at the mobile unit, if extra films were 
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required for technical reasons, a second visit was required, since films taken at the mobile unit were 
not processed at the time, but were sent to Dunedin for batch processing at the end of each day. 
In the first eighteen months for the Otago and Southland programme 1.2% of all the women 
screened were recalled because of technical problems. The 95% confidence interval was 0.97 to 
1.48 percent (Rothman and Boice 1982). The technical recall rate compared reasonably well with 
published technical recall rates in other breast cancer screening programmes which range from 
0.4% in the United States (Sickles et al 1987) to 3.8% in Australia (Rickard et al 1991). 
5.2.2 Film reading 
In the pilot programme each woman's films were independently read by two radiologists. The 
radiologists had only two possible decisions; either to refer the woman for further assessment, or to 
enter her name for routine rescreening in two years time if she was still under sixty-five. Where 
there was disagreement the radiologists met to discuss the films and made a joint decision. 
Infonnation about their film-reading was given to the radiologists at intervals after the pilot 
programme started. This information included two by two tables showing recall rates and 
agreement for each of the film readers. For women who were diagnosed with cancer through the 
programme we checked that both readers had considered the films to be abnonnal. The 
radiologists were also given a printout with the NMPI numbers for all the women who had been 
referred for assessment and the final outcome after assessment, to allow later re-assessment of the 
films, in the knowledge of the final outcome for each woman. As part of the evaluation, the effect 
of double reading compared with single reading, and the agreement between readers were assessed. 
The assessment of agreement was designed as part of the evaluation of the effectiveness of the pilot 
programme but the analysis was carried out by Sheila Williams, the biostatistician who worked on 
the evaluation (Williams et al 1995). A paper reporting these results is included as Appendix One 
and the results are summarised below. 
The extent of agreement between the two main radiologists in the pilot programme was kappa = 
0.65 (95% CI 0.62 to 0.67). This was higher than in other major studies on agreement in breast 
cancer screening programmes. An interesting result is that double reading increased the breast 
cancer detection rate in this study. Had there been only one reader, three to five percent of women 
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with breast cancer would have been missed, depending on which radiologist did the reading. In 
Finland (Anttinen et al 1993) single reading would have led to either six percent or ten percent of 
the women with breast cancer being missed. In a study from Scotland (Anderson et al 1994) 
10. 9% of women with breast cancer would not have been detected without double reading. 
5.3 Referral for assessment 
Methods 
Information from the assessment clinic was collected on the download from the screerung 
programme computer system. Validity checks were carried out to ensure that the information 
obtained from the download was accurate (Chapter Four, section 4.4). In the Otago and Southland 
programme all women attending for screening were asked to complete a consent form and a 
questionnaire which included questions about breast symptoms. A copy of the consent form and 
symptom questionnaire is included as Appendix Five. If a woman had recent symptoms 
documented on the questionnaire she was automatically referred for assessment even if her 
mammogram was normal. This did not happen in most screening programmes. To allow for this 
difference, the recall rate for Otago and Southland has also been given excluding symptomatic 
women who had normal mammograms. 
Women were recalled for assessment if their films were abnormal, if they had recent symptoms on 
the symptom questionnaire, if their films were technically inadequate, or for any combination of 
these reasons. The women were recalled to a special clinic staffed by a radiographer, radiologist, 
nurse, counsellor, and surgeon. Most women were seen at the assessment clinic within two weeks 
of receiving their screen results. 
Some screening programmes have two phases leading to referral, where some women are recalled 
for more detailed mammograms, and only those with abnormalities on detailed views are referred. 
Programmes that have two-phase referral, such as the Swedish programmes, referred five percent 
of women for assessment in the first screening round (Gad et al 1984, Tabar et al 1992). The 
Otago and Southland pilot programme did not refer women for detailed mammograms as an 




of their mammogram results. These policies increased the referral rate. Initially the target referral 
rate for the New Zealand pilot programmes was set at five to ten percent (Chapter Four, section 
4.1.3) to allow for the differences in referral policy between the pilot programme and some other 
programmes. The referral rate calculated in the Otago and Southland pilot programme included all 
women who were ref erred to the assessment clinic, even if it was only for more detailed 
mammography. 
Results 
Of the 7,182 women screened in the Otago and Southland programme in its first eighteen months, 
832 women (11.6%) were referred for assessment. After excluding women with symptoms the 
referral rate was 10.4%. Most of the women referred required further mammography and/or 
physical examination alone but some women had several investigations. Altogether, of the 832 
women referred to the assessment clinics, 735 had mammograms, 307 had physical examinations, 
213 women had ultrasound examinations, 150 had fine needle aspiration cytology (FNA), and 141 
(two percent) of the women had biopsies (Table 5.4). Seventy-three women were diagnosed with 
breast cancer, giving a detection rate of ten breast cancers per thousand women screened. The 
benign: malignant ratio was 0.9: 1. Breast cancer detection is discussed in detail in section 5.4. 
Symptomatic women 
None of the women diagnosed with breast cancer were symptomatic at the time of screening (Table 
5.5). This suggests that the symptom questionnaire was not a useful indicator of the likelihood of 
breast cancer, and consideration should be given to modifying it or eliminating it. Alternatively the 
questionnaire could be retained but symptomatic women be given the option of further assessment 
rather than an automatic referral, as some symptomatic women may be anxious if they are not 
referred. 
Discussion 
The referral rate of eleven percent (or 10.4% excluding women with symptoms) in the pilot 
programme was higher than that reported in many breast cancer screening trials for the first round 
of screening and exceeded the target of between five and ten percent. The referral rate was 1.5% in 
the first screening round of the Stockholm trial (Frisell et al 1986, Frisell et al 1991) and five 










Assessment results for the first eighteen months of screening in the 
Otago and Southland pilot programme 
Women screened 7,182 
Women referred 832 
Referral rate 11.6% 
Referral rate ( excluding women with symptoms) 10.4% 
Biopsies ( excludes fine needle aspiration) 141 
Biopsy rate 1.96% 
Benign:Malignant ratio 0.9:1 
Women diagnosed with breast cancer 73 
Detection rate per 1000 women screened 10.2 
(95% CI 7.8 to 12.5) 
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abnormal films 72 588 
symptoms, normal films 0 63 
- \ 
abnormal films & symptoms 0 20 
technical problem 0 79 
~ 
abnormal films & technical problem 1 7 :., 
symptoms & technical problem 0 1 
abnormal films, symptoms & technical 0 1 
> -'\ 
\ 





Insurance Plan (HIP) trial the referral rate was five percent but this was averaged over all screening 
rounds (Shapiro 1977, Shapiro et al 1982) and is likely to have been higher in the first round 
(Kopans and Swann 1988). But in the Canada II trial where the women were aged fifty to fifty-
nine (Miller et al 1992b) the referral rate in the first screening round was 11.0%. In the first 
screening round of the Sydney breast x-ray programme for women aged 45 and over, the referral 
rate was 16.5% (Rickard et al 1991). The Sydney programme, like the Otago and Southland 
programme, had a policy of referring symptomatic women irrespective of their screen results. 
Low referral rates may mean that the test is accurately distinguishing between women who require 
further assessment and those who do not. However, it may mean that the sensitivity of the test is 
low and women who require further assessment have not been referred. It is difficult to combine 
high sensitivity with a low referral rate in the early stages of a new breast cancer screening 
programme. The referral rate in the pilot programme dropped from twelve percent to ten percent 
during the first eighteen months of screening (Table 5.6) but this decline was not significant (x2 for 
trend= 0.3, p = 0.58). It was encouraging to observe that the proportion of mammograms initially 
regarded as abnormal by one reader and leading to referral declined significantly over the first 
eighteen months of the pilot programme (Appendix One). 
Biopsy rate and benign to malignant biopsy ratio 
A high referral rate means that too many women experience anxiety related to screening. 
Fortunately in the pilot programme, although the referral rate was high, the biopsy rate and the 
benign to malignant ratio were low, so that few of these women underwent unnecessary biopsies. 
The biopsy rate of 1.96 percent just met the target of less than two percent, and the benign to 
malignant biopsy ratio of0.9 : 1 was well within the target range (less than 3 : 1). The low benign 
to malignant biopsy ratio partly compensated for a high referral rate in that very few women in the 
pilot programme underwent unnecessary biopsies. In other programmes the benign to malignant 
ratio has been considerably higher; four to one in the HIP trial (Shapiro et al 1982), and two to one 
in the Swedish Two-Counties trial (Tabar et al 1985) and the Edinburgh trial (Roberts et al 1989). 
The Malmo and Stockholm trials had benign to malignant ratios of 0.7 and 0.5 to one respectively 







5.4 Breast cancer diagnosis in the pilot programme 
Infonnation from the New Zealand Cancer Register, the National Master Patient Index (NMPI), 
the histology departments at Dunedin and Kew hospitals, the private pathology laboratories in 
Dunedin and Invercargill, and the screening register was used to calculate the incidence of breast 
cancer in women aged fifty to sixty-four in Otago and Southland prior to the introduction of breast 
cancer screening (section 5.4.1), breast cancer detection by screening (section 5.4.2), breast cancers 
(interval cancers) diagnosed in women in the twelve months following a negative screen (section 
5.4.3), and breast cancer diagnosis outside the screening programme (section 5.4.4). The 
infonnation described in sections 5.4.2 to 5.4.4 was then used to calculate the sensitivity, 
specificity, and positive predictive value of the screening test (section 5.4.5) as part of the 
evaluation of the effectiveness of the pilot programme. Infonnation about breast cancer in women 
aged fifty and over was collected from the Dunedin Hospital Pathology Department computer 
system, and the NMPI number was used to determine whether the women were diagnosed as a 
result of screening or not. Information on breast histology for Southland women was produced 
from the Southland Hospital pathology computer system. The Southland Area Health Board did 
not adopt the N1-1PI system which meant that printouts with patient numbers could not be used to 
identify screened women. When a woman over fifty was diagnosed with breast cancer through the 
Southland hospital pathology department or one of the private pathology laboratories a photocopy 
of the histology form was obtained. Each fonn had the woman's name blanked out. Date of birth 
was used to look for possible matches with the screening register, and where there was a match and 
the name was required the woman's surgeon (who could identify the woman from her laboratory 
number on the histology fonn) asked her for permission to release her name for the evaluation. This 
method was cumbersome but was the only way to identify women diagnosed with breast cancer 
outside the programme, while still maintaining confidentiality between the pathologist and the 
patient. No women refused permission. With the recent passage of the Cancer Registry Act 1993, 
which made it compulsory for all pathologists to notify diagnoses of cancer from July 1994 
(Chapter Two, section 2.1) identification of women diagnosed with breast cancer outside the 
screening programme should become considerably more straightforward. 
The stage-distribution of cancers detected by screening was recorded so that it could be compared 












Referral rates from September 1991 to March 1993 for the two main film-readers 
Time period Total Total referred 
n % 
September - October 1991 407 48 11.7 
November- December 1991 167 20 12.0 
January - February 1992 417 35 8.4 
March - April 1992 785 63 8.0 
May - June 1992 709 65 9.2 
July - August 1992 870 100 11.5 
September - October 1992 667 83 12.4 
November 1992 - January 1993 * 678 75 11.1 
February- March 1993 959 93 9.7 
X,2 for trend= 0.3, p = 0.58 
* no screening in December 1992 
Source: Williams SM, Doyle TCA, Chartres S, Richardson AK, Elwood JM Impact of independent double reading 




was carried out by one of the surgeons in the pilot programme, the programme manager, and the 
author. The TNM stage classification was used (Beahrs et al 1988). 
The histological grade (Bloom and Richardson 1957, Scarff and Tortoni 1968) of the tumours was 
assessed by the pathologists who carried out the histology for the pilot programme. Tumour size, 
grade, and nodal status in the pilot programme were also compared with those in the Swedish 
Two-Counties trial (section 5.4.6). 
5.4.1 Breast cancer incidence before the pilot programme 
Before the introduction of screening the recorded incidence of breast cancer in women aged fifty to 
sixty-four in Otago and Southland was 2.2 per thousand per year. This incidence was calculated 
from ten years of breast cancer registrations at the national cancer registry from 1979 to 1988 
(New Zealand Cancer Registry 1990), and 1981 and 1986 census data (Table 5.7). The incidence 
of breast cancer in women aged fifty to sixty-four in Otago and Southland from 1979 to 1988 was 
similar to that for the whole of New Zealand, which was 1.9 per 1000 per year, and the incidence 
did not change significantly over the ten years from 1979 to 1988 (x.2 test for trend= 2.537, p = 
0.11) (Table 5.7). 
5.4.2 Breast cancer detection by screening 
This is the number of women per thousand screened in whom breast cancer was detected by 
screening. There were seventy-three women, of 7,182 women screened in the first eighteen 
months of the pilot programme, who had breast cancer diagnosed through the screening 
programme. This is a detection rate of ten per thousand, with a 95% confidence interval of 7. 8 to 
12.5 (Rothman and Boice 1982), which is significantly higher than the expected incidence of 2.2 
per thousand per year in the absence of screening (Table 5. 7) and exceeded the target of three times 
the expected incidence (Chapter Four, Table 4.1). This is further discussed in Chapter Seven, 
section 7.2.8 . 
5.4.3 Interval cancers 
Interval cancers are cancers diagnosed in women who had a negative screen, in the interval 









Breast cancer incidence in women aged 50-64 in Otago and Southland 
before the establishment of the screening programme (1979-1988) 
Breast cancer No. ofwomen Breast cancer 
Year Registrations aged 50-64* Incidence# 
1979 59 19755 2.99 
1980 46 19755 2.33 
1981 46 19755 2.33 
1982 43 19755 2.18 
1983 37 19755 1.87 
1984 46 18918 2.43 
1985 31 18918 1.64 
1986 42 18918 2.22 
1987 42 18918 2.22 
1988 41 18918 2.17 
x2 test for trend= 2.537, p = 0.11 
Breast cancer incidence ( 1979-88) in women aged 50-64 in Otago and Southland = 2.2 per 1000 women per year. 
Source: New Zealand Cancer Registry computer tape. Breast cancer registrations 1979-88. Wellington, 1990. 
* Denominator for 1979-83 taken from the 1981 census, and for 1984-88 from the 1986 census. 









cancers which were not detected at the screening test, or they may be cancers which have entered 
the pre-symptomatic screen-detectable phase, and then the symptomatic phase, within the interval 
since the negative screening test. One way to measure interval cancers is to include all women 
diagnosed with breast cancer within twelve months of a negative screening result. By designating 
interval cancers as "false negatives" it is possible to estimate the sensitivity of screening (section 
5.4.5). Of the 7,182 women who were screened in the first eighteen months, 6,350 had negative 
mammograms, and a further 759 had a negative result after assessment. Six of these 7,109 women 
were diagnosed with breast cancer in the twelve months following a negative screening result. Thus 
the number of interval cancers was six, with a 95%confidence interval of2.5 to 12.7 (Rothman and 
Boice 1982). 
The difference between the number of interval cancers and the number of cancers that would 
otherwise have been expected in the year following screening gives an indication of the number of 
cancers that were detected early by screening (Day 1991, Tabar et al 1992). This comparison is 
best made by comparing the number of interval cancers with the number of cancers detected in the 
control group in a randomised controlled trial. In the absence of a control group historical data can 
be used, but this is not ideal as, unlike the two arms of a randomised controlled trial, the women in 
the two groups being compared may differ in their underlying risk of breast cancer. Because of the 
lack of a control group and the delay in registrations at the Cancer Registry, the historical incidence 
of breast cancer in women aged fifty to sixty-four in Otago and Southland was used as an estimate 
of the expected incidence among screened women, in the absence of screening. Each of the 7,109 
women was followed for a year after her screening. In the pilot programme the expected incidence 
in the absence of screening was 2.2 per thousand per year. The expected incidence in 7,109 women 
in a year would have been sixteen. Only six women were diagnosed with breast cancer during the 
twelve month follow up period, so the incidence of breast cancer was 37.5 percent of that expected 
ma year. 
This result is similar to the recent results from the National Health Service breast screening 
programme in Britain, where the incidence was thirty-one percent of that expected in the first year 
(V/oodman et al 1995). However a better result was seen in the Nijmegen programme, where the 
proportional incidence of interval cancers was twenty-five percent (VI oodman et al 1995), and the 





screening for women aged fifty to fifty-nine was ten percent of that expected, and for women aged 
sixty to sixty-nine was seventeen percent of that expected (Tabar et al 1992). These results should 
be compared cautiously, since some (the Swedish results) are derived from comparisons made 
within randomised controlled trials while others (the Dutch and British results) are not. 
5.4.4 Breast cancer diagnosis outside the screening programme 
Of the 11,373 women aged fifty to sixty-four in Otago and Southland who had not been screened 
in the first eighteen months of the pilot programme, seventy-one were diagnosed with breast cancer 
within eighteen months of the start of the programme ( about 48 women per year, or four per 
thousand per year). The number of women diagnosed with breast cancer outside the screening 
programme was.higher than the number of women previously diagnosed each year in the whole of 
Otago and Southland in the years 1979 to 1988 (Table 5.7). 
This incidence is clearly much higher than expected from the previous Cancer Registry figures. 
Three factors could have contributed to this. Firstly, the unscreened women may have had a higher 
underlying risk of breast cancer. However this seems unlikely since the detection rate among 
screened women in the pilot programme was high compared with other screening programmes. 
Secondly, some of the women who were not screened in the pilot programme may have had 
mammography outside the programme, as there was a private screening service available to 
Dunedin women from about the time that the pilot programme started. If this was so it would 
explain a higher than expected incidence of breast cancer among women outside the pilot 
programme. But this also seems unlikely since a survey of women who did not attend the pilot 
programme found that less than five percent gave their reason for non-attendance as having already 
had a recent mammogram (Chapter Six, Table 6.21 ). The third possibility is that registration of 
women with breast cancer has been incomplete in the past, so that the true incidence of breast 
cancer in Otago and Southland was higher than the published data suggested. It was thought that 
cancer registrations for the period 1980 to 1991 represented at least ninety-five percent of all 
tumours (National Health Statistics Centre 1989, New Zealand Health Information Service 1994). 
However, the reviews of the Cancer Registry that were carried out in 1988 and 1991 (Cancer 





been incomplete registration of cancers, and two studies of melanoma in New Zealand, based on 
pathology reports, found that there was considerable under-reporting to the Cancer Registry 
(National Health Statistics Centre 1989, Brown and Palmer 1991, Cooke et al 1992). It is also 
possible that there had been under-reporting of breast cancer in Otago and Southland. Once the 
Cancer Registry data for the first screening round are available it will be possible to compare the 
number of registrations with the number of women identified through the evaluation of the 
screening programme to find out if under-registration occurred during the first screening round. 
Another indication of past under-reporting to the Cancer Registry will be if there is an increase in 
registrations across all cancer sites from July 1994 when compulsory reporting from pathology 
laboratories was introduced. 
5.4.5 Sensitivity and Specificity 
Sensitivity is usually calculated as true positive screen results divided by the sum of true positives 
and false negatives. If interval cancers are regarded as "false negatives" it is possible to estimate 
the sensitivity of screening by dividing screen-detected cancers by the sum of screen-detected 
cancers plus interval cancers in the year following screening. This method of estimating sensitivity 
was described ~s Method One in Chapter Four, section 4.1.2. There were 7,182 women screened 
in the first eighteen months of the pilot programme, seventy-three of whom had breast cancer 
detected by screening, and six women with interval cancers diagnosed in the year following a 
negative screen. So the sensitivity of the screening process in the pilot programme calculated using 
Method One was seventy-three divided by seventy-nine, or ninety-two percent, with a 95% 
confidence interval of 84.4 to 96.5% (Rothman and Boice 1982). This was a very good result 
compared with other screening programmes, where sensitivity in the first screening round, 
calculated using the same method, ranged from seventy-eight percent to ninety-six percent 
(Chapter Four, Table 4.1). The target set for the pilot programme was eighty-five percent 
sensitivity. 
One of the women who had an interval cancer had actually had a positive mammography result, but 
subsequently nothing was found at assessment. It is difficult to be certain even in retrospect, 
whether the initial mammogram was correct and the tumour was missed at assessment, or the 
assessment was correct, and a tumour only became detectable subsequently. If the initial 





screen result was a true positive result and there were really only five interval cancers rather than 
six. In this scenario the sensitivity of the screening test was ninety-four percent. However, this 
woman did have a cancer that was diagnosed after she had been cleared by the programme, so the 
sensitivity of the screening process was ninety-two percent. There is no discussion of this type of 
problem, nor the most appropriate response to it, in the literature, and it appears that sensitivity is 
usually calculated with reference to the screening process, while specificity is calculated with 
reference to the screening test. In this situation where there is uncertainty, rather than overestimate 
sensitivity, and because this better represents the actual outcome of screening, the "process" 
sensitivity of ninety-two percent has been used, and the woman's result has been categorised as a 
false negative (Table 5.8). 
The proportional incidence of interval cancers can also be used to estimate the sensitivity of the 
screening test (Method Two, described in Chapter Four, section 4.1.2), using the formula 1 - PI1 
where PI1 is the proportional incidence of interval cancers (Day 1985). Using this formula, the 
sensitivity of the test is only 62.5%, since the proportional incidence of interval cancers was 
calculated as 37.5% (section 5.4.3). This method of estimating sensitivity consistently produces 
lower estimates of sensitivity than Method One (Chapter Four, Table 4.2). Moreover, it is likely 
that there was under-registration of breast cancer at the Cancer Registry in the past (section 5.4.4.). 
Since historical data were used to estimate the expected incidence of breast cancer among screened 
women in the absence of screening, the expected incidence may have been underestimated. This 
would have caused the proportional incidence of interval cancers to be overestimated, thus 
underestimating sensitivity in the pilot programme. Because of this, sensitivity calculated by 
Method One rather than Method Two (Chapter Four, section 4.1.2) was used for the evaluation of 
the pilot progrannne. 
The specificity of the pilot programme in its first eighteen months was estimated using the method 
described in Chapter Four (section 4.1.2) where specificity is estimated before the second screening 
round by dividing all negative tests (including false negatives) by the sum of all negatives and false 
positives (Miller 1985, Morrison 1985). This is an adequate estimate of specificity (although false 
negatives have been included in the numerator and the denominator) because the number of false 
negatives is very small in relation to the number of true negatives. In the first eighteen months of 







assessment clinic). Of the 832 women who were referred for assessment, seventy-three were 
diagnosed with breast cancer, leaving 759 women as "false positives". So the specificity of 
screening in the pilot programme was 6,350 divided by 7,109 or eighty-nine percent, with a 95% 
confidence interval of88.6 to 90.0% (Rothman and Boice 1982). This is lower than the specificity 
in the first round of screening in other programmes, which ranged from ninety-five to ninety-seven 
percent (Chapter Four, Table 4.1). The low specificity is partly related to the high referral rate in 
the pilot programme. The target set for the pilot programme was ninety-five percent specificity. 
The positive predictive value, or the predictive value of a positive screening test (PPV) measures 
the likelihood that a woman with a positive screening test actually has breast cancer. The PPV is 
calculated by dividing the number of true positive tests by all positive tests, and therefore gives the 
proportion of positive tests that are true positives. In the pilot programme the predictive value of a 
positive test in the first eighteen months was nine percent, with a 95% confidence interval of 7.0 to 
10.9% (Rothman and Boice 1982). Unlike sensitivity and specificity, which measure the validity of 
the screening test, and are independent of the prevalence of the disease, the PPV is affected by 
disease prevalence. As the prevalence of the disease that is being screened for increases, the PPV 
will increase. This should be kept in mind when comparisons of PPV are made between 
programmes where the prevalence of breast cancer in the screened population may differ. 
The PPV is a useful measure for the clinicians working in the assessment clinic who want to 
provide information for women who have had positive tests. The PPV is affected by the referral 
rate, in that a high referral rate will tend to result in a low PPV, since there will usually be a high 
number of false positive tests if the referral rate is high. In other breast cancer screening 
programmes the PPV in the first screening round ranged from 1.5 percent to over thirty-eight 
percent (Hurley and Kaldor 1992). This range is determined partly by the underlying prevalence of 
breast cancer in the population being screened, and partly by the referral rate. Sensitivity, 
specificity and PPV results for the first eighteen months of the Otago and Southland pilot 
programme are shown in Table 5.8. The sensitivity of screening, combined with the coverage of 
the eligible population gives the maximum breast cancer detection that can be achieved by the 
screening programme. The lowest reported breast cancer detection in a successful screening 
programme was sixty-four percent (Chapter Four, section 4.1.2). In the Otago and Southland 











Sensitivity, specificity and predictive value in the first eighteen months of the 
Otago and Southland pilot breast cancer screening programme 
Breast Cancer 
Yes No Total 
Positive 73 759 832 
Test 
Result Negative 6 6,344 6,350 
Total 79 7,103 7,182 
Sensitivity 92% Specificity 89% PPV* 90/o 
(95% CI= 84.4 to 96.5) (95% CI= 88.6 to 90.0) (95% CI= 7.0 to 10.9) 
The data in this table are derived from the results of the first eighteen months of screening in the pilot programme, 
with twelve months follow-up for all the women screened in the first eighteen months. Sensitivity and specificity are 
calculated with respect to the outcome of the initial screening test A positive test result is defined as referral to the 
assessment clinic. One of the women who had an interval cancer had previously had a positive mammography result, 
but subsequently nothing was found at assessment. To avoid an overestimate of sensitivity her result has been 
categorised as a false negative, with respect to the cancer which was subsequently diagnosed (section 5.4.5). 
* PPV is the predictive value of a positive test 
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seventy-four percent coverage and ninety-two percent programme sensitivity achieved during the 
first eighteen months of screening. 
5.4.6 Characteristics of cancers detected at screening 
If screening detects breast cancer early then there should be a higher proportion of early stage 
disease among screen-detected cancers than among non-screen-detected cancers. It is interesting 
to compare the stage distribution of cancers detected in the pilot programme with those detected in 
existing programmes, but it is uncertain whether this can be used as an indicator of effectiveness 
since the stage distribution is likely to be affected by length, selection, and over-diagnosis biases, 
and the lead-time resulting from screening could cause a shift in stage distribution even if there 
there were no effect on breast cancer mortality. The stage-distribution of screen-detected cancers 
has been suggested as a surrogate endpoint for reduced mortality (Bull and Mountney 1991 ), on 
the basis that in order to be effective, screening programmes must detect breast cancers earlier than 
they would otherwise have been detected. It is interesting to compare the stage distribution of 
tumours detected in the pilot programme with the Swedish Two-Counties trial, where there was a 
proven mortality reduction. But stage distribution is vulnerable to the biases described above. This 
means it can only be used as a rough indicator of the likely effect of the programme on breast 
cancer mortality, and it should be interpreted cautiously. The stage-distribution of cancers detected 
in the first eighteen months of the Otago and Southland pilot programme is shown in Table 5.9. 
In the Swedish Two-Counties programme 33.3 percent of tumours detected at the prevalence 
screen in women aged 50-59 were stage two or higher, and 34.3 percent in women 60-69 were 
stage two or higher (Day et al 1989). In the Otago and Southland programme three tumours could 
not be staged. Depending on the status of these three tumours, between thirty-eight (95% CI 
28.1% to 49.8%) and forty-two percent (95% CI 31.8% to 53.9°/o) of the tumours detected in the 
first eighteen months were stage two or higher (Table 5.9). The diagnosis of ductal carcinoma in 
situ (DCIS) is made only rarely in the absence of mammographic screening ( de Koning et al 1990) 
but twelve percent of tumours diagnosed in the first eighteen months of screening in the pilot 
programme were DCIS. Diagnosis of these very early tumours, where the prognosis is uncertain 
since they were previously rare, has led to concern about over-diagnosis in screening programmes. 




Stage distribution of tumours detected in the Otago and Southland programme 
ii 
,I 
Stage Number Percent 
Ductal carcinoma in situ 8 12 
> 
I 
Stage I 34 49 
Stage II 24 34 
.l 
Stage III 3 4 
, 
Stage IV 1 1 
Unknown 3 
















Breast cancers detected in the Otago and Southland prevalence screen compared with the 
Swedish Two-Counties prevalence screen: 
O&S (°/o) S2C (°/o) 
Size (mm) 1- 9 19 33 74 26 
10-14 15 26 84 29 
15-19 12 21 56 20 
20-29 8 14 40 14 
30-49 3 5 18 6 
So+ 1 2 12 4 
not known 7 1 
(x2 = 1.9, df = 5, p = o.86) 
Node status positive 21 37 56 21 
negative 36 63 213 79 
not known 8 14 
(x2= 6.5, df= 1, p = 0.01) 
Histological 
grade 1 19 
2 14 
3 5 
not known 27 





The distribution of tumour size for the first eighteen months of the pilot programme was similar (x2 
= 1.9, df= 5, p = 0.86) to that for the prevalence screen of the Swedish Two-Counties trial (Table 
5.10). The programmes differed for nodal status, with a higher proportion of node-negative 
tumours detected in the Swedish Two-Counties trial (x2 = 6.5, df= 1, p = 0.01). No comparison 
was made for grade, partly because some of the tumours detected in the operation of the pilot 
programme had not been graded, but also because in the Swedish Two-Counties trial the 
distribution of grades differed significantly between Ostergotland and Kopparberg, the two counties 
in the trial. It was suggested that this was due to "the subjective nature of histological grading" 
(Tabar et al 1992). This is of considerable concern because if grading is this subjective its use as a 
prognostic indicator must be in question. 
It has been suggested that tumour grade, size and nodal status could be used to predict the effect of 
screening on breast cancer mortality (Duffy et al 1991, Tabar et al 1992). Duffy et al collected 
information on women diagnosed with breast cancer in the Swedish Two-Counties trial. Data were 
collected from the prevalence screen on women diagnosed with breast cancer in the group offered 
screening (screen-detected cancers, interval cancers, and cancers diagnosed in women who refused 
screening) and in the control group. Incidence screen data were collected for the period from 
immediately after a screening test to immediately after the subsequent screening test. Because the 
screening test was of high sensitivity, cancers diagnosed in this period would not be greatly affected 
by length bias. These cancers plus breast cancers diagnosed in women who refused the offer of 
screening were then compared with breast cancer diagnosed in the control group over the same 
period. Cancers in the two groups were equivalent except that those in the group offered screening 
were diagnosed earlier overall. The effect of earlier diagnosis on tumour size, stage, and grade 
could then be assessed without being distorted by length bias. The survival of women with screen-
detected breast cancer was better than that of women with breast cancer in the control group or 
women with interval cancers, and the survival of women with breast cancer who had refused 
screening was worst. Size, nodal status, and grade explained much of the difference in survival 
between women with incidence screen-detected, interval and control group breast cancers. These 
three factors explained much less of the difference between screen-detected cancers, interval 
cancers and control group cancers in the prevalence screen where the effect of length bias is 





grade than those diagnosed in the control group and Duffy et al hypothesised that tumour grade 
worsens as the size of the tumour increases. 
These results led to the development of targets for the size, nodal status and grade of tumours 
detected in breast screening programmes (Tabar et al 1992). The suggested targets are listed in 
Table 5.11. The results from the prevalence screen of the Otago and Southland programme are 
given for each of the targets, with ninety-five percent confidence intervals where appropriate. 
Comparisons such as that made in Table 5.11 should be interpreted with caution because a similar 
study was carried out using data from the United Kingdom trial of early detection of breast cancer 
(Moss et al 1994). In this study only about a third of the improved prognosis in women who were 
diagnosed by screening could be explained by changes in size and nodal status. It was suggested 
that the difference between the British and Swedish results could be partly because the British 
analysis could not adjust for tumour grade. Another possible reason for the discrepancy between 
the two studies is that participation in screening was lower in the United Kingdom and there was 
self-selection of women with a poor prognosis into the non-participant group (Moss et al 1994). 
5.4. 7 Over-diagnosis 
The amount of over-diagnosis in a screening programme can be estimated by examining the deficit 
in the number of cancers diagnosed in the interval after screening ( compared with that expected in 
the absence of screening), and comparing this to the total number of cancers diagnosed at 
screening. The most accurate way of determining the deficit in interval cancers is where breast 
cancer incidence following a negative test in screened women can be compared with the incidence 
in a comparison group (ideally in a randomised controlled trial, but in the absence of a comparison 
group a historical comparison may be used). The extent to which the screening prevalence exceeds 
the interval deficit indicates the extent to which cancers diagnosed at screening would not have 
surfaced in the time interval considered (Day 1991). 
Since the lead time gained by screening in women over fifty has been estimated at about two years 
(Day and Chamberlain 1988), it is not appropriate to use this method to estimate over-diagnosis in 
the Otago and Southland pilot programme until the second screening round ( when data on two 







Suggested targets for size, histological grade, and nodal status for tumours detected in breast 
cancer screening programmes 
Suggested 
Target 
At least 50% of screen-detected 
tumours should be less than 
15mm diameter 
At least 30% of grade 3 tumours 
should be less than 15mm. 
At least 70% should be node negative 
These targets should be met 
with a recall rate ofless than 9% 
Otago & Southland 95% confidence 
first screen result interval 
59% 46%to72% 
Not assessed 
( only 4 detected) 
63% 50%to 76% 
10 .4 % recall rate 
Source: Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft 0. Update of the Swedish Tw<rCounty 





The results of the evaluation of the effectiveness of the pilot programme are summarised briefly 
here. Detailed comparisons with other screening programmes, implications, and recommendations 
for the pilot programme and for a national breast cancer screening programme in New Zealand are 
discussed in Chapter Seven. The pilot programme met the targets that had been set for 
identification of eligible women and coverage of the target population. An appropriate invitation 
method was developed, which resulted in a seventy-one percent response rate to an invitation. The 
technical quality of the mammography in the pilot programme was high, and double-reading of 
films increased sensitivity. The referral rate of eleven percent (or 10.4 percent excluding women 
with symptoms) in the pilot programme was higher than that reported in many breast cancer 
screening trials for the first round of screening and exceeded the target of between five and ten 
percent. A high referral rate means that too many women experience unnecessary anxiety related 
to screening. Fortunately in the pilot programme, although the referral rate was high, the biopsy 
rate and the benign : malignant biopsy ratio were low. The biopsy rate of 1.96 percent just met the 
target of less than two percent, and the benign : malignant ratio of 0.9 : 1 was well within the 
target range (less than 3 : 1 ). The low benign : malignant ratio partly compensated for a high 
referral rate in that very few women in the pilot programme underwent unnecessary biopsies. The 
pilot programme easily met the target set for sensitivity, but did not meet the target set for 
specificity ( due in part to the high referral rate in the first eighteen months of screening). The 
implications of this, and recommendations for the future are discussed in Chapter Seven. 
The stage-distribution of cancers detected in the Otago and Southland programme was recorded 
(Table 5.9). It has been suggested that, in the prevalence screen of breast cancer screening 
programmes, not more than forty percent of cancers detected should be stage two or higher (Day 
et al 1989). In the Otago and Southland programme between thirty-eight (95% CI 28.1% to 
49.8%) and forty-two percent (95% CI 31.8% to 53.9%) of the tumours detected in the first 
eighteen months were stage two or higher (section 5.4.6). The suitability of the stage distribution 
of screen-detected cancers as an indicator of the effectiveness of screening is discussed further in 
Chapter Seven. 
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CHAPTER SIX 
The Acceptability of the Pilot Programme 
Introduction 
An important factor affecting the success of any screening programme is the level of participation 
among the target population. When participation is high the benefits from screening are available 
to a greater proportion of eligible women. The efficiency and cost effectiveness of screening are 
;- also improved by high participation levels (Sickles et al 1986: McLelland 1987, UK Trial of Early 
Detection of Breast Cancer Group 1988). Participation depends on several factors, including 
awareness of the service, perception of its relevance, and its acceptability (Strax 1980). Several 
studies have investigated factors which affect participation in mammographic screening 
programmes (French et al 1982, Calnan 1984a, Calnan 1984b, Roberts et al 1986, Hobbs et al 
1980, Fink et al 1968, Leather and Roberts 1985, MacLean et al 1984). Participation in screening 
programmes has been associated with younger age, higher socioeconomic group, higher 
educational level, greater knowledge and beliefs about breast cancer, and previous health-related 
behaviour (such as attending for cervical smears), but results vary according to region. 
The acceptability of the programme could affect not only the continued participation of the women 
who had already taken part, but also that of women who had not yet attended but heard about the 
programme "by word of mouth". The acceptability of the pilot programme was one of the three 
key areas (acceptability, effectiveness, and economic efficiency) that were recommended for 
evaluation by the Skegg committee (Skegg et al 1988). Several surveys were undertaken to find 
out about the acceptability of the pilot programme. These surveys are described in this chapter. 
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6.1 Pre-screening survey: factors likely to affect participation in mammographic screening. 
Before the pilot programme began, a random sample of 290 Otago and Southland women was 
surveyed to find out about aspects of a programme which would make it more acceptable and 
thereby enhance participation (Richardson 1990). The aim was to use the findings from this survey 
to help design a pilot programme that would be acceptable and would thereby encourage 
participation. This survey was carried out before the pilot programme (and its evaluation) started, 
but the results were used in planning the pilot programme and the evaluation, so it is included here 
to provide background information. 
Methods 
The survey population was women aged between forty and seventy who lived in Otago and 
Southland. This age range was chosen because the recommendations for screening in New Zealand 
(Skegg et al 1988) had not been released when the study was designed, but it was recognised that 
eligibility was likely to be somewhere within that range. 
A random sample of a thousand women whose names appeared on the electoral roll was contacted 
by mail. Each woman was asked to indicate whether she was in the required age range for the 
study, since the study was carried out before the electoral roll centre was able to provide lists of 
voters by age-group for health-related purposes (Chapter Four, section 4.1.1). Each woman was 
asked whether she would be prepared to answer a postal questionnaire. Follow up phone calls 
were used to contact women who did not reply, or who were within the required age range but 
were not prepared to answer a postal questionnaire. (The second group was asked if they would 
be prepared to answer the questionnaire by telephone.) 
Replies were received to sixty-five percent of the initial letters. Fifty-five percent ( 192) of those 
who did not reply were contacted by telephone. Of all women contacted forty-two percent (353) 
were in the eligible age range, and of these eighty-seven percent (307) agreed to complete a postal 
questionnaire. Of forty-six women who were not prepared to complete a postal questionnaire, 
sixteen agreed to complete the questionnaire by telephone. The results from the 290 questionnaires 






The 290 respondents were representative of women in the forty to seventy age range in Otago and 
Southland according to the 1986 census, in terms of age, ethnic group, domicile, and marital status 
(Table .6.1). However women who had attended university were over-represented; fourteen 
percent of the respondents had attended university at some time compared with six percent of 
Otago and Southland women in the age range. 
Eighty-four percent (244) of the women surveyed intended to participate in screening. Eight 
percent stated that they would participate according to certain conditions; the most common were 
distance to the screening centre, appointment time, and finding time to attend. Eight percent did 
not intend to participate. Of those not intending to participate, half were over sixty, although 
women in this age group made up only a third of the women surveyed. 
Knowledge about breast cancer and mammographic screening was scored according to the 
women's responses to five true/false statements about breast cancer and mammographic screening 
(the expected response is given in parentheses after each statement): 
(1) most lumps in the breast are harmless (true) 
(2) the risk of breast cancer increases with age (true) 
(3) breast cancer is common in young women (false) 
( 4) early diagnosis of breast cancer increases the chance of cure (true) 
(5) mammographic screening can detect breast cancer early (true) 
The more women knew about breast cancer and mammographic screening the more likely they 
were to intend to participate in a screening programme (Table 6.2). 
Health related behaviour ( such as attending a dentist regularly, or having a cervical smear within the 
last three years) was associated with an intention to participate in mammographic screening (Table 
6.2). Women who knew someone who had been diagnosed with breast cancer were more likely to 
intend to be screened. A greater proportion of those intending to be screened had a family history 














Demographic characteristics of eligible respondents and women aged forty to seventy in 
Otago and Southland at the 1986 census 
Characteristic Women surveyed O&Swomen 
No. (%) (%) 
Age (years) 
40-44 64 22 19 
45-49 58 20 17 
50-54 41 14 15 
55-59 43 15 16 
60-64 46 16 16 
65-69 38 13 17 
Ethnic group 
Maori 3 I 2 
Non Maori 287 99 98 
Domicile 
Dunedin 118 41 38 
Other urban 113 39 41 
Rural 59 20 21 
Marital status 
Never married 7 2 5 
Married 230 79 74 
Separated 10 3 3 
Widowed 29 10 13 
Divorced 14 5 4 
Education 
University attendance 40 14 6 
Trade qualification 24 8 
Secondary school 199 69 } 94 










Factors affecting intention to participate in mammographic screening 
Intended Participation 
Yes No 
Number Percent Number Percent p 
Age 
40-49 107 88 14 12 
50-59 74 88 10 12 0.01 
60-69 59 74 21 26 
Knowledge1 
5 118 91 12 9 
<5 123 79 32 21 0.01 
Cervical smear request 
Yes 137 90 15 10 
No 104 78 29 22 0.01 
Friend/acquaintance with 
breast cancer 
Yes 154 89 20 11 
No 84 77 25 23 0.02 
1 Knowledge was scored according to the women's responses to five true/false statements about breast cancer and 
manunographic screening 











Preferred location for a screening centre (women who intend to be screened) 
Location Dunedin women (%) Other women (%) 
Mobile unit 11 11 79 58 
Hospital 47 47 34 25 






























Seventeen percent of the women said they would prefer to attend outside normal working hours 
( this was particularly the case for city women, where twenty percent said they would prefer 
appointments outside working hours). Only twenty-eight percent of respondents felt it would be 
reasonable to expect women to travel more than thirty minutes to get to a screening centre. Women 
who lived outside Dunedin city and who intended to participate said they would prefer to be 
screened at a mobile unit (Table 6.3). 
Thirty-five percent of the women said they would prefer to be screened by female staff while 65% 
did not think the gender of staff was important. Among women who were not definitely intending 
to be screened, fifty-eight percent preferred female staff. Intention to participate was not associated 
with state of health ( women who rated their health as good or excellent were as likely to intend to 
participate in screening as women who rated their health as fair or poor), occupation, educational 
level, or socioeconomic group. Neither were these factors associated with having had a cervical 
smear within three years. Seventy-one percent of respondents thought that some women would 
decline an invitation to mammographic screening. Respondents were asked to suggest a reason for 
this. One hundred and ninety-six women (sixty-eight percent) suggested possible reasons. The 
most common reasons given were fear (of the procedure or the outcome) or embarrassment (Table 
6.4). 
Discussion 
The pre-screening survey identified some features of a screening service and of eligible women that 
were likely to affect participation. Intention to participate varied according to response group. 
Women who replied to the initial letter and were prepared to complete the questionnaire had the 
highest level of intended participation (eighty-nine percent). Seventy-two percent of women who 
responded after a telephone reminder intended to participate. Only forty percent of women who 
had not wished to complete a postal questionnaire but completed the telephone questionnaire 




The survey results indicated that the screening centre should be within thirty minutes travel by car. 
For planning purposes this meant that mobile units would be required to screen women outside 
main centres. The staff at the screening centre would preferably be female. This was especially 
important for women who were undecided or thought that they might not participate in a screening 
programme. The results suggested that some appointment times outside normal working hours 
would be needed. In Dunedin approximately a fifth of women who answered the questionnaire said 
they would prefer appointments outside normal working hours. 
It was planned that publicity and information programmes about screerung would provide 
information so that women knew what to expect when they attended for screening. Fear ( of 
embarrassment associated with screening, or of the outcome of screening) was suggested as the 
main reason for nonparticipation; publicity about the screening programme therefore endeavoured 
to (a) reduce fear of the outcome by emphasising that screening would be negative for the majority 
of women screened, and that early detection and treatment increase the chance of cure, and (b) 
reduce women's expectation of embarrassment by explaining what the procedure involved and by 
assunng pnvacy. 
Intention to participate and knowledge about breast cancer and mammographic screerung 
decreased with age. It was kept in mind that it might be necessary to specifically target women 
over sixty. Women outside Dunedin were more likely to state that their participation would be 
influenced by the location of a screening centre. A mobile screening centre was included in the 
pilot programme so that screening would be more accessible to women outside the main centres. 
Women whose knowledge about breast cancer and mammographic screening was good, were 
more likely to intend to participate. This suggested that education programmes could have a 
significant effect in increasing participation. 
The pilot programme was designed to incorporate the features that were identified in this survey as 
likely to affect participation, with a mobile unit so that rural women did not have to travel too far 
for screening, some evening sessions, female radiographers and clerical staff: and publicity and 
educational leaflets about the programme. Publicity was targeted to specific areas such as rural 




6.2 Participation in screening 
One of the most important determinants of the effectiveness and efficiency of a screerung 
programme is the involvement of the target group. When participation is high, the benefits of 
screening are available to more of the eligible women. In the evaluation of the pilot programme the 
participation rate was defined as the percentage of invited women who were screened as a result of 
an invitation. Coverage was defined as the percentage of the target population screened. The two 
measures were required since some women were screened without having received an invitation. In 
order to approach or exceed the lowest recorded coverage· for successful programmes, the pilot 
programme had a target participation rate of seventy-eight percent or higher in the first screening 
round (Chapter Four, Table 4.1 ). With over ninety percent identification of eligible women, so that 
ninety percent of the eligible population could be invited, a participation rate of seventy-eight 
percent would result in seventy percent coverage (seventy percent of women in the target 
population being screened). 
In screening programmes which had access to population registers, and where invitations were sent 
out to all women on the register, participation has been defined as the percentage of women on the 
register who attended for screening (Breast Cancer Screening Working Group 1987). This is not 
exactly the same as the definition used in the evaluation of the Otago and Southland pilot 
programme. In many published reports from breast cancer screening programmes it is not clear 
whether the reported participation rates include self-referred women, although in the United 
Kingdom national breast cancer screening programme the percentage of eligible women screened, 
which included self-referred women was called "acceptance" rather than participation (Chamberlain 
et al 1993). Discrepancies in the way participation rates are calculated mean that using 
participation as the only measure of the response to screening in the pilot programme could be 
misleading. By calculating two measures, participation and coverage, both the response to an 
invitation and the percentage of eligible women who were screened in the Otago and Southland 
pilot programme were examined. 
Methods 
Each month information was collected on the number of women invited, the number responding, 




women screened, the number of booked women who did not attend, and the total number of 
women screened. This information was collected manually, from the appointment books at the 
screening centres, because although it had been specified as part of the evaluation download, the 
data was not available from the computer system. The manual system that was devised was very 
time-consuming, but was the only means to collect information on participation, given that the 
computer system could not provide the required information. On every invitation that was sent out 
there was a suggested appointment time, and the woman's name was written in the appointment 
book for this time, with the initial "f' against her name to identify her as a woman who had been 
sent an invitation. If a woman phoned to change her appointment her name was removed from the 
original appointment and inserted at the new appointment time and also identified with an 'T'. If a 
woman had not replied to her invitation, a self-referred woman was sometimes given that 
appointment time, but this was added at the bottom of each page, so that the information about the 
number of invited women who declined, cancelled, or did not attend could still be collected. 
Women who self-referred were given an appointment time, and their names were flagged with the 
initials "SR" in the appointment book. Similarly women who had been referred by general 
practitioners were identified with "GP" in the appointment book. Women who attended were 
checked off in the book, and women who did not attend were identified with a cross against their 
names. Each month a member of the evaluation team would extract the data about the number of 
women who attended or did not attend in each of the three categories (invited, self-referred, and 
GP-referred) from the appointment books. 
Although there were limitations to this manual system, which are discussed below with the results, 
it was the only way that it was possible to estimate how many women were screened as a result of 
an invitation, were self-referred, or were referred by their general practitioners each month. It was 
also the only way to identify women who had declined an invitation, so that they could be included 
in the survey of non-attenders (section 6.5). This survey of non-attenders was a very important 
part of the evaluation, to discover whether there were aspects of the screening programme that 
could be changed to encourage such women to attend. 
The coverage of the programme (percentage of eligible women screened) could not be calculated 
until the end of the first screening round since the total number of women screened in the first 










screened in the whole of the first screening round by the number of women who were eligible for 
screening in that round according to the census. 
The participation rate was the number of invited women screened divided by the number of women 
invited, and this measured the response to the invitations. When the evaluation targets were set, it 
was thought that a very high participation (seventy-eight percent) would be required to compensate 
for the fact that not all women would be identified and invited, since some eligible women would be 
on neither the electoral roll nor on general practice registers. It had been expected that nearly all 
the women who attended for screening would do so in response to an invitation. But in the Otago 
and Southland programme there was a constant level of self-referral (women who requested 
screening although they had not received an invitation). As well as self-referred women there were 
also women who were referred by their general practitioners or through the Radiology Department 
of Dunedin Hospital. This meant that the number of women who were screened as a result of an 
invitation was constantly supplemented by women who had self-referred or had been referred. It 
also meant that by the time some women received their invitations, they had already been screened. 
Results 
The participation rate (response to an invitation) was fifty-eight percent (Table 6.5). This was the 
percentage of women who, having been sent an invitation in the first eighteen months of screening, 
had attended screening (women who were invited during the eighteenth month of screening had to 
have attended within the following month to be included). It does not include women who 
attended before being invited; these women were designated "self-referred" or "general 
practitioner-referred". The names of women who had self-referred or been referred by a general 
practitioner were crossed off the electoral roll so that they would not be invited again in the first 
screening round. General practitioners also removed the names of women who had already 
attended the programme from the screening lists derived from their age-sex registers. It is possible 
nonetheless, that some invitations could have been sent out inappropriately (for instance if a self-
referred woman had changed her address since the electoral roll was updated). This would cause 
the true participation rate to be underestimated. Also any woman who declined an invitation but 
later changed her mind and made an appointment would be categorised as "self-referred" for that 
appointment. This would cause the number of self-referrals to be overestimated. A third possible 





the programme, while the women who waited to receive an invitation may have been less 
enthusiastic about screening. The response of these women to an invitation could therefore 
underestimate the true response for all eligible women. The target was that seventy-eight percent 
of women who received an invitation would be screened. This was on the assumption that about 
ninety percent of women would be accurately identified, so with a participation rate of about 
seventy-eight percent, seventy percent of the women living in Otago and Southland aged fifty to 
sixty-four would be screened. In fact, the participation rate was considerably below the target that 
had been set (Chapter Four, Table 4.1). 
At the end of the first screening round 14, 129 women had been screened, out of a total of 18,555 
women aged fifty to sixty-four and living in Otago and Southland at the 1991 census. Using the 
1991 census figure as the denominator gave the programme seventy-six percent coverage of the 
eligible women in Otago and Southland. However, some women aged into the eligible age-range 
during the first screening round, thus increasing the number of eligible women, and during the same 
period some women who were aged sixty-three and sixty-four in 1991 aged out of the eligible age-
range, thus reducing the number of eligible women. In.1991 there were 2,886 women in Otago 
and Southland aged forty-eight and forty-nine. These women would have entered the eligible age-
range over the following two years. However, there were 2,382 women aged sixty-three and sixty-
four at the 1991 census, who would have become ineligible over the following two years. The 
result is a 2. 7 percent increase ( 504 women) over two years in the number of women eligible for 
screemng. If this increase in the denominator is taken into account the coverage is seventy-four 
percent. 
Discussion 
The target coverage of seventy percent of fifty to sixty-four year old women living in Otago and 
Southland screened had been met by the end of the first screening round, but this was despite a 














Participation rate* in response to an invitation 
in the first eighteen months of screening . 
Screening centre No. invited No. of invited 
women screened 
Dunedin 4,596 2,385 
Invercargill 3,258 2,003 
Mobile# 1,803 1,188 






* the participation rate is calculated as the percentage of invited women who attended as the result of an 
invitation issued in the first eighteen months of screening in the Otago and Southland pilot programme. 
# the mobile unit had only been operating for six months during this period. 
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general practitioners it was found that a seventy-one percent participation rate could be achieved 
(Chapter Five, section 5.1.3). However, because of the consistently high level of self-referral 
throughout the first screening round, a target for participation in the Otago and Southland 
programme became almost irrelevant once the programme started. When the pilot programme was 
being planned the very high level of self-referral and referral by general practitioners that occurred 
throughout the first screening round was not anticipated. This meant that many women were 
screened despite never receiving an invitation, and some women would already have been screened 
by the time they received an invitation. The implications of this are discussed further in Chapter 
Seven. 
Initially the programme functioned under its expected capacity, because of problems recruiting 
staff, and also because there were unavoidable delays in commissioning the mobile unit, which did 
not start screening until a year after the programme started. Despite these difficulties, the 
programme still managed to exceed the target of screening seventy percent of the eligible 
population in the first screening round. 
6.3 Acceptability of Screening 
A survey was carried out to measure satisfaction with the screening service, to provide feedback 
for programme staff, and to obtain an indication of future participation in the programme. 
Information about the costs to participating women was also collected so that it could be used later 
in the economic analysis of the pilot programme. 
Methods 
The questionnaire was finalised after a draft questionnaire had been piloted on the first 140 women 
to participate in the screening programme. Screening at the fixed units in Dunedin and Invercargill 
started in September 1991 and November 1991 respectively, and screening on the mobile unit 
started later, in September 1992. A random sample of ten in every fifty women screened at the 
fixed units was selected by computer-generated random numbers based on the order in which the 
women were screened during February to April 1992. This "urban" sample was sent a self-
administered questionnaire (Appendix Six) with a reply-paid envelope. The proportions of 
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screened women sampled were the same for each of the two fixed units. Women who did not 
respond within a month were sent a follow-up letter and a second copy of the questionnaire. Of 
168 women sent questionnaires, 156 ( ninety-three percent) replied. The results from this sample 
can be interpreted allowing a margin of error of up to ten percent with 95% confidence. The initial 
smvey was carried out early in the course of the programme so that rapid action could be taken if 
any major problems were identified. The survey was designed to be repeated during the course of 
the pilot programme. 
The same questionnaire was . subsequently posted to all the women who attended the mobile 
screening unit in its first three months of operation (September to November 1992) to give the 
'rural' sample. The same follow up reminders were used. Questionnaires were sent to 306 women 
and 286 (ninety-three percent) replied. Results were analysed by cross tabulation and r: statistics. 
Results 
Replies were received from 156 'urban' and 286 'rural' women, the response rates being the same 
(ninety-three percent) in each of these groups. 
Demographic characteristics: 
Ninety percent of the respondents answered all of the demographic questions (Table 6.6). The 
urban and rural samples of women were similar in age and ethnic group. They differed in 
education, with fewer rural women having attended university, while more had trade or vocational 
qualifications. Their occupations also differed; fewer rural women were in paid employment but 
more were self-employed. The women were asked about their yearly household income before tax. 
Three categories which corresponded to the categories used by the government to assess eligibility 
for community support were used in the questionnaire. The rural women had significantly lower 
household incomes than the urban women ( although it is difficult to assess farm incomes in this 
way). 
Participation in the screening programme 
Twenty percent of the women were self-referred (i.e. attended screening without having received 












Demographic characteristics of urban and rural participants in the 
Otago and Southland breast cancer screening pilot programme 
Characteristic Urban Women Rural Women 
Number Percent Number 
Total 156 100 286 
Age (years) 
50-54 54 35 118 
55-59 47 30 91 
60-64 55 35 77 
(x2 = 3.6, df = 2, p = 0.17) 
Ethnic group 
Maori 2 1 5 
Non Maori 148 98 272 
Education 
Primary school 13 9 21 
Secondaty school 102 71 208 
University 16 11 6 
Trade qualification 12 8 41 
(x2 = 18.2, df= 3, p < 0.001) 
Jlouseholdincome 
(before tax) 
less than $15,000 45 33 118 
$15,000 - $30,000 56 41 99 
more than $30,000 36 26 41 
(x2 = 8.7, df= 2, p = 0.01) 
Occupation 
Paid employment 52 35 48 
Self-employed 9 6 51 
No paid 32 21 77 
employment 
Retired 57 38 103 






















were screened because they had received an invitation from the programme. Half of the women 
said that they first found out about the programme when they received the invitation to take part. 
The women were asked whether they would have arranged to have a mammogram if they had not 
been invited to the screening programme; fewer than half (forty-seven percent) said that they 
would have, and only a third (thirty-two percent) said they would have had mammograms if they 
had had to pay for them. There was no difference between urban and rural women for any of these. 
Anxiety related to screening 
The women were asked how they felt when they received the invitation to be screened (Table 
6.7a). While most women were not worried or only slightly worried by the invitation, significantly 
more of the urban women (thirteen percent) were 'very worried' by the invitation compared with 
less than one percent of rural women (Table 6.7a). For both rural and urban women there was no 
difference in the anxiety experienced during screening or while awaiting the results of screening so 
the results from the two groups were combined (Table 6.7b). Anxiety was not related to a history 
of breast cancer in family or close friends (p = 0.06, Table 6.8). There was no significant difference 
in anxiety related to screening for women who had had family or close friends with breast cancer 
compared with women who had not. Although there was a downward trend in the percent not at 
all worried with time until results were received, there was no significant relationship between 
anxiety and the time that it took for the women to receive their results (p = 0.7, Table 6.9). The 
women who worried most while waiting for their results were the women who had also worried 
most about the screening invitation (p < 0.001, Table 6.10). 
Experience of the screening test 
Most women found the mammogram uncomfortable rather than painful (Table 6.11 ). There was 
no difference between screening centres nor between urban and rural women in their experience of 
the screening test. Eleven women (three percent) had severe bruising after the mammogram. 
Women with bruising were significantly more likely to have found the mammogram painful (p 
<0.001). Results for urban women are shown in Tables 6.12 and 6.13. The level of anxiety before 
the screening test was not related to the amount of discomfort felt (p = 0.12, Table 6.12), but 
anxiety while awaiting the results of the screening test was positively related to the amount of 











Anxiety related to screening 
(a) Anxiety 011 receiving invitation to be screened 
Not ;,1.t all worried 
















(b) Anxiety due to screening and while awaiting the result of screening 
Screening Results 
Number (%) Number 
Not at all worried 224 (51) 221 
A little bit worried 192 (44) 192 
Quite worried 15 (3) 21 
Very worried 4 (1) 5 
(x2 = 1.1, df= 3, p < 0.77) 


















Anxiety related to screening by history of breast cancer in family or close friend 
Anxiety related to screening 
Not at all worried 
A little bit worried 
Quite to very worried 
















Anxiety while awaiting results and time until results received 
' ( 
Time until results received (weeks) 
\,( 
,\ <I 1-2 2+ 
Anxiety while awaiting results No. (%) No. (%) No. (%) 
Not at all wonied 21 (60) 39 (48) 11 (42) 
' A little bit wonied 12 (34) 36 (44) 13 (50) ' 4 Quite worried 
' 
2 (6) 4 (5) 1 (4) 
'J Verywonied 0 (0) 3 (4) 1 (4) 
Total 35 82 26 
.! 
., 
(x2 = 6, df= 6, p = o.7) 
(Not all women answered every question so the totals in the tables may differ) 
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TABLE 6.10 
' Anxiety on receiving invitation by anxiety while awaiting results 
Anxiety while awaiting results 
Not at all A little bit Quite Vety 
'\ 
worried worried worried worried 
Anxiety on receiving 
screening invitation 
} Not at all worried 177 51 2 0 
i A little bit worried 43 136 11 2 
Quite worried 3 4 7 1 
_, 
Vety worried 0 1 I 2 
J 
} 
cx2 = 2s2, elf= 9, p < 0.0001) 
\ 
·) 
(Not all women answered every question so the totals in the tables may differ) 
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TABLE 6.11 
Experience of the screening test 
Number (%) 
Experience 
A little uncomfortable 194 (45) 
Very uncomfortable 102 (24) 
I 
\ Painful 82 (19) 
Very painful 53 (12) 






















Anxiety before screening and experience of screening 
Experience of screening 
A little Very Painful Very 
uncomfortable uncomfortable Painful 
(No.) (No.) (No.) (No.) 
Anxiety before screening 
Not at all worried 42 13 12 8 
A little bit worried 28 20 9 12 
Quite worried 2 2 0 1 
Very worried 0 I 0 2 
Total 152 
(x2 = 14, df= 9, p = 0.12) 






Anxiety while awaiting results and experience of screening 
Experience of screening 
A little Very Painful Very 
uncomfortable uncomfortable Painful 
(No.) (No.) (No.) (No.) 
Anxiety while awaiting 
results 
Not at all worried 45 14 9 10 
A little bit worried 25 17 12 11 
Quite worried 2 5 1 1 
Very worried 0 2 0 2 
Total 156 
(:x2 = 17, df = 9, p = 0.04) 









Experience of the screening unit 
Information was collected about each screening centre. This included waiting times, time spent at 
the centre, and women's opinions about the waiting area, changing rooms, and the attitude of staff 
at the screening centre. At the fixed units eighty percent of women were screened within fifteen 
minutes of their appointment time. At the mobile unit ninety percent of women were screened 
within fifteen minutes of the time that they had been given. Waiting times are slightly shorter at the 
mobile screening unit because film processing is not carried out there; at the fixed units the women 
wait until their films have been processed in case any extra views need to be taken; if extra views 
are taken this can sometimes increase the waiting time for the next woman to be screened. When 
asked what they thought was an acceptable time to have to wait for a mammogram forty-eight 
percent thought less than fifteen minutes, forty-nine percent thought up to thirty minutes, and three 
percent thought up to an hour. 
Over ninety-five percent of the women were happy with the size of the waiting areas and the 
temperature and privacy of the changing rooms. There was no difference between screening 
centres. Nmety-:five percent of women were happy with the way the staff had treated them. Once 
again there was no significant difference between screening centres. 
Costs to women 
When the women were asked their reasons for participating in the pilot programme 154 women 
(thirty-five percent) gave the fact that it was a free service as one of their reasons. When they were 
asked how much they would be prepared to pay if the screening programme could not continue as 
a free service (Table 6.14) twenty percent of women said that they would not take part in the 
programme if there were a charge. Forty-two percent said they would pay up to twenty dollars, 
thirty-two percent said they would pay between twenty and fifty dollars, and six percent said they 
would be prepared to pay more than fifty dollars. 
Although the two groups differ in household income there was no difference between urban and 
rural women for these questions. There was no relationship between household income and the 
amount women would be prepared to pay if the screening programme were not free. Most women 
travelled to the screening centre by car ( eighty-one percent of urban women and ninety-two percent 
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TABLE6.14 
Amount women would be prepared to pay if the screening programme 
could not continue as a free service 
< 
; 
Number (%) __ , 
Amount prepared to pay 
Would not take part if charged 86 (20) 
( Under$20 180 (42) 
'· 
\ 
$20 to $50 135 (32) > 
Over $50 25 (6) 





of rural women). Several rural women said that they would have used car pools if they had known 
when other women would be attending. 
Future participation in screening 
When asked whether they would return for another screen in two years if they received an 
invitation, almost all the women (ninety-four percent) said they would. This percentage was lower 
(seventy-five percent) in those who had found the mammogram 'very painful' (p < 0.01). The 
number of women in this category was very small, so no further analysis of this subgroup was 
undertaken. 
Discussion 
The response rate to this survey was very hi~ ninety-three percent after one reminder. This is 
probably partly because accurate addresses were available for all the women from the screening 
programme records. More importantly these women had already accepted an invitation to 
participate in the programme, and as part of giving their informed consent they were informed that 
they might be asked to take part in surveys about the pilot programme. The women were aware 
that the infonnation they provided would be used to help with decisions about a national breast 
cancer screening programme. Some demographic characteristics of urban and rural women 
differed but their opinions about the screening programme were similar. 
Although the pilot programme had received a lot of publicity, about half the women said that they 
found out about the programme only when they received an invitation to take part. About six 
weeks before invitations were sent out in a particular area the programme manager spoke to 
women's groups in the area and distributed posters and pamphlets locally. Most local newspapers 
gave the programme considerable coverage, and radio interviews and talkbacks were afso used. 
Television campaigns were not used as they could not be directed specifically at small local areas. 
Most women found the mammogram uncomfortable rather than painful. This is consistent with 
other investigations (Stamper et al 1988, Jackson et al 1988, Wolosin 1989, Rutter et al 1992). 
The suggestion that discomfort is related to anxiety before the test (Rutter et al 1992) is not 
supported by the results of this study, although the women who experienced the most discomfort 









the most pain also had more bruising after the mammogram. The small number of women who do 
not intend to participate in the programme again were more likely to have found the mammogram 
very painful. 
As in other reports (Dean et al 1986, Ellman et al 1989, Baines et al 1990) most women were 
either not worried or only slightly worried by talcing part in the screening programme. The women 
who worried most while waiting for their results were the women who had also worried most 
about the screening appointment. Anxiety was not related to a history of breast cancer in family or 
close friends, nor to the time that the women had to wait to get their results. 
A third of the women in this survey said that one of the reasons they took part in the screening 
programme was because it was free, and a third said that they would not have had a mammogram 
in the absence of the programme if they had had to pay for it. When asked how much they would 
be prepared to pay if the programme could not continue as a free service, twenty percent said they 
would not take part if there was a charge and only twenty-five women (six percent) said they 
would be prepared to pay more than fifty dollars. It is interesting to note that in the private sector 
in New Zealand it is not possible to have a mammogram for less than fifty dollars (Department of 
Health 1992). 
It is very important that a screening service is acceptable to eligible women. If the service is 
unsatisfactory participation at re-screening will drop, and other women may decline to take part 
because of adverse comments from participants. In this survey overall satisfaction with the service 
was extremely high, with over ninety percent of respondents satisfied with the screening units and 
staff, and ninety-four percent planning to have another mammogram in two years. The fixed and 
mobile units were equally acceptable. 
The survey results provided valuable management information for the programme, for example the 
survey showed that some women did not receive their results within the ten day maximum period 
initially set for the programme, and so an additional clerical person was appointed. The method of 
processing results was also been changed as a result of the survey. Because films have to be 
forwarded by courier for reporting, it is not possible to provide results as rapidly from the mobile 
screening unit. The ten day target was extended for the mobile unit. 
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Several rural women said that they would have used car pools if they had known when other 
women were being screened, but the need for confidentiality prevents the distribution of 
appointment lists. However there is always a public meeting before the mobile unit goes to a rural 
town and some women have organised car pools at these meetings, voluntarily giving their names 
to the programme staff 
Although the demographic characteristics of urban and rural women differed, their responses to the 
screening programme were similar. Satisfaction with the service was extremely high, with 94% of 
respondents planning fo participate again in two years. Women who had found the mammogram 
very painful were less likely to intend to participate again. The radiographers are aware of this and 
are conscious of the need to maintain a balance between achieving adequate compression for a 
good image, and not causing pain to the women. The results of this survey, with a high level of 
satisfaction and a high level of intention to participate in future, suggest that the pilot programme 
provides a service which is acceptable to eligible women in Otago and Southland. 
6.4 Acceptability of assessment 
It is accepted that screening reduces breast cancer mortality among women aged fifty to sixty-four. 
However as well as this benefit there can be problems associated with screening. In order to detect 
and treat breast cancer, women with abnormal mammograms are referred for further investigations. 
Some of the women referred are found not to have breast cancer and have then needlessly suffered 
the anxiety associated with a positive screen result and the subsequent investigations. In order to 
minimise this problem it is important that the screening test has high specificity ( and therefore few 
false positives) but also that the process of assessment for women with abnormal mammograms is 
acceptable. 
A survey was carried out to measure satisfaction with the assessment process, to provide 
information for the assessment clinic staff, and to collect information about costs to women which 




A self-administered questionnaire (Appendix Seven) was posted to all women who had attended 
the Invercargill and Dunedin assessment clinics during November 1991 to April 1992. Women 
who did not respond were sent a reminder letter and another copy of the questionnaire. The 
questionnaires were analysed using SPSS-X (Statistical Package for Social Sciences 1990). 
Comparisons have been made between this survey and the earlier survey of women after screening 
which was described in section 6.3. 
Results 
The questionnaire was posted to 140 women and 125 (eighty-nine percent) responded. The 
women in this survey in general had higher household incomes (x2 = 9.24, df= 2, p < 0.01) than 
those in the screening survey (Tables 6.6 and 6.15), but did not differ from the women in the earlier 
screening survey in age distribution, ethnic group, education, and occupation. 
Anxiety was measured using a four point Likert scale, as in the screening survey (section 6.3). In 
the assessment survey, the women were asked about their level of anxiety upon receiving the 
assessment clinic appointment and also about their level of anxiety on receiving an invitation to the 
screening clinic. Because this comparison was made within the same group of women, the sign test 
rather than chi-squared test was used to test for significance. The women surveyed had been more 
anxious on receiving the assessment appointment than they had been on receiving their screening 
appointment (Sign test (37+, 78=, 8-) x2 = 17.6, df = 1, p < 0.005). This increase in anxiety 
affected thirty percent of the women; it is important to note that for most women (seventy-eight of 
the 123 women who answered both questions) their level of anxiety did not change. Where the 
level of anxiety changed, it was significantly more likely to increase than to decrease (Table 6.16). 
The level of anxiety experienced by the assessment survey respondents on attending the assessment 
clinic was also compared with that of the screening survey respondents ( a different group of 
women} on attending the screening clinic. Comparing the responses in the assessment survey with 
those in the screening survey (Table 6.17) showed that attending the assessment clinic caused more 
anxiety (x2 = 38.6, df = 2, p < 0.001) than attending the screening clinic. Most women (sixty-





























No paid employment 
Retired 
Household income (before tax) 
less than $15,000 
$15,000 - $30,000 













































Anxiety related to assessment appointment compared with screening invitation 
in 125 women who attended the assessment clinic 
Screening Assessment 
Jnvi talion Appointment 
No. Percent No. Percent 
Anxiety 
Not at all worried 61 49 46 37 
A little bit worried 51 41 50 41 
Quite to very worried 13 10 27 22 













Anxiety related to being screened and being assessed 
Screening Assessment 
No. Percent No . Percent 
Anxiety 
. Not at all worried 224 51 35 29 
A little bit worried 192 44 64 53 
Quite to very worried 19 4 23 19 
cx2 = 38.6, df= 2, p < 0.001) 
(In this table the responses of two separate groups of women, in two separate surveys, have been compared; the 





thirty-nine percent of the women being given the results while they were still at the assessment 
clinic. Twelve percent of women waited for more than two weeks to receive their results (Table 
6. 18). The level of anxiety while waiting for the results from the assessment clinic was not related 
to the length of time that the women had to wait for their results (Table 6.19, x2 = 13.3, df = 9, p = 
0.15). 
While there were three screening centres (the two fixed screerung centres in Dunedin and 
Invercargill, and a mobile unit for rural women), there were only two assessment clinics, one in 
Dunedin and the other in Invercargill. 
Most women (eighty-six percent) travelled to the assessment clinic by car. Only two women had to 
travel for more than an hour to reach the assessment clinic. Most women (seventy-seven percent) 
attended the clinic on their own but eleven women came with an accompanying person to provide 
support. 
Over half the women (fifty-two percent) spent less than thirty minutes at the clinic, and only 
thirteen percent were there for more than an hour. Over ninety-five percent of the women found 
the staff fiiendly and the clinic surroundings satisfactory. 
Of the women who responded ninety-eight percent said they would take part in the screening 
programme again in two years if they received another invitation (Table 6.20). This is higher than 
the percentage (ninety-four percent) of women in the screening survey who said they would take 
part in the screening programme in future (x2 = 4.08, p = 0.04). 
Discussion 
The results from this survey are similar to assessment clinic surveys carried out elsewhere, where 
over ninety-five percent of women who attended assessment clinics planned to attend for 








Immediately 47 39 
Within 1 week 33 28 
1 - 2 weeks 26 22 
More than 2 weeks 14 12 
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TABLE 6.19 
Anxiety while awaiting results of assessment by time until results received 
Time until results received 






Not at all worried 7 10 9 3 




I "i Quite worried 8 1 4 2 
' i 
Very worried 11 5 0 2 
·, 
;< (x2 = 13.3, df= 9, p = 0.15) 
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TABLE 6.20 
Intention to participate in future 
Number Percent 
'.\ 
Yes 116 98 









difference between women who had false positive results at a previous screen compared with 
women who had negative screen results, in their subsequent participation in screening. 
It has been shown that women who have had routine breast cancer screening examinations do not 
experience increased psychiatric morbidity (Dean et al 1986,. Elhnan et al 1989). But, as in the 
Otago and Southland assessment survey, women requiring further assessment have significantly 
higher anxiety scores than those attending for routine screening (Lerman et al 1991, Elhnan et al 
1989 Gram et al 1990). It is important to minimise the anxiety related to assessment; ensuring 
relaxed surroundings, providing adequate information, and minimising waiting times for results are 
important (Marteau 1990, Smith et al 1991 ). Two studies of the effects of attending an assessment 
clinic have found that there are few long-term consequences of assessment, even for women with 
false positive results (Elhnan et al 1989, Gram et al 1990) although one study found that women 
who have experienced false positive tests remain more anxious about breast cancer afterwards (Bull 
and Campbell 1991) This study concluded that "the psychological effects of breast cancer 
screening are small in the general population, but of note in women who undergo open biopsy of a 
benign lesion". 
The Otago and Southland assessment survey results are consistent with those from other similar 
surveys. The results also show that the Dunedin and Invercargill assessment clinics are providing 
an acceptable service for women who take part in the pilot programme, at least in the shorter term. 
Determination of the longer-term consequences of assessment in the pilot programme will require 
longer follow-up. 
6.5 Survey of women who did not attend after an invitation to screening 
A survey was carried out to identify factors that influenced attendance or non-attendance at the 
screening programme. The aim of this study was to identify any characteristics of eligible women, 
and of the screening programme, that had deterred women from participating. If any of these 
characteristics were modifiable it could be possible to increase participation, for instance by 
changing features of the programme, or by specifically targeting certain groups of women. The 






acceptability of the pilot programme, but the survey was still ongoing at the time the author left 
New Zealand. The data management and analysis of the results were carried out by Bronwen 
McNoe and Mark Elwood (McNoe et al, in press). A description of the survey, and its results 
follows. 
Methods 
A random sample of ten in every hundred women who attended the screening programme from 
January to July 1993 after being sent an invitation, and who had a normal screening result was 
taken. Another random sample of ten in every thirty women who had been invited but did not 
attend for screening from January 1993 to March 1994 was taken. The sampling methods and time 
frames differed for the two groups of women because there were fewer non-attenders than 
attenders, and non-attenders were considerably more difficult to contact. 
There were 272 attenders identified, and of these one had changed address, four had no known 
telephone numbers ( although telephone numbers were requested at the time of screening), and 
forty-four women could not be contacted after three attempts. Of the 223 women contacted, 
twenty-nine had self-referred and so were ineligible. Of the 194 eligible attenders, one had hearing 
problems and two declined to participate in the study. The remaining 191 attenders were 
interviewed; this is ninety-eight percent of those contacted and seventy-nine percent of the 
estimated total sampling frame (272 minus twenty-nine). Copies of the questionnaires are included 
as Appendix Eight. 
Four hundred and ninety-seven non-attenders were identified, but five had changed address, 156 
had no telephone numbers, and 115 could not be contacted after three attempts. There were 
seventeen women among the non-attenders who said that they had not received an invitation 
although the screening programme records showed that an invitation had been sent. There were 
204 women who had definitely received an invitation but declined screening, of these three could 
not be interviewed because of language problems or severe illness, and t~nty-seven declined to be 
interviewed. This left 17 4 ( eighty-six percent) of those who could be contacted and had definitely 
declined an invitation, but this was only thirty-five percent of the 497 women who had been sent an 






Standardised telephone interviews were carried out by an experienced interviewer from the 
evaluation team. The interview included both closed and open questions. Where possible the 
interviews were identical for attenders and non-attenders, but they differed in terms of questions 
about reasons for attendance or non-attendance. The interviewer could not be blinded to the 
attendance status of the interviewee as different introductory statements were required (Appendix 
Eight). Confidentiality was guaranteed. 
Results 
There were 191 attenders and 174 non-attenders interviewed in the survey. There were no 
differences in age, education, income, socioeconomic status, or current employment between the 
two groups. Several closed questions and an open question, were asked to determine why the 
women had attended ( or not attended) for screening (Table 6.21 ). 
About two thirds of the attenders selected reassurance (sixty-nine percent) and early detection of 
breast cancer (sixty-five percent) as reasons for attendance. Forty-two percent selected the free 
service as one of the reasons that they had attended, thirty-four percent because it was 
recommended by their general practitioner, and thirty-one percent because it was a pilot 
programme. Seventeen percent said they had been influenced by positive reports from other 
women, ten percent because of a family history of breast cancer, and four percent because of a 
current breast symptom. Thirty-four women (eighteen percent) answered the open question and 
most ( seventeen) gave a perception that they were at increased risk (because of a personal or family 
history of breast cancer, or because they were on hormone replacement therapy) as reasons for 
attending. 
Most of the non-attenders (seventy-four percent) answered the open question on their reasons for 
non-attendance. Twenty-three percent of them said they had not attended because they could not 
easily attend (because of health problems or other activities). Twenty-one percent were not 
convinced that mammography was valuable. Responses to the closed questions are shown in Table 
6.21. Fifteen percent of the non-attenders said that negative reports from other women had 
influenced them. Seven percent thought they would be ineligible (having had a recent mammogram 









Reasons for attendance or non-attendance at screening 
Attenders (n = 191) Reasons for attendance 
(multiple responses could be given) 
Reassurance 
To detect breast cancer early 
Because it is a free service 
Recommended by my family doctor 
Because it is a pilot programme 
Positive reports from other women 
Family history of breast cancer 
Breast symptom 
Non-attenders (n = 174) Reasons for non-attendance 
(within major categories, multiple responses could be given) 
Likely to be ineligible 
Recent mammogram 
Being treated for breast problem 
Practical difficulties 
Inconvenient appointment time 
No transport 
Too far from screening centre 
Negative opinion of screening 
Fear of procedure 
Negative reports from other women 
Fear of possible outcome 







































Source: McNoe B, Richardson AK, Elwood JM Factors affecting participation in mammography screening. NZ 






decide against attending, and another twenty percent cited fear of the procedure. Three percent of 
the non-attenders objected to the invitation procedure, either because an appointment had been 
made in advance, or because they were not happy that the programme had access to their names 
and addresses. Both groups of women were asked about practical aspects of attending for 
screening (Table 6.22), including the time it would take to travel there, their mode of transport, 
what they would otherwise have been doing at the time specified for the screen, and whether it 
would be easy for them to fit such an appointment into their usual routine. There was no difference 
in mode of transport, but the attenders assessed the time for them to travel to the screening centre 
as significantly less than non-attenders (p = 0.02). The groups also differed in what they would 
otherwise have been doing at the time specified for the screen (p < 0.01), with attenders less likely 
to be in paid employment or caring for children. Nine percent of the non-attenders were ill. Ninety-
five percent of attenders found it very easy or quite easy to fit a screening appointment into their 
usual routine, compared with only forty-nine percent of non-attenders (p < 0.01 ). 
The women were also asked, using a four-point Likert scale, how anxious the invitation to 
screening had made them feel (Table 6.23), how they perceived their risk of breast cancer, and 
whether they had any family members or close friends who had breast cancer. There was no 
difference between the groups in their level of anxiety on receiving the invitation. Attenders were 
more likely to regard themselves at higher risk of breast cancer compared with other women their 
age (p = 0.02). 
Both groups were asked whether they would attend for screening if they received an invitation in 
two years (Table 6.24). Ninety percent of the attenders said they would attend, and forty-three 
percent of the non-attenders said they would attend the next screening round (X2 = 90, p < 0001). 
Intention to participate varied among the non-attenders according to their reason for non-
attendance. In the non-attenders who cited practical difficulties as their main reason for not 
attending, intended participation at the next screening round was eighty percent, which is not 
significantly different from the attenders. The rest of the non-attenders had intended participation 










Practicalities of screening for women invited to screening 





Time to travel to screening centre 
Less than 15 minutes 
15 to 3 0 minutes 
3 0 minutes or more 
missing 
Usual activity at time of screening appointment 
Working (paid & voluntary) 
Leisure activity 




How easy was it to fit in a screening visit? 
Very easy 
Quite easy 
A little difficult 
Quite/very difficult 
missing 
% attenders % non-attenders 























x2 = 116.6 (3 df) p < 0.01 
Source: McNoe B, Richardson AK, Elwood JM. Factors affecting participation in mammography screening. NZ 
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TABLE 6.23 





How worried did the invitation make you? 
Not worried 
A little worried 
Quite/very worried 
missing 
Women's self-perceived breast cancer risk 
Less at risk 
Sarne risk 
More at risk 
Don't know 
missing 



























x2 = o.6 (1 df) p = 0.42 
Source: McNoe B, Richardson AK, Elwood JM. Factors affecting participation in mammography screening. NZ 
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TABLE 6.24 
Intention to participate in future screening 
Intend to participate in next screening round 
Total number Yes Percent No/uncertain 
Attenders (all) 191 172 90.1 19 
Non-attenders 
practical difficulties 35 28 80.0 7 
thought ineligible 12 5 41.7 7 
no reason given 93 33 35.5 60 
negative opinion 34 9 26.5 25 
all non-attenders 174 75 43.1 99 
Intention to participate in attenders compared with non-attenders x2 = 90, p < 0001 . 
Source: McNoe B, Richardson AK, Elwood JM. Factors affecting participation in mammography screening. NZ 




This study showed that the major difference between attenders and non-attenders was that women 
who did not attend rated breast cancer screening as less important in comparison to the time and 
effort needed to attend. Although non-attenders assessed the time for them to travel to the 
screening centre as significantly more than attenders, this perception was not supported by the 
actual distances involved. The actual distance from each woman's residence to the screening centre 
was measured on a map, and there was no significant difference between the attenders (mean 
distance 9.2 km) and non-attenders (mean distance 10. 7 km, p = 0.43). A study carried out in 
London found that the actual distance from a woman's home to the screening centre was not 
related to attendance (Sutton et al 1994). These :findings are in accord with the Health Belief 
Model, which proposes that decisions are related to beliefs about the seriousness of the condition, 
personal susceptibility, and effectiveness of the measures suggested, compared to the costs 
described as inconvenience, discomfort, or risk (Calnan 1984). 
The results of this study suggest that participation could be increased by reducing practical barriers 
to screening (for instance greater availability of appointments outside normal working hours) and 
by increasing women's knowledge about breast screening. But it is important to respect the right 
of women not to take part in screening if they do not wish to. Women who have been provided 
with appropriate information about breast cancer screening should not feel pressured to participate 
if they do not wish to. An important result is that forty-four percent of the women who did not 
attend in the first screening round said that they would attend if they received an invitation to the 
second round. This means that it is reasonable to continue to invite women who have declined an 
invitation to a previous screening round. However this survey was restricted to those women who 
could be contacted and who had definitely declined an invitation, so this result may not apply to all 
women who are sent an invitation but do not attend. 
6.6 Summary 
This chapter has examined the acceptability of the Otago and Southland pilot programme to the 
women who are eligible for screening. The pilot programme was designed to incorporate the 







screening for women in Otago and Southland. The pilot programme included a mobile unit so that 
rural women would not have to travel too far for screening, some evening screening sessions, 
female radiographers and clerical staff, and publicity about the programme. 
Intended participation had been high in the pre-screening survey, and many women referred 
themselves for screening rather than waiting for an invitation. But this level of self-referral may not 
happen in other places, and means that one cannot predict what will happen in other parts of New 
Zealand. It seems likely however, that many women will self-refer or be referred by their general 
practitioners before receiving an invitation. In the Waikato pilot programme sixteen percent of the 
women screened in 1994 were self-referred or had been referred by their general practitioners 
before receiving an invitation, and in 1995 fifteen percent of the women screened were self-referred 
or referred by their general practitioners (McKinnon, 1996 personal communication). It is very 
helpful to know however, that seventy-one percent participation can be achieved with an 
appropriate invitation signed by a general practitioner (Chapter Five, section 5.1.3), although this 
may not apply to all general practices. It will be important to monitor participation at re-screening 
in the second round of the pilot programme, as continuing high participation will be necessary to 
maintain over seventy percent coverage of the women in the target population. This is discussed 
further in Chapter Seven. 
There was a very high level of satisfaction with all aspects of the screening service, with no 
difference between centres. Ninety-four percent of the women would return for another screen in 
two years. The survey showed that some women did not receive their results within the maximum 
period initially set for the programme. An additional clerical person was appointed as a result. The 
method of processing results has also been changed as a result of the survey. There was a high 
level of satisfaction with the assessment clinics, although understandably assessment caused women 
more anxiety than screening. Women who could be contacted and who had definitely declined an 
invitation to take part in screening did not differ in demographic characteristics from the women 
who took part, but they assessed the value of being screened as less than the practical problems of 
attending. The acceptability of screening in the Otago and Southland pilot programme and the 
implications for the acceptability of screening in a national breast cancer screening programme are 
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CHAPTER SEVEN 
Summary and Discussion 
Introduction 
This chapter summarises the results of the evaluation of the Otago and Southland pilot programme. 
The strengths and weaknesses of the evaluation method are examined in section 7.1, and the 
principal findings of the evaluation are discussed in sections 7.2 to 7.4, under the three areas 
specified for the evaluation (Skegg et al 1988); effectiveness (section 7.2), acceptability (section 
7.3), and economic efficiency (section 7.4). The implications of these results are discussed in 
section 7.5, some recommendations are made in section 7.6, and conclusions are drawn in section 
7.7. 
7 .1 Method strengths and limitations 
The evaluation method used here required information from randomised controlled trials for the 
development of targets. The method was appropriate for the evaluation of the pilot programme 
because it had already been shown in randomised controlled trials that mammographic screening 
can reduce breast cancer mortality. Randomised controlled trials provide the best evidence of the 
efficacy of a health intervention, so a particular strength of this evaluation method was that the pilot 
programme could be compared against programmes which had proven efficacy. The evaluation 
targets were derived from reviewing the relevant literature (Chapter One), and methods were 
developed for measuring these targets in the pilot programme (Chapters Three and Four). The 
targets provided a means to ensure that the pilot programme was similar to programmes which had 
been shown to reduce breast cancer mortality. It was assumed that if the pilot programme was 
similar in its early performance to successful programmes, it too would reduce breast cancer 









programmes, where interim measures have been used to predict the likely outcome of screening 
(Hakamaetal 1985, Day et al 1989, Paci et al 1990, Verbeeketal, 1991, Morrison 1991). In this 
evaluation method suitable interim measures, or targets, were selected after reviewing the results 
from randomised controlled trials, in order to develop a standard against which the pilot 
programme could be evaluated. Although this approach has the advantages described above, the 
use of randomised controlled trials is also a limitation of this method. The method is useful in 
evaluating interventions or programmes where there is evidence of efficacy from randomised 
controlled trials. In many cases such evidence is not available, so this evaluation method would not 
be applicable. 
Another advantage of the evaluation method used here is its flexibility; targets can be chosen that 
relate to the specific objectives of the evaluation, and this information can easily be supplemented 
with other information that is not part of the goal-attainment evaluation. The goal-attainment 
method was used to evaluate the effectiveness and one aspect of the acceptability of the pilot 
programme (participation), and supplemented with information from acceptability surveys and an 
economic analysis. The objectives of the evaluation of the Otago and Southland pilot programme 
were to ensure that the programme was well-organised, therefore keeping the benefit : risk ratio 
high, and to measure the acceptability, effectiveness, and economic efficiency of population-based 
mammographic screening in New Zealand. The evaluation required the collection of diverse data, 
from several sources. This is a strength of the evaluation method, in that more than one aspect of 
the pilot programme could be examined. However the collection of diverse data from several 
sources is also a potential weakness of this evaluation method, since it is time-consuming and 
complex to organise such data collection. The collection of data for the evaluation is summarised 
in section 7 .1.1 below. 
7.1.1 Data collection 
In order to assess the acceptability, effectiveness, and efficiency of the pilot programme, a 
considerable amount of information had to be collected for the evaluation. Because of the diversity 
of data that had to be collected, several sources were used (Chapter Four, section 4.4). These 
sources included the pilot programme computer system and records, the pathology departments at 
Dunedin and Invercargill Hospitals, private pathology laboratories in Dunedin and Invercargill, 
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general practitioners in Otago and Southland, women in the eligible population, the Resource 
Utilisation System at Dunedin Hospital, and the National Health Information service. 
Collecting the information for the evaluation of the Otago and Southland pilot programme required 
help from all the people involved in the programme, and in many cases, generated extra work for 
them. The evaluation could not have been carried out without this help, and this should be kept in 
mind when plans for a national screening programme are made (section 7.6). Some information 
had to be specially generated for the evaluation of the pilot programme. For instance, information 
about double reading was collected in a separate database so that analysis of inter-rater reliability 
could be carried out for the evaluation. Before the introduction of the screening programme 
grading of breast tumours had routinely been done at neither Dunedin Hospital nor Invercargill 
Hospital. The introduction of histological grading increased the workload of the pathologists who 
read the slides for the pilot programme. Staging was also carried out specifically for the 
programme, although it would normally have been done anyway, in the department of surgery, to 
help determine the treatment offered to women undergoing surgery for breast cancer. Staging 
involved regular meetings of the specialist breast surgeon, screening programme manager, and 
evaluation coordinator. 
Collecting much of the information for the evaluation relied on the goodwill of people who took 
part in surveys related to the pilot programme. Many surveys were carried out during the 
evaluation, including surveys of women who were eligible for screening, women who had attended 
screening, women who had attended the assessment clinic, women who had declined an offer of 
screening, and general practitioners in Otago and Southland. The response rates were high ( over 
eighty percent) in all these surveys. The survey of general practitioners included all general 
practitioners in Otago and Southland. Because random samples were used in the surveys of 
women, and response rates were high, the results can be generalised to the wider population of 
eligible women in Otago and Southland. 
There were two areas in which there was particular difficulty in collecting data for the evaluation; 
the pilot programme computer system, and obtaining information about women diagnosed with 
breast cancer outside the pilot programme: 
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The pilot programme computer system 
The first problem with collecting data from the pilot programme computer system was the 
requirement by Dunedin Hospital that the screening programme computer system should be part of 
the Dunedin Hospital information system, rather than a stand-alone system. This meant that the 
pilot programme was restricted to a computer system modified from the pre-existing Radiology 
system. Because of the limitations of this system some information had to be collected manually, 
for instance invitation and participation data, (Chapter Four, section 4.4, Chapter Six, section 6.2). 
Also, the screening programme computer system was not user-friendly, and was not sophisticated 
enough to prevent incorrect data entry; for instance incorrect dates could be entered with impunity. 
This meant that a considerable effort had to be made to ensure that the data for the evaluation of 
the screening programme was of high quality. Regular validity checks were carried out on the data 
that was obtained from the screening programme computer system, and corrections were made 
when necessary (Chapter Four, section 4.4). Validity checks are very important in clinical 
databases as published error rates in clinical databases range from two percent to thirty-eight 
percent (Reynolds-Haertle and McBride 1992, Hohnloser et al 1994, Horbar and Leahy 1995). 
Even more importantly, the Dunedin Hospital information system was modified in mid-1994, 
during the second screening round, and this affected the screening programme computer system 
with the result that the screening programme data was no longer available in the format required for 
the evaluation download. From mid-1994 the evaluation download was unusable. This was 
completely unsatisfactory, and after many months spent trying to solve the problem, a data manager 
was appointed by the pilot programme to work with the evaluation team to ensure that the required 
data could be downloaded properly. 
Identifying women diagnosed outside the screening programme 
A further problem was that of identifying women who were diagnosed with breast cancer outside 
the screening programme. At the time the evaluation began, there was no legislation to make 
cancer registration compulsory. There was concern among pathologists that releasing information 
about women who were diagnosed outside the screening programme would breach confidentiality. 
It was essential to identify women with interval cancers so that the sensitivity of screening could be 
estimated, as this was one of the key targets for the evaluation of the pilot programme. In Dunedin, 







matched with the screening records. Names were not required, thus maintaining confidentiality. 
Nl\llPI numbers were not used at Invercargill Hospital nor in the private pathology laboratories so 
another method was devised to identify women who were diagnosed with interval cancers outside 
Dunedin hospital. It was possible to identify all woman over fifty who were diagnosed with breast 
cancer either through the Southland hospital pathology department or one of the private pathology 
laboratories, using the laboratory computer records. For Southland hospital copies of histology 
reports for women over fifty were routinely sent to the evaluation coordinator, and for the private 
pathology laboratories (where smaller numbers were involved) the evaluation coordinator 
requested copies of the forms at regular intervals. In each case the histology fonn had the woman's 
name blanked out. Date of birth was used to look for possible matches with the screening register, 
and where there was a match and the name was required the woman's surgeon (who could identify 
the woman from her laboratory nnmber on the histology fonn) asked her permission to release her 
name for the evaluation. This method was cumbersome but was the only way to identify women 
diagnosed with breast cancer outside the programme while still maintaining confidentiality between 
the pathologist and the patient. An audit of the accuracy of this method is planned; the names of 
women diagnosed with interval cancers in the evaluation will be compared with those registered at 
the Cancer Registry (this check could not be done straight away because of the time-lag between 
cancer diagnosis and subsequent registration at the Cancer Registry). 
With the recent passage of the Cancer Registry Act 1993, which made it compulsory from July 
1994 for all pathologists to notify diagnoses of cancer (Chapter Two, section 2.1) identification of 
women diagnosed with breast cancer outside the screening programme should become 
considerably easier. It is to be hoped that the pathologists could send copies of the histology forms 
( with names), directly to the evaluation team, as well as to the Cancer Registry, so that the 
identification of women with interval cancers can be carried out simply and rapidly. 
The advantages and limitations of the method used in the evaluation of the Otago and Southland 
pilot programme have been outlined, with particular reference to the collection of data. The 
advantages of the method are its use of evidence from randomised controlled trials as a standard, its 
flexibility, and its ability to evaluate several aspects of a programme concurrently. The method 
would not be appropriate for evaluating interventions where evidence of efficacy from randomised 
controlled trials is lacking. However, it may be possible to adapt this method to situations where 
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there is adequate infonnation from observational studies to allow the development of suitable 
targets. The timely collection of accurate and appropriate data is essential to this method, as it is to 
any evaluation method. The implications and relevance of this evaluation are discussed in sections 
7.5 to 7.7, but first the results of the evaluation of the Otago and Southland pilot programme are 
summarised in sections 7.2 to 7.4, under effectiveness (section 7.2), acceptability (section 7.3), and 
economic efficiency (section 7.4). 
7.2 The effectiveness of the pilot programme 
This section and sections 7.3 and 7.4 give the principal findings of the evaluation of the Otago and 
Southland pilot programme. The perfonnance of the pilot programme, measured against the 
targets that were set as part of the evaluation, is shown in Table 7.1. 
7.2.1 Identification of eligible women 
The target for the programme was to identify ninety percent of eligible women. Actually ninety-
two percent of women aged fifty to sixty-four and living in Otago and Southland were identified 
using the electoral roll alone (Chapter Five, section 5.1.1 ). General practice age-sex registers were 
also used. Each woman identified from a general practice list was checked off on the electoral roll, 
and the remaining women who had not been identified through the general practice registers were 
sent invitations later. Because general practice age-sex registers were used as well as the electoral 
roll, identification of eligible women was well over the target of ninety percent (Chapter Five, 
sections 5 .1.1 and 5 .1.2). It was very important to identify a high proportion of eligible women so 
that as many women as possible could be invited for screening. 
7 .2.2 Invitation method 
Two studies were carried out to assess different methods of inviting women to take part in the 
screening programme (Chapter Five, section 5.1.3). In the first study the effect of general 
practitioners' letters endorsing screening was assessed in 482 women who were on the register of a 
large health centre. Each woman was randomly allocated to receive a letter from her general 
practitioner with her invitation or to receive only an invitation. Including those who had 
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Characteristics of the first screening round compared with the targets for the pilot 
programme 
Characteristic evaluated: Target: Actual: 
Identification of eligible women 90% 92% 
Coverage* 70% 74% 
Sensitivity 85% 92% 
Specificity 95% 89% 
Percent of screened women referred 5-10% 11.6% 
Biopsy rate (% of screened women) <2% 1.96% 
Benign:malignant ratio of biopsies <3:1 0.9:1 
screen prevalence 3+ 4.5 
expected incidence 






required reminders, participation among eligible women who had received letters was seventy-one 
percent compared with sixty-two percent among women who did not receive letters from their 
general practitioners (p = 0.059). Participation resulting from an invitation alone, with no reminder, 
was only forty-three percent. Forty-three percent is an unsatisfactory participation rate for a 
population-based screening programme. 
The second study was carried out to see whether telephone reminders were as effective as postal 
reminders for women who did not reply to an invitation to take part in the screening programme. 
495 women who had not replied to an invitation and who had telephone numbers were randomly 
allocated to receive either a telephone or a postal reminder. There was no difference in participation 
between the group receiving telephone reminders (forty-eight percent) and the group receiving 
postal reminders (forty-nine percent). As might be expected, participation was lower among these 
women, who had not replied to an earlier invitation. 
In the pilot programme, as in breast cancer screening programmes overseas, general practitioner 
endorsement of invitations increased participation in breast cancer screening. Postal reminders were 
as effective as telephone reminders in encouraging women who did not respond to an initial 
invitation, to participate in screening. 
7 .2.3 The screening test 
In the first eighteen months of the Otago and Southland pilot programme 1.2 percent of all the 
women screened were recalled because of technical problems (Chapter Five, section 5.2.1). The 
95% confidence interval was from 0.97 to 1.48 percent. This result compared reasonably well with 
the range published for technical recall rates in other breast cancer screening programmes which 
was from 0.4 to 3.8 percent (Sickles et al 1987, Rickard et al 1991). 
Film reading was carried out to a high standard in the pilot programme (Chapter Five, section 
5.2.2). Inter-rater reliability was as high as that reported from any other screening programmes 
(Boyd et al 1982, Boyd et al 1986, Baines et al 1986, Ciccone et al 1992). All the radiologists 
involved in reading had attended special courses in screening mammography before the programme 
began. Originally it was planned to use "gold standard films" from an established screening centre 
to ensure that the standard of film reading was acceptable before the programme started. 
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Arrangements were made for the gold standard films to be sent to New Zealand from Britain, but 
unfortunately their production was delayed. It was accepted instead that the courses attended by 
the radiologists had provided suitable training for them to achieve an adequate standard of film 
reading. This proved to be so for the Otago and Southland programme, in terms of sensitivity, but 
not specificity. Ideally new programmes should not begin until it has been demonstrated that the 
level of film reading is adequate. Possibly a set of gold-standard films, to be used for reviewing 
films and training new radiologists, could be developed by the radiologists in the two pilot 
programmes, for use both in the pilot programmes and in other parts of New Zealand. This may 
help to reduce the recall rate and improve specificity in the pilot programme, and also help to 
ensure appropriate sensitivity and specificity of mammography in other screening centres. 
The extent of agreement between the two radiologists who did most of the film-reading in the pilot 
programme was higher than in similar studies which have been published (Appendix One). An 
interesting result is that the double reading process did not necessarily increase the number of 
women referred for assessment. Had the initial radiological decision from a single radiologist been 
used, without double reading, the referral rate would have ranged from 9 .4 to 12.3 percent 
depending on the radiologist. The breast cancer detection rate in the pilot programme would have 
been lower without double reading of the mammography films. If there had been only one reader 
three to five percent of women with breast cancer would have been missed, depending on which 
radiologist did the reading. These results are consistent with findings from other screening 
programmes. In Finland (Anttinen et al 1993) single reading would have led to either six percent 
or ten percent of the women with breast cancer being missed. In a study from Scotland (Anderson 
et al 1994) 10.9 percent of breast cancers would not have been detected without double reading. 
Double-view mammography was used in the pilot programme. A randomised controlled trial 
comparing single-view with double-view mammography in England (Wald et al 1995) found that 
double-view mammography reduced the proportion of screened women recalled from 8.16% to 
6.97%, a fifteen percent reduction (95% CI 6% to 23%). Also, two-view mammography detected 
twenty-four percent more women with breast cancer (95% CI 16% to 31 % ) than one-view 
mammography (Wald et al 1995). The study by Wald et al also found that although the cost of 
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per cancer detected was similar (£5,330 compared with £5,310) and the marginal cost per extra 
cancer detected with two views was similar to the average cost (£5,400). 
7 .2.4 Recall for assessment 
The target recall rate in the pilot programme was between five and ten percent. In the first eighteen 
months of screening the Otago and Southland programme recalled 11. 6 percent of women for 
further assessment. With symptomatic women excluded the recall rate was 10.4 percent (Chapter 
Five, section 5.3). This was higher than expected and it did not decline during the first year of 
screening. The referral rate was higher than that reported in many breast cancer screening trials for 
the first round of screening. The referral rate was 1.5 percent in the first screening round of the 
Stockholm trial (Frisell et al 1986, Frisell et al 1991) and five percent in the first round of the 
Swedish Two-Counties trial (Tabar et al 1992), but these programmes had an intermediate recall 
phase for more detailed mammography before women were referred for assessment. In the Health 
Insurance Plan (HIP) trial the referral rate was five percent but this was averaged over all screening 
rounds (Shapiro 1977, Shapiro et al 1982) and is likely to have been higher in the first round 
(Kopans and Swann 1988). In the Canada II trial in women aged fifty to fifty-nine (Miller et al 
1992b) the referral rate in the first screening round was eleven percent. In the first screening round 
of the Sydney Breast X-Ray programme for women aged forty-five and over (Rickard et al 1991), 
which also had a policy of referring symptomatic women irrespective of their screen results, the 
referral rate was 16.5 percent. It is possible to reduce referral rates fairly quickly; in the British 
national screening programme there was a significant decline (p < 0.0001) in referral rates from 6.2 
percent in 1991-2 to 5.4 percent in 1992-3 (National Health Service Breast Screening Programme 
1994). However, part of this decline was probably due to a lower prevalence of pre-symptomatic, 
screen-detectable breast cancer in the screened population in the latter period, since some of the 
women screened in 1992-3 were undergoing incidence (second) screens. The breast cancer 
detection rate also declined over the same time from 6.2 to 5.7 per 100 women screened (National 
Health Service Breast Screening Programme 1994). Also, the availability of previous films for 
comparison tends to lead to lower referral rates in the incidence screening round (Chamberlain et al 
1993). 
A high referral rate means that too many women experience unnecessary anxiety related to 
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To improve specificity the level of suspicion at film reading must be altered, so that fewer women 
are referred, but this carries the risk of reducing sensitivity. Fortunately in the pilot programme, 
although the referral rate was high the biopsy rate and the benign to malignant ratio were low, so 
that few of the referred women underwent unnecessary biopsies. The radiologists are aware of the 
relatively high recall rate and are endeavouring to reduce it while still maintaining high sensitivity. 
This is discussed further in section 7.2.7. 
7.2.5 Benign: malignant biopsy ratio 
The biopsy rate of 1.96 percent just met the target biopsy rate of less than two percent, and the 
benign: malignant ratio of 0.9 : 1 was well within the target range ofless than 3 : 1 (Chapter Five, 
section 5.3). The low benign : malignant ratio partly compensated for a high referral rate, in that 
very few women in the pilot programme underwent unnecessary biopsies. In other programmes 
the benign : malignant ratio was considerably higher; 4 : 1 in the HIP trial (Shapiro et al 1982), and 
2 : 1 in the Swedish Two-Counties trial (Tabar et al 1985) and the Edinburgh trial (Roberts et al 
1989). However, the Malmo and Stockholm trials had benign to malignant ratios of 0.7: 1 and 
0.5 : 1 respectively (Andersson et al 1988, Frisell et al 1986, Frisell et al 1991). 
7.2.6 Sensitivity 
Sensitivity in the pilot programme was estimated at ninety-two percent, with a 95% confidence 
interval of 84.4 to 96.5 percent (Chapter Five, section 5.4.5). This was a very good result 
compared with other breast cancer screening programmes, where sensitivity in the first screening 
round, calculated using the same method, ranged from seventy-eight to ninety-six percent (Chapter 
Four, Table 4.1). It means that very few women with breast cancer were missed in the pilot 
programme compared with other programmes. The target set for the pilot programme was eighty-
five percent sensitivity. The estimate of sensitivity in the pilot programme depended on identifying 
all women with interval cancers. Women with interval cancers were identified from copies of 
histology fonns from pathology laboratories in Otago and Southland for all women aged fifty or 
over who were diagnosed with breast cancer (Chapter Four, section 4.4). This method should have 
identified all women with interval cancers diagnosed in Otago and Southland. However, if a 
woman had a negative screen in the pilot programme and then moved to a different region and was 
subsequently diagnosed with breast cancer outside Otago and Southland, she would not have been 
identified as having an interval cancer. Six of the 7,109 women who had negative screen results 
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were identified as having developed interval cancers after screening. The 95% confidence interval 
was 2.5 to 12.7 (Rothman and Boice 1982). Because the number of interval cancers was smali 
missing even one interval cancer could mean that sensitivity was overestimated. However, several 
interval cancers would have to have been missed for sensitivity to have been below the target that 
was set for the pilot programme. If the actual number of interval cancers had been seven rather 
than six, sensitivity would have been ninety-one percent rather than ninety-two percent, and only if 
the actual number of interval cancers had been more than double the number identified, would 
sensitivity have been below the target of eighty-five percent. 
7.2. 7 Specificity 
Specificity measures the ability of the screening test to correctly identify women who do not have 
breast cancer. It provides an indication of the number of screened women who were referred 
unnecessarily for assessment, and thus is a useful quality control measure. The specificity in the 
first eighteen months of the pilot programme was eighty-nine percent, with a 95% confidence 
interval of 88.6 to 90.0 percent (Chapter Five, section 5.4.5). This was lower than the specificity 
in the first round of screening in other programmes, which ranged from ninety-five to ninety-seven 
percent. The low specificity was related to the high referral rate in the pilot programme. The 
target set for the pilot programme was ninety-five percent specificity. 
One way to increase specificity is to reduce the number of women with false positive results, and 
this means reducing the referral rate. To do this the radiologists will need to reassess their criteria 
for referral, so that fewer women are referred for assessment. This is a difficult task because of the 
possibility that reducing the referral rate in order to increase specificity could reduce sensitivity. But 
the radiologists now have the advantage of being able to review films for which the outcome is 
known, and this should help in reviewing the criteria for referral. Such films have been used in the 
United States and in England, for standardising mammographic interpretation (Breast Cancer 
Screening Working Group 1987, Elmore et al 1994, Warren and Duffy 1995). Referral rates can 
be expected to drop in the incidence screening rounds, because for most of the women, the 
radiologists have access to previous films for comparison (Chamberlain et al 1993). This is further 





The targets for sensitivity and coverage for the pilot programme were eighty-five percent sensitivity 
and seventy percent coverage of the target population. Meeting these targets would have given the 
programme a maximum breast cancer detection rate of sixty percent, which is close to the lowest 
detection rate for a successful programme (Chapter Four, section 4.1.2). In fact the Otago and 
Southland programme had sixty-eight percent maximum detection of breast cancers, based on the 
seventy-four percent coverage and ninety-two percent sensitivity achieved during the first eighteen 
months of the programme (Chapter Five, section 5.4.5). This compares very well with other breast 
cancer screening programmes (Chapter Four, Table 4.3). 
7 .2.8 Breast cancer diagnosis in the pilot programme 
The first round detection rate including ductal carcinoma in situ (DCIS) was 10.2 women with 
breast cancer detected per thousand women screened with a 95% confidence interval of 7.8 to 12.5 
(Chapter Five, section 5.4.2). This detection rate was higher than that in the latest results from the 
national breast screening programme in Britain where the first round detection rate including ductal 
carcinoma in situ (DCIS) was 6.3 per thousand (Chamberlain et al 1993). The detection rate for 
invasive tumours less than or equal to ten millimetres in the British national screening programme 
was 1. 4 per thousand. The target for the British national screening programme had been at least 
1.5 per thousand. The Otago and Southland result was 2.9 per thousand (95% confidence interval 
1. 7 per thousand to 4 .1 per thousand) . 
The detection rate of ten per thousand was 4.5 times the expected breast cancer incidence in the 
absence of screening and thus easily met the target of more than three times the expected incidence 
in the absence of screening (Table 7.1 ). The expected incidence of breast cancer in women aged 
fifty to sixty-four in Otago and Southland was 2.2 per thousand (Chapter Five, section 5.4.1). This 
expected incidence was calculated using the most recent ten years of Cancer Registry data 
available. Surprisingly, the number of women diagnosed with cancer outside the screening 
programme was much higher than expected based on Cancer Registry data, and this raises the 
possibility of under-reporting to the Cancer Registry in the past (Chapter Five, section 5.4.4). 
As part of the evaluation of the pilot programme, information about all diagnoses of breast cancer 
in women over fifty years in Otago and Southland has been collected. Once the Cancer Registry 






screening programme it will be possible to compare the registrations with the information collected 
directly from the pathology labs in Otago and Southland. This will be a useful quality control check 
both for the evaluation and for the Cancer Registry. If there had previously been under-reporting 
of breast cancer to the Cancer Registry, the expected incidence in the absence of screening would 
have been higher than 2.2 per thousand and the ratio of screen prevalence to expected incidence 
would be lower than 4. 5. However, the ratio would only fall below the target of 3 : 1 if a third of all 
diagnoses of breast cancer in Otago and Southland had previously not been reported to the Cancer 
Registry, or in other words, if the true incidence of breast cancer had been over 3.3 per thousand, 
rather than 2.2 per thousand. 
7.2.9 Tumour characteristics 
The stage distribution of cancers detected by screening will be affected by lead time. A shift in 
stage distribution is therefore "necessary but not sufficient" (Day et al 1989) for an effective 
screening programme. Stage distribution alone cannot be used to determine the efficacy of 
screening in reducing breast cancer mortality, since it would be possible for a shift in stage 
distribution to occur even without any reduction in mortality. Size, grade, and nodal status have 
been used to predict the reduction in breast cancer mortality that can be achieved by ·screening 
(Duffy et al 1991, Tabar et al 1992). Duffy et al collected information on women diagnosed with 
breast cancer in the Swedish Two-Counties trial. In the Swedish Two-Counties trial, differences in 
size, nodal status, and grade explained the difference in survival between screened women and 
controls diagnosed during incidence screening rounds. But a recent analysis of survival of patients 
with breast cancer dit;ignosed in the United Kingdom Trial of Early Detection of Breast Cancer 
(Moss et al 1994) found that only about a third of the improved prognosis in women who had been 
diagnosed by screening could be explained by differences in size and nodal status. It was suggested 
that the disparity between the British and Swedish results could be partly because the British 
analysis could not adjust for tumour grade. However, in the Swedish Two-Counties trial the 
distribution of grades differed significantly between Ostergotland and Kopparberg, the two counties 
in the trial. It was suggested that this was due to "the subjective nature of histological grading" 
(Tabar et al 1992). If the subjectivity of grading allows such differences, then the utility of grade as 
a prognostic indicator must be in question. Another possible reason for the discrepancy between 
the British and Swedish results is that participation was lower in the United Kingdom, and there 






7 .3 The acceptability of the pilot programme 
7 .3.1 Pre-screening survey 
Before the pilot programme began, a random sample of 290 Otago and Southland women was 
surveyed to establish which aspects of a programme would increase acceptability, thereby 
enhancing participation (Chapter Six, section 6.1 ). Aspects of the service that were likely to 
improve participation included the presence of a screening centre within thirty minutes travel by car 
( only twenty-eight percent of women surveyed thought more than thirty minutes travel time was 
reasonable), appointment times outside normal working hours, female staff, and publicity before 
invitations are sent out. 
The pilot programme was designed to incorporate these features, with a mobile unit so that rural 
women did not have to travel excessive distances for screening, some evening sessions, female 
radiographers and clerical staff, and publicity about the programme. Publicity was targeted to 
specific areas such as rural towns in the month before invitations to attend the mobile unit were sent 
out. 
7.3.2 Participation and coverage 
The randomised controlled trials of invitation methods (Chapter Five, section 5.1.3), showed that 
seventy-one percent of women who received general practitioner letters (with reminders for those 
who did not reply) took part in screening. It was worth sending reminders to women who did not 
respond initially, as nearly half of these women took part after receiving a second letter. However, 
participation in response to an invitation only partly accounted for the coverage achieved by the 
Otago and Southland pilot programme. 
Coverage is the proportion of eligible women who were screened in the first screening round of the 
Otago and Southland pilot programme. A target of seventy percent had been set (Chapter Four, 
section 4.2.1). At the end of the first screening round 14,129 women had been screened, out of a 
total of 18,555 women aged fifty to sixty-four and living in Otago and Southland at the 1991 
census, with an additional 504 women becoming eligible during the first screening round. This 







(Chapter Six, section 6.2). This compared extremely favourably with other programmes (Chapter 
Four, Table 4.1, section 4.2.1) where coverage ranged from fifty to seventy-eight percent. 
Participation was also calculated, by dividing the number of invited women screened as a result of 
the invitation, by the number of women invited. This measured the response to the invitations, and 
was one measure of acceptability (Chapter Six, section 6.2). When the evaluation targets were set, 
it had been thought that a very high participation rate would be needed, and a target of seventy-
eight percent participation was set (Chapter Four, section 4.2.1). The target was set at this high 
level to compensate for the fact that not all women could be identified and invited for screening, 
since some eligible women would be on neither the electoral roll nor on general practice registers. 
Also, it had been expected that almost all the women who attended for screening would do so in 
response to an invitation. However, in the Otago and Southland programme there was a constant 
demand from women who had self-referred or had been referred by their general practitioners or 
through the Radiology Department of Dunedin Hospital. About twenty percent of women had 
self-referred or been referred. Intended participation had been high in the pre-screening survey, 
and it may be that some women were very eager to take part in screening. The high level of self-
referral and general practice referral meant that the number of women who were screened as a 
result of an invitation was constantly supplemented by women who had self-referred or had been 
referred. It also meant that by the time some women received their invitations, they had already 
been screened. This was unexpected, and although it reflected the positive response to the pilot 
programme in Otago and Southland, it meant that the participation rate after an invitation was 
lower than expected, at fifty-eight percent (Chapter Six, section 6.2). 
The survey of screened women (Chapter Six, section 6.3) illustrates the relationship between 
participation and coverage; twenty percent of the respondents had self-referred or been referred by 
their general practitioners, and eighty percent had attended as the result of an invitation. These 
results suggested that the ratio of referred to invited women was 1 :4. Extrapolating from these 
results suggests that for every hundred eligible women, fifty-eight percent would respond to an 
invitation, and fourteen would be self-referred or referred by general practitioners, giving a total 
coverage of seventy-two percent. This is close to the seventy-four percent coverage measured in 




Whether there will be equally high self-referral and general practitioner-referral rates in other parts 
of New Zealand is unknown. However, the Waikato pilot programme had a similarly high level of 
self-referral and general practitioner-referral (Chapter Six, section 6.6). If the pilot programme had 
had a policy of screening women only after an invitation had been sent (by reassuring women who 
self-referred that they would definitely be invited, and asking them to wait until they received an 
invitation), a better indication of the true response to an invitation would have been obtained. But 
this policy may have dissuaded some women from attending at all. It is helpful to know that 
seventy-one percent participation can be achieved, with an appropriate invitation signed by a 
general practitioner. However a limitation of this result is that it was obtained in one large group-
practice in Dunedin, which may not be representative of all general practices in New Zealand. It 
will be important to monitor participation at re-screening in the second round of the pilot 
programme, to investigate whether women who have already been screened once, maintain similar 
levels of acceptance of screening. It is encouraging that the acceptability of the Otago and 
Southland programme is high, with ninety-four percent of screened women intending to return for a 
second screen (Chapter Six, section 6.3). 
Because the target for participation was later found to be inappropriate, given the unexpectedly 
high numbers of women who were screened without receiving an invitation, coverage is a better 
measure of the acceptability of the pilot programme than participation, which is why only coverage 
has been reported in the summary of results in Table 7.1. A crucial issue for the effectiveness of 
the programme will be the coverage in the second screening round. Most programmes experience 
a decline in second and subsequent screens (Breast Cancer Screening Working Group 1987). 
7.3.3 Post-screening survey 
A post-screening survey was carried out to investigate the acceptability of breast cancer screening 
(Chapter Six, section 6.3). A questionnaire was sent to 474 women, and the response rate was 
very high, with ninety-three percent of women returning the questionnaires. There was a very high 
level of satisfaction with all aspects of the screening service, with no difference between screening 
centres. Ninety-four percent of the women said they would return for another screen in two years. 
The survey showed that some women did not receive their results within the maximum period 








finding. The method of processing results was also changed in response to the results of the 
survey. 
7.3.4 Assessment clinic survey 
Questionnaires were sent to 140 women who had been to the assessment clinics (Chapter Six, 
section 6.4). There was an eighty-nine percent response rate. There was a high level of satisfaction 
with the assessment clinics, with ninety-five percent of women being satisfied, and ninety-eight 
percent intending to be screened again. Assessment caused women more anxiety than screening, 
which underlines the importance of reducing the referral rate in the pilot programme as far as 
possible without decreasing sensitivity. 
7.3.5 Survey of non-attenders 
A telephone survey was carried out to compare women who attended for screening with women 
who declined an invitation to be screened (Chapter Six, section 6.5). Women who did not attend 
perceived that the worth of screening was outweighed by the practical difficulties of attending. The 
results suggested that participation in breast cancer screening could be increased by reducing 
practical barriers to screening, for instance by improving the availability of appointments outside 
normal working hours, and by increasing women's knowledge about breast screening. However, 
women should be provided with information about screening with the understanding that, having 
received the information, it is their right to decide not to take part in screening if they do not wish 
to. Forty-four percent of the women who did not attend in the first screening round said that they 
would attend if they received an invitation to the second round. This means that it would be 
appropriate to invite women who have declined an invitation to screening, to the next screening 
round. 
7.4 The economic effectiveness of the pilot programme 
Economic analyses of the pilot programme were planned as part of the evaluation, but because the 
work required expertise in health economics, the economic analysis was carried out by a consultant 
health economist and a Masters in Public Health student. A paper presenting the results of an 





provide background information and so that the economic aspects of breast cancer screening in 
New Zealand can be commented on here. 
One of the three areas which were to be evaluated (Skegg et al 1988) was the economic efficiency 
of the pilot programme. Two issues were particularly important. First, it was important to 
discover whether the pilot programme could provide screening in a way- that would not be 
"wasteful of scarce resources" (Skegg et al 1988), and secondly it was important to be able to 
extrapolate from the pilot programme so that an estimate of the cost of a national breast cancer 
screening programme could be made. When resources are finite, any decision to implement a 
particular health intervention means that fewer resources are available for other health 
interventions. It has been argued therefore that it is unethical not to consider economic factors in 
allocating health care resources (Williams 1992, Warnock 1994). Economic analysis is used in the 
health service to help make decisions when choices have to be made between several courses of 
action, so it is important to find out how breast cancer screening compares with other competing 
potential uses of health resources. Economic "efficiency'' occurs when choices in health care are 
made that derive the maximum benefit from the resources available (Drummond 1990). 
There are three main types of economic analysis; cost-benefit, cost-effectiveness, and cost-utility 
analyses (Drummond et al 1993, Robinson 1993a). In economic terms cost refers to benefits that 
are forgone elsewhere, or opportunities that are forsaken by deciding to take a certain course of 
action (Drummond 1990). 
A cost-effectiveness analysis is conducted to find out how much a programme costs to produce a 
certain effect. This is then expressed in terms of cost per unit of effectiveness, such as the cost per 
year of life gained, the cost per life saved, or the cost per pain-free day (Robinson 1993b). It is 
possible to compare different programmes using this approach, provided the outcomes of the 
programmes can be expressed in the same units of effectiveness. 
A cost-utility analysis compares the costs of different procedures, with their outcomes measured in 
units that are adjusted for a person's well-being, for instance per quality-adjusted life year, or 
QAL Y (Robinson 1993c). Because ranking quality of life is a subjective assessment, and varies 





there has been some criticism of the use of QAL Y s (Smith 1990, Petrou and Renton 1993, Nord 
. 1994). When information on the QAL Ys obtainable for different procedures is available it is 
possible to rank the procedures in terms of their costs per QAL Y. Such a ranking is called a 
QAL Y table, and these tables can be used by policy makers to help decide where health resources 
should best be spent. The major problem with QAL Y tables is that the methodologies used in 
determining the costs and the QALYs for various cost-utility analyses may differ. This means that 
it may be inappropriate to compare certain cost-utility analyses with other analyses. A second 
problem is that the results of cost-utility analyses may be specific to a certain health system or 
country, so that international comparisons across countries with widely differing systems of health 
care may be questionable (Robinson 1993c). 
A cost-benefit analysis requires that all the costs of an undertaking, such as a screening programme, 
(for example staff and equipment for the programme, and travel, time away from work, and anxiety 
for women) and all the benefits (for instance reduced breast cancer mortality and earlier treatment 
of breast cancer) are valued in monetary terms. This can be problematic, as many benefits (such as 
reassurance or extra years of life) and costs (such as anxiety) are difficult to measure in monetary 
terms (Drummond 1990). 
7.4.1 The economic evaluation of the pilot programme 
The economic part of the evaluation of the Otago and Southland pilot programme was designed to 
find out whether the pilot programme was efficient compared with existing programmes, and by 
extrapolating from the cost of the pilot programme, to provide information on the likely cost of a 
national breast cancer screening programme. 
It was decided that two methods of economic analysis would be used in the evaluation of the pilot 
programme. First, it would be possible to calculate two costs, the cost per woman screened, and 
the cost per cancer detected, relatively early in the operation of the programme. These measures 
had been calculated for other screening programmes, so the costs per woman screened and per 
cancer detected in the pilot programme could be compared with the equivalent costs in other breast 
cancer screening programmes. Later, provided the programme reached the targets set for 
effectiveness, it would be possible to estimate, by extrapolation from randomised controlled trials of 






to calculate the cost per year of life gained for the pilot programme, and this could be compared 
with other uses of health resources in New Zealand where similar cost-effectiveness analyses had 
been done. 
The second analysis that was planned as part of the economic evaluation of the pilot programme 
was a cost-benefit analysis. This would allow policy makers to decide whether the social benefits 
generated by the programme would outweigh its costs. The costs of the programme would include 
health service costs such as the costs of staff: equipment, publicity, and hospital-based procedures, 
and costs to the women including travel costs, the opportunity cost of the time required to 
participate in the programme, anxiety, any unnecessary investigations (for women with false 
positive tests), and delay resulting from false negative tests. The benefits of the programme would 
include savings resulting from fewer women requiring treatment for advanced breast cancer, less 
invasive treatment, and decreased breast cancer mortality. The preliminary results from the cost-
effectiveness analysis are presented as Appendix Two, and are briefly summarised below. The 
cost-benefit analysis is still under way, as it requires information from the second screening round. 
7.4.2 Results from the cost-effectiveness analysis 
The cost per woman screened in the first year of screening was $178, which dropped to $117 in the 
second year, and is expected to be $113 in each year after that, assuming that eight thousand 
women are screened in the programme each year from year three onwards. On the basis of the cost 
per woman screened in the pilot programmes in year three, and assuming an eighty percent 
participation rate, it is estimated that a national screening programme would add between $9.3 and 
$9.9 million to health service costs each year in New Zealand, in 1991 dollars (Appendix Two). 
7.4.3 Is breast cancer screening an efficient use of health resources? 
Based on the results from the pilot programmes (Devlin et al 1993, Menon et al 1994), the cost to 
the health service when a national screening programme is introduced in New Zealand will be 
between 9.3 and 9.9 million dollars per year. The costs will be higher in the early years when the 
programme is first being set up. It is important to know whether spending this amount of money 
on breast cancer screening is an efficient use of resources. This can be investigated by comparing 
the cost-effectiveness of breast cancer screening with the cost-effectiveness of other health care 









programme can be estimated, later in the evaluation, it will be possible to compare these with 
similar measures from other health care programmes in New Zealand. In the absence of New 
Zealand data at present, (the cost per year of life saved for the New Zealand pilot programmes will 
not be estimated until there are some results from the second screening round), some indication can 
be obtained from published reports from other countries. 
A cost-effectiveness analysis of breast cancer screening in the Netherlands (de Koning et al 1991) 
found that the cost per year of life gained from screening women aged fifty to seventy, assuming 
seventy percent participation, was between US$3,000 and $5,000, and the cost per QALY was 
between US$3,200 and $5,300. The authors reported that to their knowledge, no superior cost-
utility ratios had been reported for other screening programmes or cancer programmes. A second 
cost-effectiveness analysis, also in the Netherlands found that two-yearly breast cancer screening in 
women aged fifty to seventy would reduce the total breast cancer mortality in the Netherlands by 
twelve percent. The costs per death prevented and per life year saved were lower than those in 
other Dutch health care programmes for which cost-effectiveness ratios had been calculated, 
including screening for cervical cancer, the treatment of end-stage liver disease, and liver 
transplantation (van der Maas et al 1989). 
A cost-effectiveness analysis of breast cancer screening in Australia (Carter et al 1993) found that, 
for two-yearly screening in women aged fifty to sixty-nine, the cost per life year gained was less 
than that in some other Australian studies where cost-effectiveness ratios had been calculated, 
including screening for cervical cancer, hospital haemodialysis, and the treatment of AIDS with 
zidovudine. 
Table 7.2 is a QAL Y table which includes the cost per QAL Y for breast cancer screening (Mason 
et al 1993). The cost of breast cancer screening in this table is less than the cost of some other 
procedures (for instance heart transplantation, and haemodialysis). However comparisons such as 
those in Table 7.2 should be made with caution. Mason et al report that although all the data in 
this QAL Y table came from British cost-utility studies, the methods used in the studies differed. In 
particular, the study investigating neurosurgical interventions discounted neither costs nor benefits. 
In programmes where costs and/or benefits occur over many years this could make a considerable 






Cost per quality adjusted life year (QAL Y) of competing treatments 
Treatment 
Cholesterol testing and diet therapy only (all adults aged 40-69) 
Neurosurgical intervention for head injury 
Advice to stop smoking from general practitioner 
Neurosurgical intervention for subarachnoid haemorrhage 
Antihypertensive treatment to prevent stroke (ages 45-64) 
Pacemaker implantation 
Valve replacement for aortic stenosis 
Hip replacement 
Cholesterol testing and treatment 
Coronary artery bypass graft (left main vessel, severe angina) 
Kidney transplant 
Breast cancer screening 
Heart transplantation 
Home haemodialysis 
Coronary artery bypass graft (one vessel disease, moderate angina) 
Continuous ambulatory peritoneal dialysis 
Hospital haemodialysis 
Neurosurgical intervention for malignant intracranial tumours 




















Source: Mason J, Drummond M, Torrance G. Some guidelines on the use of cost effectiveness league tables. Br Med 





to procedures have been included as benefits, or subtracted from the costs in cost-utility analyses. 
QAL Y tables should ideally include only studies that were undertaken in similar health care 
systems, and using similar methodology, including consistent use of discounting. They provide a 
guide to policy makers, but because of the potential problems outlined above they should be 
interpreted with caution. 
7.4.4 Savings resulting from screening 
The estimates in the cost-effectiveness analysis of the pilot programme (Appendix Two) did not 
take into account any savings related to the earlier detection of breast cancer. Breast screening 
results in fewer women requiring treatment for advanced disease, with associated savings to the 
health service. In terms of cost to the health service alone, it has already been shown that it is 
initially more expensive to screen than not to screen, but in Sweden it was found that five years 
after the introduction of screening in Kopparberg county, the cost of continued screening was less 
than the saving in treatment costs that had resulted from fewer women needing treatment for 
advanced breast cancer (Tabar 1987). In other words, after five years of screening it would have 
been more expensive to discontinue the breast cancer screening programme than to continue it. In 
the Netherlands it was found that a third of the cost of breast cancer screening was offset by 
savings in treatment costs (van der Maas et al 1989), and in the longer term it is estimated that 
almost half of the annual cost of breast cancer screening in the Netherlands will be offset by savings 
in the cost of treatment for advanced disease ( de Koning et al 1992). Two analyses in Australia 
estimated that savings resulting from reduced treatment costs would offset the cost of screening by 
about eighteen percent (Hall et al 1992, Salkeld and Gerard 1994). The difference between these 
estimates and those for the Netherlands was attributed to "differences in treatment patterns" there 
being no generally accepted protocol for the treatment of breast cancer in Australia (Salkeld and 
Gerard 1994). In addition, both Australian analyses excluded nursing home and hospice costs 
associated with advanced breast cancer, while the Dutch study by de Koning et al included these 
costs. 
If there were similar savings in treatment costs in New Zealand, the estimated annual cost of a 
national breast cancer screening programme (between $9.3 and $9.9 million) could drop to 
between $7.6 and $8.1 million, based on the Australian reduction of eighteen percent (Hall et al 






Dutch estimate (de Koning et al 1992). This projected decrease in costs should be taken into 
account when the national breast cancer screening programme in New Zealand is considered, 
especially over the longer tenn. 
7.5 Implications 
It is important to examine the results from the pilot programme with respect to the future of the 
Otago and Southland pilot programme, but also with respect to a national breast cancer screening 
programme in New Zealand. 
7.5.1 What do these results mean for the Otago and Southland pilot programme? 
The pilot programme met the targets that had been set for identification of eligible women, 
coverage, sensitivity, the biopsy rate, the benign to malignant biopsy ratio, and the screen 
prevalence. The acceptability of the programme was high, and its cost was similar to that of other 
breast cancer screening programmes. However, the pilot programme failed to reach the targets set 
for participation, referral rate, and specificity. 
In terms of its likely effect on breast cancer mortality, the programme matched all the important 
predictors of success, including coverage, sensitivity, and screen prevalence. The high sensitivity in 
the pilot programme meant that very few women with breast cancer were missed, and as a result, 
the screen-detected prevalence was more than three times higher than the incidence expected in the 
absence of screening. The stage and size distributions in the pilot programme were similar to those 
in the prevalence screen of the Swedish Two-Counties study, but a slightly higher proportion than 
expected were node-positive. It is suggested that at least seventy percent of tumours detected by 
screening should be node-negative, whereas sixty-three percent of those detected in the pilot 
programme were node-negative. The proportion of node-negative tumours is likely to increase in 
the second and subsequent screening rounds (Tabar et al 1992). 
The results for sensitivity, tumour size and stage suggest that the main benefit of screening, a 
reduction in breast cancer mortality, is likely to be achieved in the longer tenn. But the referral rate 










of this too many women underwent unnecessary investigations in the pilot programme, and this is a 
negative aspect of screening which every programme aims to minimise. Fortunately very few of 
these women had unnecessary biopsies, and the biopsy rate and benign to malignant ratio met the 
targets that had been set. In Chapter Four (Table 4.4) it was suggested that failure to reach this 
target should result in a reassessment of the criteria used for referral. In the pilot programme the 
focus is now on reducing the referral rate. This should continue to be evaluated, against second 
round screening targets (Table 7.3), in the second screening round. 
The results from the surveys of women showed that the programme is acceptable to most women, 
and there is a very high rate of intended participation in the next screening round. But intended 
participation does not always translate into actual coverage ( although the intended participation 
rate in women aged fifty to sixty-nine in the pre-screening survey was seventy-nine percent, and 
seventy-four percent of the eligible population were actually screened in the first screening round). 
Because of the high level of self-referral in the first screening round, a target for participation 
became almost irrelevant (section 7.3.2). In terms of evaluating the proportion of eligible women 
screened, coverage is the more important target. It will be important to measure coverage in the 
second screening round. 
Information collected during the first round of screening showed that the acceptable results for 
effectiveness and acceptability described above were accomplished at a similar cost to other breast 
cancer screening programmes. A cost-benefit analysis is being undertaken to determine whether in 
New Zealand the benefits of screening outweigh the costs. 
7.5.2 Targets for the incidence screening rounds 
The results from the pilot programme suggest that the programme is acceptable, and is likely to be 
effective and economically efficient, according to the standards set for the evaluation. However, 
the programme is still in its early stages, and continued evaluation is required, especially since many 
of the targets set for the first round of screening do not apply to subsequent rounds. Targets for 
the incidence screening rounds should be developed. Suggested targets are given in Table 7.3. An 
explanation for the choice of these targets follows. 
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TABLE 7.3 
Suggested targets for the incidence screens of the Otago and Southland pilot programme 
'r 
Characteristic to be evaluated: Target: 




' Specificity 95% 
,, Percent of screened women referred 5% 
~ 
Biopsy rate (% of screened women) <2% 








The target for identification of eligible women remains unchanged as this is unaffected by which 
screening round is taking place. It is clearly possible to identify ninety percent of eligible women 
using the electoral roll and general practice registers, but because of changes of address, the 
electoral roll rapidly becomes out of date. If it is used as the basis for a screening register regular 
updates of the roll have to be purchased from the electoral roll centre. A target for participation 
has not been included, since it was not particularly relevant due to the high rate of self-referral in 
the first round of the pilot programme. It would be interesting to measure participation in response 
to an invitation and self-referral rates in the second screening and subsequent rounds however, to 
see whether these change compared to the first round. The more important measure is the 
coverage ( or what proportion of the eligible women are screened), and this target has been reduced 
slightly, in recognition of the results from other screening programmes, where the percentage of 
eligible women screened invariably declined in the second round compared with the first screening 
round, ranging from fifty-five to seventy percent (Breast Cancer Screening Working Group 1987). 
The targets for sensitivity and specificity remain unchanged, but the target for the referral rate has 
been reduced because the underlying prevalence of breast cancer is lower in incidence screens, and 
since, in many cases, the radiologists will have the benefit of previous films for comparison. Both 
of these factors tend to lower the referral rate in incidence screening rounds compared with the 
prevalence screening round (Chamberlain et al 1993, National Health Service Breast Screening 
Programme 1994). If the programme meets the referral rate target in the second screening round it 
should also meet the target for specificity. 
The target biopsy rate has been set at less than two percent. In the prevalence screen the biopsy 
rate was 1.96 percent, which, combined with a low benign to malignant ratio (0.9 : 1) is a good 
result since it means that not too many women underwent unnecessary biopsies. In the second 
screening round it should be possible to reduce the biopsy rate further, since the underlying 
prevalence of breast cancer will be less in the second round, with most of the women having been 
screened two years previously. 
The target benign : malignant biopsy rate has been reduced for the incidence screening rounds, so 
that it is in line with ratios reported in European screening programmes, and because the ratio 




pilot progranune should meet this target easily, since the benign : malignant biopsy ratio in the 
prevalence screen was already below 0.9: 1. 
7.5.3 What do these results mean for a national breast cancer screening programme? 
The purpose of the evaluation was to investigate the acceptability, effectiveness, and economic 
efficiency of population based mammographic screening in New Zealand. The results of the 
evaluation of the Otago and Southland pilot programme showed that it is possible for an acceptable 
and effective breast cancer screening programme to be carried out in New Zealand. The 
preliminary results of the economic analysis showed that breast cancer screening can be 
accomplished in New Zealand at a cost similar to that of breast cancer screening programmes in 
other countries. Using cost data from the pilot programmes, an estimate was made of the likely 
cost of a national breast cancer screening programme in New Zealand. 
The results from the evaluation of the Otago and Southland pilot programme suggest that, if the 
national breast cancer screening programme can be carried out to a similar standard, it would start 
to reduce breast cancer mortality after about five years (Chapter One, section 1.2), among women 
aged fifty to sixty-four. Each year as a result of screening, about fifty-eight fewer women would 
die from breast cancer in New Zealand (Chapter Two, section 2.2). The cost of a national breast 
cancer screening programme in New Zealand is estimated to be between $9.3 and $9.9 million per 
year initially. Later, this cost will be partly offset by reduced treatment costs (section 7.4.4), and 
could drop to between $7.6 and $8.1 million, based on Australian estimates (Hall et al 1992, 
Salkeld and Gerard 1994) or even to between $4.7 and $5 million, based on Dutch estimates (de 
Koning et al 1992). 
7.6 Recommendations for the national breast cancer screening programme 
The New Zealand Ministry of Health received interim reports from the Otago and Southland, and 
Waikato pilot programmes in September 1993 (Richardson et al 1993, Health Waikato Ltd 1993). 
In June 1995, the Minister of Health announced plans for the introduction of a national breast 










to be fully implemented by the end of 1998 (Ministry of Health, 1995a). The decision to implement 
a national breast cancer screening programme was made for four reasons: 
• breast cancer is a significant health problem in New Zealand 
• there is now very strong evidence of the efficacy of breast cancer screening in reducing breast 
cancer mortality among women aged 50-64 years 
• studies show that breast cancer screening is value for money relative to other health interventions 
• the early results of the pilot programmes demonstrate that screening can be done effectively and 
efficiently in New Zealand. 
(Ministry of Health, 1995b) 
The national programme is to be an organised, population-based programme which will offer free 
two-view mammographic screening every two years to all asymptomatic women aged from fifty to 
sixty-four in New Zealand. The national breast cancer screening programme will be modelled on 
the two pilot programmes (Ministry of Health 1995a). 
The following recommendations are made for the New Zealand national breast cancer screening 
programme. 
7.6.1 Organisation of the screening programme 
The best way to minimise risks and ensure that screening reduces breast cancer mortality is to offer 
screening in a coordinated fashion, ensuring that each stage of the screening process is of high 
quality (Hakama et al 1985). Central coordination of the national breast cancer screening 
programme will be essential. It will not be adequate to contract out aspects of the programme 
piecemeal, because it is very important that all the stages of screening are coordinated to ensure 
timely and appropriate follow-up and adequate facilities for assessment and treatment ( especially in 
the prevalence screen, when the flow-on from screening is highest). 
Setting up a breast cancer screening service will require substantial managerial effort Considerable 
co-operation between health authorities or boards, hospital specialists, Family Practitioner 
Committees and general practitioners will be needed. There will be training needs to be met and 
there may be difficulties in attracting suitable staff to a relatively narrow field of practice. The 






authorities. Experience gained in the few existing breast cancer screening centres and the cervical 
cancer screening programme will be invaluable during the development of this new service. 
(Breast Cancer Screening Working Group 1987) 
The evaluation team was not charged with evaluating the way the Otago and Southland pilot 
programme was managed, but it became clear during the evaluation that the management of the 
programme was crucial to its success. Management of a breast cancer screening programme is 
very complex. It involves coordinating the efforts of people from many disciplines, and in different 
centres, often in a hospital setting, but in a programme dealing with well women. 
Programme managers should have an overview of all screening, further investigation and 
treatment activities associated with the programme, coordinate all components and make decisions 
for monitoring and evaluation. They are responsible for identifying and calling all eligible women 
for mammographic examinations and ensuring that those ,vith 'abnormal' findings are recalled for 
further investigation and referred to a specialist assessment team. 
(Austoker 1990) 
Each stage of screening must be carried out to a high standard if the programme as a whole is to be 
successful. The stages of screening include identifying and inviting eligible women, taking the 
screening mammograms, interpreting the films, informing women and their general practitioners of 
the results, referring some women to the assessment clinic, carrying out appropriate assessments, 
interpreting the results, informing women of these results, and referring women for appropriate 
treatment if required, and recalling women to the next screening round. 
These stages require coordination between clerical staff, radiographers, radiologists, surgeons, 
pathologists, medical physicists, and breast care nurses or counsellors. For each stage to be carried 
out to a high standard experienced and dedicated staff are essential. Good management means that 
women who take part in screening experience a smooth and rapid transition from one stage to the 
next, and the staff working in the programme feel part of a team rather than isolated individuals 
offering part of a fragmented service (Breast Cancer Screening Working Group 1987, Austoker 
1990). Fortunately the Otago and Southland pilot programme had an experienced manager with 
both clinical and management qualifications, and very dedicated staff It will be essential that 






7 .6.2 Programme staff 
All the staff involved in the screening programme should be expert. A screening programme 
requires radiographers with expertise and experience in talcing screening mammograms, a medical 
physicist with the expertise to calibrate and maintain the equipment so that the best images are 
produced at the lowest radiation exposure, radiologists with appropriate experience in reading 
screening films, pathologists with expertise in breast cancer histology, and surgeons with 
experience in treating women with screen-detected early breast cancer. The level of expertise of 
surgeons has been shown to affect the outcome for women with breast cancer (Gillis and Hole 
1996). It would be sensible for the pilot programmes to become training centres for the national 
breast cancer screening programme. This approach was suggested and used successfully in Britain 
(Breast Cancer Screening Working Group 1987). The coordinator of the national breast cancer 
screening programme should be a person who has experience in managing a screening programme. 
Management of a screening programme is complex in a regional programme let alone a national 
programme, and requires a person with appropriate experience and expertise. 
7 .6.3 Invitation method 
Personal invitations should be used, since these have been shown to increase participation in 
screening (Hobbs 1986, Williams and Vessey 1990), and contributed to the high coverage of the 
eligible population in the pilot programme (Chapter Five, section 5.1.3, Chapter Six, sections 6.2 
and 6.6). The high level of self-referral that occurred in the Otago and Southland and Waikato 
pilot programmes may not occur in other parts of New Zealand, for instance major urban centres 
such as Auckland, or very isolated areas such as the West Coast of the South Island, so it will be 
important to have an efficient and effective system of inviting eligible women. The Otago and 
Southland pilot programme did not investigate alternative ways of inviting Maori women to be 
screened, since only about two percent of the eligible women in Otago and Southland were Maori. 
The Waikato pilot programme investigated Marae-based screening (Health Waikato Ltd. 1993), 
and is still developing appropriate ways to invite Maori women for screening. These results will be 
very important for the national breast cancer screening programme. 
7 .6.4 Referral rates 
The pilot programme achieved excellent results by international standards, in most areas, including 













expected. Low specificity is directly related to a high referral rate, and this is a major challenge for 
screening in New Zealand. Women who were referred for assessment but did not have breast 
cancer did not benefit from talcing part in the programme, but experienced unnecessary anxiety and 
investigations. Fortunately for most of these women, the investigations were not invasive, since the 
pilot programme achieved a low biopsy rate and a very good benign to malignant biopsy ratio. 
Ideally a screening programme should combine a reduction in breast cancer mortality among 
women diagnosed with cancer, with the lowest possible risk for other women who take part in the 
programme. To achieve this, the referral rate in the national breast cancer screening programme 
must be lower than it was in the pilot programme. Methods to reduce the referral rate in the pilot 
programme should continue to be investigated so that appropriate referral criteria are adopted and 
can be taught to other radiologists who wish to read screening mammograms in the national breast 
cancer screening programme (Chapter Five, sections 5.3 and 5.4, Chapter Seven, section 7.2.7). 
Two-view mammography and double reading of films should be continued since these increase 
sensitivity and reduce referrals without markedly increasing costs (Wald et al 1995, Williams et al 
1995). 
7.6.5 Assessment of women with abnormal films 
There should be specialist breast assessment clinics and clearly defined surgical and treatment 
protocols for the national screening programme (Forrest 1989, Aitken et al 1992). It has been 
shown that the ten-year survival of women with breast cancer treated by specialist breast surgeons 
is eight percent better than women treated by non-specialist surgeons (Gillis and Hole 1996). There 
was a sixteen percent (95% CI 6% to 25%) reduction in risk of dying over ten years, after 
adjustment for age, tumour size, socioeconomic status, and nodal involvement for women treated 
by specialist breast surgeons ( Gillis and Hole 1996). This is probably related to specialist surgeons 
offering the optimum treatment, which has been shown to improve survival (Early Breast Cancer 
Triallists' Collaborative Group 1990) in women with early breast cancer (Chapter Two, section 
2.2.3). The establishment of a nationwide network of specialist breast assessment centres is likely 
to improve treatment for symptomatic women as well as for women diagnosed through screening. 
In Britain, the National Health Service Breast Screening Programme's quality assurance guidelines 
for surgeons inspired the development of new guidelines for the treatment of symptomatic women 





7.6.6 Involvement of general practitioners 
It has been shown that the response to an invitation is higher if the invitation is signed by the 
woman's general practitioner (Chapter Five, section 5.IJ). The other advantages of involving 
general practitioners in the screening programme are the avoidance of inappropriate invitations (for 
instance to women who are already being followed up after a diagnosis of breast cancer), and that 
women can discuss the invitation and the screening programme with their general practitioners, 
who will know when women in their practices are being invited and can provide support for 
women who require further assessment and investigation as part of the programme. A possible 
disadvantage to women of this involvement is the cost associated with consulting their general 
practitioners about breast cancer screening. 
7.6.7 Screening programme computer systems 
The screening programme should have a stand-alone computer system (preferably the same 
computer system should be used for all centres within the national programme). It is essential that 
all the screening centres can produce the information required for the management and evaluation 
of the programme quickly and easily. The computer system used for the Otago and Southland pilot 
programme was unsatisfactory (Chapter Four, section 4.4, Chapter Seven, section 7.1.1 ). In New 
Zealand we have the opportunity to learn from the experiences of other national screening 
programmes that are already in existence; in the United Kingdom limitations of the computer 
software used caused problems with the evaluation of the national breast cancer screening 
programme (Chamberlain et al 1993). Ideally the system chosen for the New Zealand national 
breast cancer screening programme should be one that has already been used successfully in breast 
cancer screening programmes. The system should be capable of managing appointments, storing 
results, flagging women who are due to be invited to each screening round, and generating 
invitation letters, results, and reports. A data manager and programming staff should be appointed 
to maintain the computer system and to ensure the efficient production of the data required for 
evaluating the national programme. 
7.6.8 Evaluation and quality assurance 
Evaluation of the pilot programmes should continue, so that information about the second and 
subsequent screening rounds can be collected, since this will be relevant to the national screening 
programme. The national programme should also be evaluated, to ensure that it offers screening in 
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a way that is acceptable, effective, and efficient. The information to be collected from each 
screening centre must be clearly specified, and it must be easy to obtain this information from each 
screening centre computer system. Appropriate standards for quality must be set and maintained 
throughout the national programme. The British national breast cancer screening programme has a 
quality assurance programme which is coordinated by national committees with representatives 
from each of the disciplines involved in the programme (Austoker 1990). A national screening 
evaluation unit specifies, checks, and analyses the data collected from each screening centre in the 
national breast cancer screening programme, and compares the results against an agreed standard 
(National Health Service Breast Screening Programme 1994). Equivalent mechanisms for quality 
assurance and evaluation should be incorporated in the New Zealand national breast cancer 
screening programme. 
7. 7 Conclusions 
This evaluation of the Otago and Southland pilot programme was carried out to establish whether 
breast cancer screening could be carried out effectively, acceptably, and efficiently in New Zealand, 
and to provide information that was used to plan a national breast cancer screening programme. A 
goal-attainment evaluation method was used, where information was collected and compared 
against a standard derived from successful screening programmes in other countries. 
The pilot programme met the targets that had been set for identification, coverage, sensitivity, 
biopsy rate, benign to malignant ratio, and screen prevalence (detection rate). These targets relate 
to the effectiveness of the pilot programme in detecting early breast cancer, and suggest that the 
Otago and Southland programme will reduce breast cancer mortality in the longer term, among 
screened women. The pilot programme failed to meet the targets set for specificity and the referral 
rate. Failure to meet these targets will not adversely affect breast cancer mortality but meant that 
too many women underwent unnecessary investigations and anxiety. The programme staff are 
aware of these results, and efforts are being made to reduce the referral rate and improve 









Surveys of women who took part in the pilot programme showed that it provided an acceptable 
service and that most women plan to continue to participate in screening. This is encouraging as 
the effectiveness of the programme is enhanced if a high proportion of the eligible population is 
screened. The programme achieved these results at a cost that was comparable with similar 
programmes in other countries. Information from the pilot programme was used to estimate the 
cost of a national breast cancer screening programme in New Zealand. 
The results of the evaluation of the Otago and Southland pilot programme influenced the decision 
to implement a national breast cancer screening programme in New Zealand (Ministry of Health 
1995b ), and the national breast cancer screening programme will be modelled on the Otago and 
Southland and Waikato pilot programmes (Ministry of Health 1995a). However there are still 
some issues which could affect the national screening programme, but could not be investigated 
fully in the pilot programmes, since the pilot areas could not be expected to be representative of the 
whole country. 
An important issue will be finding the appropriate way to invite women and deliver screening to 
women in very isolated areas such as the West Coast of the South Island. Such women may have 
to travel considerable distances for screening, despite having mobile units available, and even 
further for assessment and treatment. Identifying and inviting highly mobile inner-city women, for 
instance in Auckland, will also be a challenge for the national programme. Another issue will be 
how to recruit and train adequate numbers of appropriate staff for a national screening programme. 
If the two pilot programmes become training centres for the rest of the country, it will be important 
to find a means to provide training while still maintaining the performance of the pilot programmes. 
A further issue will be establishing the best way to coordinate local and regional programmes into 
an acceptable, effective, and efficient national programme. 
This method of evaluation has provided an early indication of the performance of the pilot 
programme compared with other breast cancer screening programmes. The method provided a 
rigorous evaluation of the acceptability, effectiveness, and economic efficiency of breast cancer 
screening in New Zealand. Breast cancer screening in New Zealand has been subjected to closer 








The evidence both for the overall benefit of the technique and for its value as applied in New 
Zealand is better than we have for the great majority of health interventions, and will justify a 
commitment to making breast cancer screening available to all women in the appropriate age 
range in New Zealand. 
(Elwood 1994) 
The evaluation method also provided rapid feedback for programme staff so that the successful 
aspects of the programme could be maintained, and changes made to any less successful aspects, as 
the pilot programme progressed. 
The use of targets such as those used in this evaluation, is becoming more common in New Zealand 
and in other countries, in the planning and evaluation of health care. The World Health 
Organisation (WHO) global strategy for Health for All by the Year 2000 encourages member 
nations to set health goals and targets (World Health Organisation 1982). Australia has been 
developing and using health goals and targets since 1985 (Health Targets and Implementation 
Committee 1988, Australian Institute of Health 1990, Leeder 1995), and "Healthy People 2000" is 
a national strategy which uses targets to assess progress on improving health and preventing 
disease in the United States (Feinleib 1995). New Zealand introduced national health goals and 
targets in 1989 (Ministry ofHealth 1989) . 
There is also increasing emphasis on evidence-based medicine in the provision of health care. 
Evidence-based medicine promotes the use of interventions that are based on sound evidence from 
randomised controlled trials (Sackett and Rosenberg 1995, Glasziou and Irwig 1995). The system 
of targets used in this evaluation was independently developed after reviewing the relevant 
literature on breast cancer screening. Because the targets were derived from programmes which 
had proven efficacy demonstrated in randomised controlled trials, the targets provided a rigorous 
assessment of the performance of the breast cancer screening pilot programme. By linking the 
targets to evidence from randomised controlled trials, this method of evaluation ensures that 
evidence-based medicine is put into practice. Similar evaluation methods could be used for other 
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Impact of independent double reading of mammograms from the inception of 
a population-based breast cancer screening programme 
S. M. Williams,* T. C. A. Doyle,+ S. Chartres,+ A. K. Richardson** and J.M. Elwood*~ 
*Department of Preventive and Social Medicine, tDepartment of Radiology, +Hugh Adam Cancer Epidemiology 
Unit, Otago Medical School, Dunedin, New 'Zealand 
S UM MA R Y. The Otago-Southland Breast Screening programme was set up to find out bow acceptable 
and effectiYe breast screening would be for New Zealand women aged between SO and 64 years. This report 
examines the performance of the radiologists in the first 18 months of the pilot programme. The majority, 5659 
(80.0% ), of the two view mammograms from 7074 women, were read independently by two radiologists. 
Women, who both radiologists believed had an abnormality, were automatically referred for further 
assessmenL The mammograms of those thought to have an abnormality by only one were reconsidered before 
a referral by consensus was made. The majority of cancers (58) were detected in mammograms read by radiolo-
gists A and B. The positive predictive value for those read as abnormal by both was 12.4%. If only one bad read 
the mammograms the number of cancers detected would have been 56 or 55 depending on the radiologisL 
Overall 73 women were found to have cancer, 67 of whom were identified by two radiologists. The positive 
predictive value for all the radiologists was 10.5% (95% CI 7.7-12.4). 
The inter-observer agreement for radiologists A and B about whether or not a woman should be referred 
for further assessment measured by kappa was 0.65. Because of the debate about whether or not kappa is the 
most appropriate measure of agreement other measures are also presented. Alpha which is based upon the idea 
that mammograms fall into two classes, those that can be consistently classified by two observers according to 
some well defined rules and those, that because they are more difficult, are cl~ified by chance. In this study 
alpha was 0.82 for radiologists A and B suggesting that they were in accord, taking account of chance, for 82 % 
of the mammograms. The intraclass correlation, a measure of agreement among all radiologists was 0.64. These 
measures show higher levels of agreement than have been reported in other larger studies. 
INTRODUCTION 
Recent studies have shown that double reading of 
screening mammograms increases the number of cancers 
detected, 1.1 but also increases the number of women 
who are unnecessarily recalled. Other studies have inves-
tigated the agreement between radiologists taking part 
in mammography screening programmes.:i-5 
The Otago-Southland Breast Screening Programme is 
the first population-based programme in New Zealand; 
since 1991 all women aged 50-64 years have been 
offered 2-yearly two-view mammography, with an 
uptake rate of 65-75% and outcomes similar to those of 
European programmes. 6•7 Mammograms were assessed 
with only two decision options: normal, that the woman 
should be offered routine screening again in 2-years 
time, or abnormal, that the woman should be referred for 
Address correspondence to: S. Williams, Department of Preventive 
and Social Medicine, Otago Medical School, PO Box 913, Dunedin, 
New Zealand 
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further assessment. Films were read independently by 
two radiologists, providing an opportunity to compare 
double reading with single reading, and to assess the 
agreement between readers. 
PATIE:NTS AND METHODS 
Data from the first 18 months of screening were 
available. Almost all mammograms were read by two 
radiologists. All women who reported breast symptoms 
were automatically referred for further assessment irre-
spective of results of their mammograms, and so were 
excluded from this analysis. The referral rate, detection 
rate of breast cancer, and positive predictive value (PPV) 
were calculated. Several measures of inter-reader agree-
ment were used. Positive agreement3 is the ratio of the 
proportion described as abnormal by both observers to 
the mean proportion of those described as abnormal 
by each observer. Negative agreement is defined in a 
similar way. Kappa8 measures the level of agreement in 
,, 
( 
I I ,, ,~ 
r 
e:c.cess of chance. PABAK is a measure of agreement 
that takes account bias and prevalence.9 Another measure 
of agreement, alpha, is based upon postulating a mixed 
model for the observations so that a proportion are 
classified consistently and a more difficult sub group 
by chance. 10 Alpha, a kappa-like statistic, provides an 
estimate of the proportion classified consistently by both 
observers. The bootstrap method was used to compute 
the 95% confidence intervals. 11 A log linear model 
using a quasi independence model12 was used to see 
whether the level of agreement changed over time for 
the two radiologists who read the majority of the films. 
RESULTS 
In the 18-month period, 7182 women attended for 
screening. Of these, 6 had no films ta.ken and 85 were 
excluded because they reported symptoms and were 
referred to the assessment clinic automatically. A further 
16 were e:c.cluded because their films were read twice 
by the same reader and one because her films were 
the only set read by an 11th radiologist. This report 
was based upon the remaining 7074 women whose 
manunograms were read independently by 2 of 10 
different radiologists. 
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Cancer detection, referral, and positive predictive 
value 
Two radiologists, readers A and B .. each independently 
read 5659 sets of mammograms. 80% of the total 
(Table I). Of these, 7 .5% were regarded as having an 
abnormality by both readers, an additional 1.9% were 
so assessed by reader A, and an additional 4.8% by 
reader B (Table 1); thus, reader A assessed 9.4% of 
women as having an abnormality, compared with 12.3% 
by reader B (P < .001). 
Overall 14.3% of screenings were regarded as abnor-
mal by one or both radiologists (Table 2). Assessed by 
2-month time periods, this proportion was high in the 
first two time periods, then fell and rose again later, x.2 
(8 df) = 28. l, P < 0.001. Where only one of the radiolo-
gists initially found an abnormality, the films were 
reassessed by both radiologists and a consensus decision 
ta.ken about referral for further assessment. The propor-
tion referred to the assessment clinic declined, over time, 
from 84% in the first 2 months to 65% in the most recent 
period, a significant trend x2 (8 df) = 49.6, p < 0.001, x2 
(for trend) = 34.3, P < 0.001. 
Of 582 women assessed 58 were found to have breast 
cancer, giving a PPV based on the assessment decision 
of 10.0%. The PPV was lower in the first two bimonthly 
periods than later (Table 2), but the trend over time was 
Table I Numbers and percentages of sets of screening mammograms classed as abnormal after independent reading 
by two radiologists (A and B) for nine 2-monthly periods 
Classification of each set of mammograms, by reader 
Both A abnormal A normal Both Total 
Time period abnormal B normal B abnormal normal 
n % n % n % n % 
September-October 1991 37 9.1 6 1.5 14 3.4 350 86.0 4(J7 
November-December 1991 II 6.6 4 2.4 13 7.8 139 83.2 167 
January-February 1992 20 4.8 4 1.0 20 4.8 373 89.4 417 
March-April 1992 43 5.5 11 1.4 29 3.7 702 89.4 785 
May-June 1992 41 5.8 10 1.4 34 4.8 624 88.0 709 
July-August 1992 73 8.4 22 2.5 48 5.5 727 83.6 870 
September-October 1992 66 9.9 12 1.8 38 5.7 551 82.6 667 
November 1992-January 1993* 61 9.0 16 2.4 32 4.7 569 83.9 678 
February-March 1993 74 7.7 23 2.4 45 4.7 817 85.2 959 
Total 426 7.5 108 l.9 273 4.8 4852 85.7 5659 
* No screening in December 1992. 
Table 2 Numbers and percentages of screening mammograms found to be abnormal and subsequently referred for 
further assessment by radiologists A and B 
Time period Total Total abnonnal Total Cancer PPV 95% CI 
by either reader referred 
n n % n % n 
September-October 1991 407 57 14.0 48 84.2 2 4 (}.15 
November-December 1991 167 28 16.7 20 71.4 l 5 (}.28 
January-February 1992 417 44 10.6 35 79.5 3 9 2-25 
March-April 1992 785 83 10.6 63 75.9 8 13 6-25 
May-June 1992 709 85 12.0 65 76.5 9 14 6-26 
July-August 1992 870 143 16.4 100 69.9 13 13 7-22 
September-October 1992 667 116 17.4 83 71.6 8 10 4-19 
November 1992-January 1993* 678 109 16.l 75 68.8 5 7 2-16 
February-March 1993 959 142 14.8 93 65.4 9 10 4-18 
Total 5659 807 14.3 582 72.l 58 10.0 7.6-12.9 
* No screening in December 1992. 
,'-
\ 
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Table 3 Prevalence of an abnormality. and measures of agreement for two radiologists by time period 
Prevalence• Positive• Negative.f Kappa PABAK Alpha 
agreement agreement 
l. September--October 199 l 0.12 0.79 0.97 0.76 0.90 0.87 
2. Sovember-December 199 l 0.12 0.56 0.94 0.51 0.80 0.73 
3. January-February 1992 0.07 0.63 0.97 0.60 0.88 0.84 
4. March-April 1992 0.08 0.68 0.97 0.66 0.90 0.85 
5. May-June 1992 0.09 0.65 0.97 0.62 0.88 0.83 
6. July-August 1992 0.12 0.68 0.95 0.63 0.84 0.79 
7. September--October 1992 0.14 0.73 0.96 0.68 0.85 0.82 
8. November 1992-January 1993 0.13 0.72 0.96 0.68 0.86 0.82 
9. February-March 1993 0.11 0.69 0.96 0.65 0.86 0.81 
Total 0.11 0.69 0.96 0.65 0.86 0.82 
95% confidence intervals (0.62~.67) (0.80--0.84) 
*Mean of proportion described as abnonnal by radiologists; tnumber described as abnormal by both/mean number described as 
abnormal; .;number described as normal by both/mean number described as abnormal. 
not statistically significant. The PPV based on an initial 
recognition of abnormality by either radiologist was 
7.2%. The PPV was higher for women in whom both 
radiologists found an abnormality, 53 cancers in 426 
women (12.4%, 95% CI 9.3-16.3%); compared with 
five of 381 women (1.3%, 95 CT 0.4-3.1) for those in 
whom only one radiologist found an abnormality. Based 
on all women regarded as abnormal by either radiologist 
independently, the PPV for reader A was 10.3% and 
that for reader B 8.0%; this difference was not significant 
(P=0.17). 
Eight other radiologists were also involved in the pro-
gramme, but none read more than 400 sets of screening 
films. Those described as abnormal by one of the radi-
ologists were reviewed, usually by radiologists A and B, 
although occasionally a third radiologist was consulted, 
before a decision to refer the woman to the assessment 
clinic was made. Altogether 73 cancers were detected, 67 
of which were found by two radiologists, making the 
positive predictive value for all the radiologists 10.5% 
(95% CI 7.7-12.4). Although the proportions regarded 
as abnormal ranged from 6% to 16%, and the PPV values 
ranged from 0% to 19%, neither of these variations is 
1.0 
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statistically significant. As the numbers are limited, the 
data are not presented in detail. 
Inter-rater agreement 
The level of agreement between the two radiologists A 
and B over the first 18 months of the programme was 
assessed by several measures, as shown in Table 3 and 
Figure l. On all measures, the level of agreement was 
high in the first time period, much lower in the second 
time period, but the trend thereafter depended upon 
the measure of agreement used. Positive agreement, and 
kappa, follow very similar patterns and show a tendency 
to increase from time-period 3. The statistics PABAK 
and alpha show a very slight trend for reduction from 
time-period 3 through the rest of the study. 
A further and rigorous method of assessment was 
made by fitting a log linear model to these data, using 
factors for each radiologist, for time and for agreement 
based on the diagonal cells. A model which excluded 
an interaction effect between time and the effect for 
agreement provided a good fit for the data, xz (8 df) = 
7.53, and addition of an interaction term did not improve 
a a 
---0- negative agr--,t -- PABAK -- alpha -- positive agreement -- kappa --- prevalence 
8 9 10 







this significantly. showing that the level of agreement 
between the radiologists did not change significantly in 
the course of the study. The model was also fined, after 
excluding the data for the first time period. In this case, 
too. a model which excluded an interaction between time 
and agreement proved to be a good fit, X2 (7 dt) = 3.59. 
To illustrate further the use of these several measures 
of agreement, their values for each of the l O radiologists 
are shown in Figure 2, although for some radiologists 
the numbers of sets of films read are fairly small. Again, 
positive agreement and kappa show very similar varia-
tions, while alpha shows some differences; for example 
radiologists E and H show similar levels of kappa but 
rather different values of alpha. 
A random effects analysis of variance was used to 
compute the intraclass correlation which provides an 
overall measure of agreement among all the raters; it was 
0.64. 
DISCUSSION 
This study is in the context of a population based screen-
ing programme for women aged 50-64 years, using invi-
tations based on general practice lists and the electoral 
roll, with an uptake rate of 65-75%.6•7 It was the first 
large scale public funded programme in New Zealand. 
The radiologists concerned had considerable experience 
of diagnostic mammography at the start of the programme, 
but only limited experience of screening mammography 
on a large scale. As the programme was designed to 
be carefully assessed, 6•7 independent double reading was 
introduced at the outset, and a system set up to ensure 
independence and systematic review of films where the 
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Detection rates and PPV 
In a research setting. the perfonnance of a screening test 
could be fully assessed if all subject£ screened were also 
assessed by a definitive 'gold standard' diagnostic test. 
This is impossible in an operating screening programme, 
and the best assessment then requires the follow-up of all 
persons screened for a sufficient time so that misse<l 
cases will be detected by other means; the recording 
of these interval cancers allows the sensitivity and 
specificity of the test to be calculated. 13 For breast cancer 
screening, this requires large numbers of subjects, as 
interval cancers are not common, and a 1 or 2 years 
follow-up period, and so is difficult to apply even to a 
whole programme. To compare the performance of 
different radiologist readers, or assess changes over 
time, is even more demanding. Thus, such assessments 
are usually restricted to those based on the initial 
mammogram result, and the follow-up of those women 
in whom the mammogram is normal. This allows calcu-
lation of the cancer detection rates, the referral rates, 
and the PPV, which can be used to compare readers. 
The PPV is the proportion of women with abnonnal 
screening mammograms who are diagnosed with breast 
cancer after further assessment. 
Most of the data relates to the two main radiologists 
(readers A and B). The proportion of women with an 
abnormal screening result who were subsequently diag-
nosed with. beast cancer (the positive predictive value, 
PPV) was 12.4% where both radiologists found an 
abnonnality; these women are likely to have had more 
clearly abnormal mammograms. Fifty-three cancers were 
dia,,onosed in this way. An additional 5 cases were initially 
regarded as abnormal by one reader; thus, had only one 
reader been used either 2 (3%) or 3 (5%) cases would 
have been missed, depending on which radiologist did 
-- negative agreement - PABAK -- a~a --- positiYe agreement --- kappa ---- prevalence 
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the reading. In the Finnish study 33% of those deemed 
abnormal by both radiologists were found to have 
cancer. and single reading would have led to either 4 
t 6q.) or 7 ( !0%) cases being missed. 1 In a Scottish study 
10.9'{: of those with cancers would not have been 
detected had the mammograms been read by a single 
radiologist;" thus, in general double reading seems to 
increase the detection rate by from 3% to 10%. A measure 
of consistency in terms of breast cancers detected would 
be the proportion of breast cancers detected in the 
opinion of both radiologists, compared with the number 
detected in the opinion of only one; which is 53/58, 91 %, 
in this study. 
In this study the positive predictive values for readers 
A and B, who read most of the mammograms, were 
10.3% and 8.0%, similar to those that can be calculated 
from data reported for other studies. The PPV values for 
the two radiologists in a Finnish screening programme, 1 
using two-view mammography, were 11.0% and 12.4%; 
and those for three radiologists in a Scottish programme, 1 
using single oblique view mammography, who had much 
more experience with reading screening mammograms, 
were between 7.6% and 12.1%. 
Effect of double reading on referral rate 
The increase in the number of cancers detected was at 
the cost of an increased number of women being referred 
for further assessment. In our study, sets of films re-
garded as abnormal by only one reader were reviewed 
at a further session, and consensus was reached on 
whether referral was necessary. This greatly reduced the 
number of women referred; overall 72% of such women 
were referred after consensus, this proportion falling 
from 84% to 65% over the 18 months of the programme. 
As the proportion regarded as abnormal by at least one 
reader did not change with time, the review process led 
to fewer referrals to the assessment clinic. In the Finnish 
study the number of referrals was reduced by 45% 
by reviewing the mammograms found to be abnormal 
by either or both radiologists. 
The PPV for women in whom only one radiologist 
categorized the films as abnormal, followed by a consen-
sus decision to refer, was relatively low: 1.3%, as this 
group of women contribute only 8.6% to the numbers of 
cancers diagnosed, but 26.8% to the number of women 
referred. Further examination of the radiological features 
in these women might allow fewer referrals to be made 
without reducing the detection rate, and such studies are 
being done. 
Single reading increased the number of referrals to the 
assessment clinic in both the Finnish and Scottish studies 
and in ours would depend upon the reader. Good agree-
ment between the readers may make single reading a 
better option so whether one or two readers should 
be used will depend on the skill of the readers as well as 
a consideration of the costs and degree of negative effect 
of the extra recalls, and also on a consideration of the 
false negative rate, that is the cancers missed. These can 
only be ascertained after at least l year's follow-up of all 
women screened negative. 
Measures of agreement 
The positive predictive value for each radiologist gives 
an indication of the sensitivity of each radiologist, but is 
of limited •,alue as it depends on the numbers of cancers 
detected, which will be small. Thus, in this study PPV 
can be assessed for the two radiologists who read several 
thousand films. but the results for other radiologists are 
too imprecise to be useful. The other way of comparing 
performance is by assessing the agreement, or consist-
ency, between pairs of readers, using all the films they 
review. However. the appropriate choice of agreement 
measure is not ob,.;ous, and in this paper we have used 
several, and shown that one analysis: the trend in agree-
ment with time, the result depends on which measure of 
agreement is used. One intuitive measure of agreement 
is the number of women for whom both radiologists 
recognized an abnormality, as a proportion of the num-
ber of women in whom either radiologist recognized an 
abnormality (the positive agreement). This is a measure 
of the consistency of making a referral decision, and 
in this study, comparing readers A and B, is 0.69. 
This takes no account of the likelihood of agreement 
by chance. 
Kappa is a commonly used measure of the level of 
agreement in excess of that found by chance, a value of l 
signifying perfect agreement and O no agreement. It is 
possible to consider its statistical significance but it is 
generally argued that it is its magnitude that is important. 
Arbitrary bench marks for kappa applied to clinical; 
measurements in general have been provided; 0.41-0.60 
is considered to be moderate agreement, 0.61-0. 80 
substantial agreement and 0.81-1.00 almost perfect 
agreement.~ Overall kappa was 0.65 for radiologists A 
and B and was between 0.48 and 0.74 when the other 
radiologists were compared with radiologist A. These 
results give a 'substantial' level of agreement. The 
intraclass correlation which provides an overall measure 
of agreement among all the raters was 0.64; it can be 
interpreted in the same way as kappa, suggesting that 
the agreement among all the raters was acceptable. 
Results compared with other studies 
The evaluation of agreement of independent assessment 
of mammography by two radiologists has been done in 
very few srudies. One Canadian study, carried out in the 
planning stage of a multicentre randomized controlled 
trial of screening for breast cancer with mammography, 
compared the interpretation by 8 radiologists3 of a set of 
100 selected xeromamrnograms, which comprised 10 
histologically proven cancers, 40 benign abnormalities 
and 50 nounal films. They were classified as a techni-
cally unsatisfactory film, normal breast, benign abnor-
mality, suspicion of cancer and cancer present. Using 
weighted kappa as the measure of agreement between 
pairs of raters, this was between 0.23 and 0.59. Agree-
ment was highest for a diagnosis of cancer, with mean 
values of kappa of 0.50 or more for all but one reader. 
The radiologists also record their recommendations for 
management. as no recommendation. follow-up after 12 
months, follow-up between 6 and 12 months, follow-up 
within 6 months and aspiration or biopsy, giving values 
of weighted kappa for agreement were between 0.15 
and 0.63. However, this study was based on small num-
bers, in a non-routine situation. A similar study in which 
10 radiologists considered 150 mammograms found only 
moderate consistency between pairs of radiologists, 
weighted kappa was 0.47.15 The authors commented 
upon widely differing recommendations for management 
among the radiologists. 
Studies within ongoing programmes are summarized 
in Table 4. In the Canadian National Breast Screening 
Study,4 a single reference radiologist blindly reviewed 
5200 randomly selected two-view mammograms from 
women not found to have breast cancer, 575 screening 
detected breast cancers cases and 102 interval cancer 
cases. Agreement, measured by kappa, between the 
reference radiologist and the centre radiologists for those 
known to have breast cancer was 0.51; for those not 
known to have breast cancer it was 0.31. The more recent 
Finnish recent study provides figures from which it is 
possible to calculate kappa, 1 which yields 0.31. Thus, 
the current results shown a significantly higher level of 
agreement than in these other two studies. Other series 
are available in which double reading has been used, but 
the data are not presented in a way in which a measure 
of agreement can be calculated. 2 
Factors which would reduce the level of agreement 
include a low prevalence of abnormalities, poor technical 
quality or radiographic technique, particularly difficult 
to interpret films for biological reasons, lack of radiolo-
gists' experience, and chance. 
Methodology 
The value of the kappa statistic 16• 17 depends on the preva-
lence of the disease as well as the sensitivity and 
specificity of the test, approaching O as the prevalence of 
the disease approaches O or l. A high level of observed 
agreement can be reduced when the prevalence of a 
condition is especially low;5• 18 which is the situation in 
many screening procedures. This makes comparisons 
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among studies or over different periods of time within a 
study difficult because it is impossible to distinguish the 
effects of changes in prevalence from those of changes in 
the pattern of agreement between the raters. \\ ben there 
is bias because the two observers differ in their assess-
ment of the prevalence of a condition, the value of kappa 
is inflated.3 Because of these drawbacks and because 
most other measures of agreement can be shown to 
be mathematically equivalent to kappa. it has been 
recommended that for ongoing studies measures of both 
positive and negative agreement as well as kappa be 
reported. Toe results of this study suggest that reporting 
all these measures of agreement is not particularly useful 
as kappa corresponded closely with the measure of posi-
tive agreement and correcting the measure of positive 
agreement for chance would convert it to kappa. Else-
where it has been suggested that kappa should be ad-
justed for bias and preva1ence.9 The prevalence adjusted, 
bias adjusted kappa (P ABAK) is linearly related to 
the observed overall agreement depending upon both 
the positive and negative results. Kappa is more strongly 
related to the agreement on positive results, that is, on 
who should be referred. It could be argued that this is 
the more important issue in a screening programme. 
Kappa is adjusted for chance by assuming that every 
observation is classified independently. The statistic 
alpha is developed from a simple model which assumes 
that mammograms arise from two hypothetical groups: 
one, where abnormalities or the appearance of normality 
are clear, which (it is assumed) are classified totally 
consistently by both observers, and a second group 
which are difficult to assess for which (it is assumed) 
the agreement between two readers is only due to 
chance. Alpha provides an estimate of the proportion 
of observations which are consistently classified. Toe 
overall value of alpha for radiologists A and B in this 
study was 0.82. Within increasing radiologists' profi-
ciency alpha might be expected to increase. Although 
alpha depends upon the prevalence the condition of 
interest, it has been shown to be less affected by preva-
lence rates lower than I 0% than is kappa. 9 In this study 
the level of concordance was consistent with each radi-
ologist finding about 10% of mammograms difficult 
to classify without much overlap for those they find 
difficult. The level of agreement in the current study as 
assessed by alpha was higher than the other available 
studies (Table 4 ). 
Table 4 Kappa and alpha for the comparisons between the reference radiologist and the others for the 
data from the Canadian National Breast Screening Study and the Otago-Southland Pilot Programme 
n Kappa 95% CI Alpha 95% CI 
Canadian Srudr 
No k:now11 cancer 5200 0.31 0.28 0.34 0.41 0.38 0.47 
Screen detected cancers 575 0.51 0.42 0.60 0.64 0.57 0.71 
Inten·al cancers 102 0.16 0.04 0.29 0.45 0.17 0.65 
Finnish Studyl 15 457 0.31 0.27 0.35 0.75 0.73 0.78 
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CONCLUSION 
The extent of agreement between the main radiologists 
was higher in this study than in other major studies 
which have been published. This result, along with the 
high cancer detection rate in the programme7 suggests 
that the standard of radiological assessment in the 
programme was high. We believe that the procedure of 
independent double reading, followed by a consensus 
decision for women whose films were initially regarded 
as abnonnal by only one reader, is a useful approach. For 
the t\\10 main readers, the use of double reading increased 
the number of cancers detected by screening by either 2 
or 3 (depending upon the radiologist) of the total of 58; 
that is by an average of 4%. This figure is somewhat 
lower than those shown in other studies, which is related 
to the higher degree of inter-observer consistency in our 
study. An interesting result is that the double reading 
process did not necessarily increase the number of 
women referred for assessment. Had the initial radiologi-
cal decision from one radiologist been used, without 
the opportunity for discussion, the referral rate would 
have ranged from 9.4% to 12.3%, depending upon 
the radiologist. All these referral rates are relatively 
high, which is probably because this represents a first 
screening in a previously unscreened population, and 
the overall detection rate of cancer at this first screen 
has been high by international standards, around 10 per 
100 women screened.7 The incidence of breast cancer is 
relatively high in New Zealand, and it is possible that 
the true incidence is higher than in many other areas 
where screening programmes have operated. 
Toe most conservative approach would be to refer 
only women in whom both radiologists found an abnor-
mality, and this would reduce the number of women 
referred by 26%. Correspondingly, the frequency of 
cancer in women referred after only one radiologist 
found an abnormality was quite low (1.3%), compared 
with the frequency where both radiologists found an 
abnormality (12.4%). However, we do not believe it is 
likely to be clinically acceptable only to refer women in 
whom both radiologists have found an abnormality. as 
there would be ethical and legal issues if no further 
investigation were undertaken on the others. 
There are substantial benefits of double reading. It 
is an important educational experience, and encourages 
radiologists to take a realistic view of their abilities, and 
to continually improve. This is particularly helpful 
when a new radiologist joins the team or as in this case 
when the whole screening programme is new. 
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Abstract 
Aims. To measure the public health service costs associated 
with New Zealand's pilot mammography screening 
programmes. To compare the early ev;dence on cost per 
woman screened and per cancer detected in those 
programmes to that of overseas screening programmes. To 
estimate the cost of introducing a national screening 
programme in New Zealand. 
Methods. Costs in each screening centre were obtained by 
a careful examination of screening budgets and public 
health service accounts; these were inflation adjusted using 
a consumers price index, and analysed in terms of 
equivalent annual operating costs. 
Results. In the first year of screening the cost per woman 
screened (in $1991) was $182 in Waikato and $178 in 
Otago/Southland. The cost per woman screened in the third 
year of screening (with an assumed full screening 
throughput of 8000 women per annum) is estimated to fall 
to $106 and $113 for the Waikato and Otago/Southland 
programmes respectively. The cost per cancer detected in 
the first screening round differs between the two 
programmes. In the first year of screening the cost per 
cancer detected was $35 975 in Waikato and $21 908 in 
Otago/Southland. The difference was primarily attributable 
to a lower cancer detection rate in Waikato in that period 
(0.51% of women screened compared with 0.81% in Otagol 
Southland). 
Conclusions. The initial performance of the New Zealand 
pilot programmes, both in terms of cost per woman screened 
and cost per cancer detected, falls within the range indicated 
from overseas experience. An established national screening 
program~e is estimated to add between $9.3 and $9.9 
million dollars (in 1991 dollar terms) to health service costs 
each year. These costs will be partly offset by savings 
resulting from the earlier detection of cancers. 
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Pilot mammography screening programmes were 
established in two regions of New Zealand, Otago/ 
Southland (in November 1990) and Waikato I in February 
1991), v,ith the objective of determining the costs and 
benefits of screening for New Zealand. In each region, 
women between the ages of 50 and 65 years were invited to 
undergo screening at two-yearly intervals. Screening in the 
Otago/Southland programme was provided from two fixed 
units (one each in Invercargill and Dunedin) and one 
mobile unit, and in Waikato from one fixed and one mobile 
unit. 
The aims of this pap€r are: (lJ To measure the public 
health service costs associated with the recruitment. 
screening and subsequent clinical investigation of women 
participating in the pilot programmes. (2) To gauge the 
initial performance of those programmes, on indicators such 
as cost p€r woman screened and p€r cancer detected, relative 
to that of overseas screening programmes. (3J To estimate 
the cost of introducing a national screening programme. 
Methods 
Data was sought from each screening programme regarding the 
costs associated with the recruitment, screening, and follow on 
investigations of participants. including diagnostic procedures such 
as clinical examination, further mammography, ultrasound, fine 
needle aspiration and surgical biopsy. Treatment costs relating to 
cancers detected by the programme have not been included. All 
costs exclude GST. 
Cost data were primarily derived from the financial records kept 
by each programme for the years ending June 1991-3. No screening 
was undertaken in 1991 lyear Ol; 1992 and 1993 represent years 1 
and 2 of screening activity. Costs relating to the use of wider 
hospital resources (such as those generated by follow on 
assessments and overheads, were based mainly upon resource 
utilisation system (RuSJ data. rather than on charges made 
against the screening programmes. In many cases such charges 
were deferred or negotiated at a rate below the actual cost. Some of 
the inputs used by the screening programmes were funded by 
pri"ate donations. In order to reflect the costs of extending 
screening beyond the pilots. all direct capital and operating costs 
have been included. regardless of how these were funded. 
Although significant overseas travel costs were incurred in 
establishing the pilot programmes. the results reported here 
include only the salary component of training costs on the basis 
that if screening were introduced on a national basis. clinicians 
and managers could be trained from the pilot centres rather than 
from overseas. 
Actual costs in year 2 have been used to project costs for later 
periods. A screening throughput of 8 000 women per annum is 
assumed to be achievable by each programme by year 3. This is 
based upon an eligible population of approximately 20 000 women 
for each programme. screened every two years. with a coverage 
rate of 80'<. Operating costs in year 3 incorporate the estimated 
additional inputs required by each programme to achieve this 
screening throughput . 
Costs were deflated by a consumers price index 1CPI · with a base 
in .June 1991. and are reported 10 terms of annual operating costs 
to allow the performance of the programme in each period to be 
compared. Capital costs were annuit1sed to calculate the 
"equi\'alent annual cost".' which incorporates both depreciation and 
opportunity cost considerations regardmg capital outlays. 1 An 
interest rate of 5't and a life of 10 years for all capital equipment is 
used. To check the sensitivitv of results to this variable. and 
allowing for the possibility or" technological change limiting the 
clinical life of equipment.' results are also reported for capital 
having a life of 5 years. 
Ev;dence on the costs of overseas screening programmes were. in 
each case. inflated to 1991 prices using the CPI for the relevant 
country. and com·erted to :Sew Zealand dollars using 1991 mid-
year exchange rates .. Given that the prices of screening inputs may 
have increa;;ed more or less quickly than consumers prices in each 
country. and the variations in exchange rates which affect the 
conversion of other currencies. the resulting figures should be 
taken as an approximate guide only to the :Sew Zealand dollar 
equivalents of the original res:i.lts 
Results 
!able 1 shows the costs lin 1991 dollar termsJ of the Otago/ 
Southland screening programme. expressed annually over a 
four year period. 
The cost per woman screened in the first year of 
screening is $178. which decreases to $117 in year 2 and 
$113 in each subsequent year. assuming an annual 
screening throughput of 8000 women from year 3 onwards. 
This result is sensitive to assumptions regarding the useful 
life of the programme's capital assets. Changing the 
assumed life of capital assets from 10 to 5 years increases 
the cost p€r woman screened to $206 in the first year of 
screening $130 in the second year and $123 in later periods. 
The cost per cancer detected is initial]v $21 908. which falls 
to $11 544 in year 2. · 
Table 1. - Otago/Southland: total annual costs of screening. cost per woman 
sc,aened. and cost per cancer detected, in 1991 dollar term. 
Year 0 Year l Year 2 
Annual equivalent 55 955: 5.5 %5 55 985 
Capital cos~ 4(· 676"' 40 676 
8 066' 
55 985 96 661 10 7'.!7 
Annual operating 174 264 385 328 657 179 
cost 
Total cost 230 249 481 989 761 906 
~o women scre<ened 2 iOl 6 491 
No cancers detected 22 66 
Cost per woman 
screened $178 $117 
Cost per cancer 
detected $21 908 $11 544 
155 985 = 432 304.'7 7217 1 annuity facwr for n = 10. r = 5) 
240 676 = 314 084'7 7217 . 
'8 066 = 62 Z&4 -; 721 7 







Table 2. -Waikato: total annual costs of screening, cost per woman screened, 
and cost per cancer cletacted, in 1991 dollar terms. 
Year 0 Year l 
Annual equivalent 5 093: 5 093 
Capital cos~ 78 166' 
5 093 83 2.59 
Annual operating 
costs 65 923 492 348 
Total co5t 71 016 5i5 607 
No women o;creened 3 1.57 
No. cancers detected 16 
Cost per woman 
screened $182 
Cost per cancer 
detected $3.5 975 
15 093 = 39 326/7. 721 •Annuity factor for n = 10. r = 51 
'i8 166 = 603 57.S.".' 7 17 
'3 323 = 25 65S'".' 721 


















Table 2 shows the costs (in 1991 dollar terms; of the 
Waikato screening programme over the same p€riod. The 
cost per woman screened in the first year of screening is 
$182, which decreases to $108 in vear 2 and an estimated 
$106 in each subsequent year .. ~suming that all capital 
equipment would need to be replaced after 5. rather than 
10 years increases the cost per woman screened to $203 in 
year 1 $117 in year 2 and $115 in later p€riods. The cost 
p€r cancer detected is initially $35 975. falling to $14 285 in 
year 2. The higher cost per cancer detected in Waikato in 
year 1 is due to both a lower cancer detection rate for that 
period than Ota go i O .51 c;. of the women screened during 
1992 compared with 0.81,.,., in Otago'S0uthland 1• and a 
higher tot2l cost in that p€riod. A higher cancer detection 
rate in \Vaikato in year 2 'Q_75r,;. ,. combined v.ith a larger 
increase in the total cost of the Otago:Southland 
programme in this period. resulted in a reduction in the 
disparity in the cost per cancer detected between the two 
programmes. The higher cancer detection rate e\ident in 
Otago.'Southland has also resulted in higher assessment 
costs. For example, in year 2 these account for 18<;;- of the 
cost p€r woman screened. compared v.ith W in Waikato. 
The Waikato programme differs from the Otago/ 
Southland programme '-'ith regards to its policy on women 
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who are invited, but not eligible. for a screen !due to, for 
example. having "aged out" of the eligible age group). The 
Otago..Southland programme screened only those eligible at 
the date of screen, while the Waikato programme screened 
all women who accepted in,itations. The costs per woman 
screened shown in Table 2 relate to all /eligible and 
ineligible! women screened in the Waikato programme. 
The results shown in Tables 1 and 2 can be used to 
estimate the cost of establishing a national screening 
programme. There are approximately 220 000 New Zealand 
women between the ages of 50 and 65 years. With a 
screemng interval of two vears, 110 000 women would be 
eligible for screening each )·ear. On the basis of the cost per 
woman screened in the pilots in year 3, and assuming a 
coverage rate of 80% of eligible women, a national 
screening programme would add between $9.3 and $9.9 
million to health service costs in each year (in 1991 dollars). 
This estimate is based upon the annual cost per woman 
screened in an established programme with a full screening 
throughput, where capital costs have been spread evenly 
over each year of operation. In year 2 the amortised capital 
cost accounts for 11 % of the cost per woman screened in 
Waikato and 14% in Otago/Southland. The actual costs of 
introducing a national screening programme would be 
higher in early years when capital costs are incurred (and 
operational costs per woman screened are higher) and lower 
in later years (when capital costs have been sunk). 
Discussion 
The costs per woman screened which are evident from the 
New Zealand pilot programmes are comparable to those 
reported from overseas programmes. 
For example, the cost per woman screened in the first 
year of screening of $182 in Waikato and $178 in Otago 
compare ,;,,ith approximately NZ$ l 75 for the Sydney Breast 
X-ray Programme. 3 The Waikato and Otago/Southland cost 
per woman screened in year 2 fell to $108 and $117 
respectively. This compares favourably "'ith the Sydney 
programme in which costs for subsequent years remained 
at around the year 1 level /personal communication, J Hall 
29 September 1993). 
These costs are considerably higher than the estimated 
cost per woman screened of NZ$5 l used by the Forrest 
report,' but fall within the range of screening costs evident 
from other interRational programmes. The cost per woman 
screened in the Netherlands varies from NZ$1625 to NZ 
$72.7 Similarly the New York Health Insurance plan 
reports a cost of NZ$96 per screen. 8 All costs are in 
equivalent 1991 New Zealand dollars and are adjusted for 
inflation in the countries concerned. However, while these 
studies allow us to make some broad comparisons ,,.,ith the 
results reported for New Zealand, comparisons need to be 
approached with care. The methodology employed in each 
case is different (with regards to what costs are considered) 
as is the characteristics of the screening programmes being 
evaluated I with respect to the eligible age group, the 
screening interval and method of screening. as well as the 
prevailing prices of screening inputs'· 
Private sector mammography screening costs !including 
the fee charged plus government subsidies paid) currently 
appear to fall in the range of $71.80 i Christchurch 
Southern Cross) to $100 1Auckland1 per woman screened . 
These costs exclude two important elements of the activity 
associated with a mass screening programme. First, the 
recruitment of women to the programme, and second, the 
costs associated with the follow on assessment of suspicious 
diagnoses from screening. Although we were unable to 
separately identify recruitment costs for the Otago/ 
Southland programme, Waikato data indicates that 
approximately one tenth of the cost per woman screened 
was attributable to recruitment and promotion activities. A 
further one tenth of the cost per woman screened was 
attributable to the follow on assessment of screened women. 
Excluding these components, the cost of the basic screen 
evident from Waikato data is comparable to pnvate sectvr 
costs at $88 in year 2. The opt10n oi contracting out th-:-
pro'vision of the basic screen under the auspices of ar; 
extended screening programme is one which may men: 
further consideration. Private sector pro,i.s1on of screening 
may, however, generate other costs I such as those arising 
from the planning and coordination of recruitment and 
screening activities; which are not included in th1~ 
comparison. 
While this paper presents some e,idence on the costs and 
intermediate outputs of the pilot programmes. these need 
to be interpreted .,..,th caution. 
First, it should be noted that the calculation of cost per 
woman screened in years 1-3 to some extent disguises the 
fact that significant set-up costs were incurred in year 0 
before screening started. In both prog-rammes there were 
lengthy delays between the start of the programme and the 
commencement of screening (9 months in Waikato and 10 
months in Otago/Southlandi. The skills and experience 
gained by managers and clinicians through the pilots could 
hopefully be used to shorten the learning curve in 
subsequent screening programmes. 
Second, the number of cancers detected in the first 
screening round is likely to b€ atypical of the longer term 
detection rate. In the first screening round most of the 
participating women ,,.,ill be screened for the first time and 
thus prevalent cancers will be detected. In later screening 
rounds most women ("'ith the exception of those aging into 
the eligible age category) will have been screened earlier so 
that only new (or incident) cancers will be detected. As a 
result, the cost per cancer detected in subsequent periods, 
all other things being equal can be expected to rise.3 
Finally, the costs reported here represent only the 
additions to cost arising from the recruitment, screening 
and assessment of screening participants. While the 
introduction of screening adds to public health service 
costs, it also has the potential to confer some resource 
sa'vings. These arise becau.,e screening effects the stage 
(extent of advancement) at which cancers are detected, 
relative to no screening conventional management. Earlier 
detection of cancers means that the treatment of the:;;e 
cancers may incur less costs las well as producing more 
years of life). For example, the resource sa,ings generated 
by breast cancer screening of the Dutch population, in 
terms of lower assessment and treatment costs, may be 
significant in the long term. offsetting up to one third of the 
costs of screening itself.-' The decision as to whether a 
national programme of mammography screening should be 
implemented in New Zealand should be based upon a 
careful examination of the net costs (including the 
opportunity cost of the benefits foregone from other health 
services), risks and benefits /both quantitative and 
qualitative) e'vident from the pilot programmes, and the 
acceptability to women of screening.3 
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EVALUATION DATA BASE: 
(Information downloaded from pilot programmes' computer 
systems. Missing data or information that does not apply to 
one of the programmes must be included in the form of blank 
fields so that files from the two programmes are 
compatible.) 
Flag P 
6 blanks (so we can add evaluation number) 
Patient number (NMPI) 7 alphanumeric 
Region: (l=Otago and Southland, 2=Waikato) 
Area code (ward) 5 numeric 
Date of birth (day, month, year) 6 numeric 
Ethnic group 
Otago: l=Maori, 2=European, 3=Pacific Island Polynesian, 
4=Asian, S=Other) 
Waikato: 
New Zealand European (l=Yes, 2=No) 
New Zealand Maori (l=Yes, 2=No) 
Samoan (l=Yes, 2=No) 
Cook Island Maori (l=Yes, 2=No) 
Tongan (l=Yes, 2=No) 
Niuean (l=Yes, 2=No) 
Other {l=Yes, 2=No) 
Identification source: 
General electoral roll (l=Yes, 2=No) 
Maori electoral roll (l=Yes, 2=No) 
GP list {l=Yes, 2=No) 
self-referred (l=Yes, 2=No) 
GP referral (l=Yes, 2=No) 
BC investigation (l=Yes, 2=No) 
BC treatment (l=Yes, 2=No) 
Maori coordinator (l=Yes, 2=No) 
other (l=Yes, 2=No) 
Eligibility {l=eligible, 2=ineligible because outside 
eligible age-range, 3=ineligible because being followed up 
for breast cancer, 4=ineligible because deceased, 
S=ineligible because of other reason) 
Screen number 1 (Flag 1) 
6 blanks (so we can add evaluation number) 
Patient number (NMPI) 7 alphanumeric 
Invitation sent? (1 numeric) 
l= Yes - from programme 
2= Yes (RCT) - programme Otago-Southland only 
3= Yes (RCT) - GP 
4= Yes - after specific request from woman 
5= Yes - after specific request from GP 
6= No - screened early (without invitation) 
7= No - ineligible 
8= No - other (does not apply to Waikato) 
Reason for screening {l=response to invitation, 2=self-
referred without invitation) 




Screening centre invited to (l=Dunedin, 2=Invercargill, 
3=0tago/Southland mobile, 4=Hamilton, 5=Waikato mobile) 
Appointment time (24h time, day, month, year) 10 numeric 
(1st 4 fields blank for Waikato) 
Response (l=accept, 2=accept for different appointment time, 
3=decline, 4=no response) 
Reason for declining (l=recent mammogram, 2=private 
screening, 3=breast disease) 
Follow-up (l=not applicable, 2=second mailing, 
3=telephone, 4=personal follow up) 
Date of follow-up invitation (day, month, year) 
6 numeric 
Appointment time (24h time, day, month, year) 
10 numeric 
Response (l=accept,2=accept for different 





centre (l=Dunedin, 2=Invercargill, 3=0tago/Southland mobile, 
4=Hamilton, S=Waikato mobile) 
Location of mobile (15 alphabetic) 
date and time (24h time, day, month, year) 10 numeric 
mammogram taken (l=Yes, 2=No) 
total number of films taken (2 numeric) 
Extra films (l=Yes, 2=No) 
Date of extra films (day, month, year) 6 numeric 
Reason for extra films: 
Technical (number of extra films taken for technical 
reasons) 2 numeric 
Other (number of extra films taken for other reasons eg: 
large breasts, breast implants) 2 numeric 
Result (2=normal, 3=abnormal) 
Date result produced (day, month, year) 6 numeric 
Result sent to (l=woman, 2=woman + GP, 3=woman +GP+ 
assessment clinic) 3 does not apply to Waikato 
Reason for referral (l=NA, 2=abnormal result, 3=symptom 
questionnaire, 4=abnormal result and symptom questionnaire, 
5=technical, 6=abnormal and technical, 7=symptoms and 
technical, 8=abnormal and symptoms and technical) 
3,4,6,7, and 8 otago-Southland only 
Assessment clinic attendance: 
clinic (l=Dunedin, 2=Invercargill, 4=Hamilton) 
date of appointment (day, month, year) 6 numeric 
date of attendance (day, month, year) 6 numeric 
Clinician number (3 numeric, 2 alpha) 
Investigation: 
Clinical Examination (l=NA, 2=normal, 3=abnormal) 
assessment mammography (l=NA, 2=normal, 3=abnormal) 
FNA (l=NA, 2=normal, 3=abnormal) 
ultrasound (l=NA, 2=normal, 3=abnormal) 
biopsy (l=NA, 2=normal, 3=abnormal) 
Result from assessment clinic: (l=normal, 2=biopsy required) 
Date of biopsy (day, month, year) 6 numeric 
Biopsy result (l=breast cancer, 2=not breast cancer) 
Final result (l=breast cancer, 2=no breast cancer) 
I ~ 
I 
Screen number 2 
Flag 2 
6 blanks (so we can add evaluation number) 
Patient number (NMPI) 7 alphanumeric 
Invitation sent? (1 numeric) 
1= Yes - from programme 
2= Yes (RCT) - programme otago-Southland only 
3= Yes (RCT) - GP 
4= Yes - after specific request 
5= Yes - early invitation after 
6= Yes - after specific request 
7= No - screened early (without 





9= No - other (does not apply to Waikato) 
from woman 
Date invitation produced (day, month, year) 6 numeric 
Appointment time (24h time, day, month, year) 10 numeric 
(1st 4 fields blank for Waikato) 
Response (l=accept, 2=accept for different appointment time, 
3=decline, 4=no response) 
Follow-up (l=not applicable, 2=second mailing, 
3=telephone, 4=personal follow up) 
Date of follow-up invitation (day, month, year) 
6 numeric 
Appointment time (24h time, day, month, year) 
10 numeric 
Response (l=accept,2=accept for different 





centre (l=Dunedin, 2=Invercargill, 3=0tago/Southland mobile, 
4=Hamilton, 5=Waikato mobile) 
Location of mobile (15 alphabetic) 
date and time (24h time, day, month, year) 10 numeric 
mammogram taken (l=Yes, 2=No) 
total number of films taken (2 numeric) 
Extra films (l=Yes, 2=No) 
Date of extra films (day, month, year) 6 numeric 
Reason for extra films: 
Technical (number of extra films taken for technical 
reasons) 2 numeric 
Other (number of extra films taken for other reasons eg: 
large breasts, breast implants) 2 numeric 
Result (2=normal, 3=abnormal) 
Date result sent (day, month, year) 6 numeric 
Result sent to (l=woman, 2=woman + GP, 3=woman +GP+ 
assessment clinic) 3 does not apply to Waikato 
Reason for referral (l=NA, 2=abnormal result, 3=symptom 
questionnaire, 4=abnormal result and symptom questionnaire, 
5=technical, 6=abnormal and technical, 7=symptoms and 
technical, 8=abnormal and symptoms and technical) 
3,4,6,7 and 8 Otago-Southland only 
Assessment clinic attendance: 
clinic (l=Dunedin, 2=Invercargill, 4=Hamilton) 
date of appointment (day, month, year) 6 numeric 
date of attendance (day, month, year) 6 numeric 
Clinician number (3 numeric, 2 alpha) 
Investigation: 
Clinical Examination (l=NA, 2=normal, 3=abnormal) 
assessment mammography (l=NA, 2=normal, 3=abnormal) 






ultrasound (l=NA, 2=normal, 3=abnormal) 
biopsy (l=NA, 2=normal, 3=abnormal) 
Result from assessment clinic: (l=normal, 2=biopsy required) 
Date of biopsy (day, month, year) 6 numeric 
Biopsy result (l=breast cancer, 2=not breast cancer) 








BREAST CANCER SCREENING QUESTIONNAIRE; 
Name: 
Practice: 
To answer each question, please circle the appropriate 
answer: 
1. Did you know before you received our letter that a pilot 
programme is being set up this year to offer free 




2. What is your present policy for recommending rnarrunographic 
screening to women in your practice? (Please indicate which 
age-groups your policy includes) 
............................................................ 
. . . . . . . . . . . . . . . ............................................. . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
3. Would you encourage eligible women in your practice to 
take part in the pilot programme? 
< 1) Yes 
(2) No 
If no, why not? ......... ................................... . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . · ...................................................... . 
. . . . . . . . . . . . . . . •· ........................................... . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. \ 
4. Is there any information that you would need before 
recommending screening to eligible women? 
(1) Yes 
(2) No 
If~, what information would you need? .................. . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
5. Does your practice have an age-sex register? 
(1) Yes 
(2) No 
(If~, please answer questions 6 to 8): 
6. Can your register produce lists of patients with their 
addresses, by sex, for certain age-groups? 
( 1) Yes 
(2) No 
7. The screening programme has a register with the names and 
addresses of women aged between 50 and 64 in Otago and 
Southland but this does not include information about each 
woman's general practitioner. During the next two years 
these women will be sent invitations to be screened. We 
would like the invitations to be sent jointly from the 
screening programme and each woman's G.P. but we cannot do 






Would you be 
addresses of 
matched with 
( 1) Yes 
willing to the names 
50-64, 
produce a list of 
women in your practice who are 
the screening register? 
(2) Conditional yes 
and 
to be 
If conditional yes, under what conditions? ................. . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
............................................................ 
(3) No 
If D..Q, why not? ......................................... . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 







be willing to sign a letter 
practice to be screened? 
inviting eligible 
If D..Q, why not? ............................................ . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. ......................................... . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 







OTAGO SOUTHLAND BREAST SCREENING PROGRAMME 
CONSENT FORM 
" -/-\ 
' It would help both of us if you would complete the information required on this form. 
Name: ........................................................................... 
Surname Given Names 
Previous Married Name (if remarried): ................................................. . 
Maiden Name: .................................................................... . 
1 
\ Present Address: .................................................................. . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . 
Home Phone Number: ................... . Date of Birth: ........................... . 
Work Phone Number: ................... . 
Name of your family Doctor: ......................................................... . 
Address of Surgery: ............................................................... . 
The result of your breast X-Ray (mammogram) will be posted to you. We would like to send a copy of 
these to your family doctor. May we do this? (Please tick the appropriate box). 
YES D NOD 
CONSENT TO PARTICIPATE IN THE PROGRAMME 
, :, 1. I have read and understood the information contained in the pamphlet provided and expect to be 
given the opportunity to ask questions regarding the screening programme. 
2. I understand that I am free to withdraw from the screening programme any time without disadvan-
1~ tage to my future relationship with either HealthCare Otago or Southern Health or my Doctor. 
3. My records and information gained from me will be used to measure how effective this programme 
could be for other New Zealand women. Complete confidentiality will be kept in terms of my 
records, and I will not in any way be identified in any reports. 




1. Have you had a mammogram before? Yes I No 
2. Have you ever had a breast lump or cyst? Yes I No 
i;~ ... 
3. Have you ever had a biopsy, or has your 
doctor ever used a needle to remove 
fluid from your breast? Yes I No 
\.,.. 
.,·i-
4. Have you had breast cancer treated? Yes I No 
., 5. Are you aware of a lump in your breast now? Yes I No 
! ·\ 
6. Have you had a breast reconstruction or 
reduction? Yes I No 
;!... 
' 'l, ' 
7. Have you had any nipple discharge? Yes I No 
8. Are you taking hormone replacement 
.\ therapy? 
I ·> 
9. Have you had painful breasts before 
menstruating? 
0 





Yes I No 
Yes I No 
Yes I No 
Yes I No 
Yes I No 
Yes I No 
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BREAST X-RAY PROGRA.MM:E QUESTIONNAIRE 
This questionnaire is aoout your experience of having a breast x-ray. We would 
be very grateful ii you would answer these questions honestly since it will help 
us to assess tr.e Breast X-ray Programme. We assure you that the answers that 
you provide will remain strictly c:onfidenthl 
Please tick in the box next to your 1.n.Swe.r. <You may need to tick more thm 
one aruwe.r for some questions). 
1. How did you find out about the Breast X-ray Progzamme? (Please tick a., 
many as apply) 
(a) When I received my invitation to have a breast x-ray D 
(b) In the news pa per D 
(c) On the radio -Or 1V D 
(d) From a friend or relative D 
(e) From a speaker at a group to which I belong D 
Cf) From my family doctor D 
(g) From lwi/Maori health co-ordinator D 
(h) Other (Please describe) D 
---·-·--·-·····-···-···-·-·---·---·-----.. ----------------.--: 
2. Why did you decide to take part in the Breast X-ray programme? 
(Please tick as many as apply} 
(a) To detect breast cancer early D 
(b) Because it was recommended by my f':ami1y doctor D 
(c) Because I have a breast symptom D 
(d) Because it is a pilot programme D 
(e) Because it i.s a free service D 
Cf) Because I have a family history of breast cancer D 
(g) For reassunnce D 
(h) Other (Please describe l:cl)w) D 
For()ffia 
U~Only 
1 I I I l 





















3. If the programme did not exist, would you have arranged 
to have a breast x-ray anyway? (Please ticx one box) 
(a) Yes D 
(b) No D 
(c) Yes, as long as it was a free service D 
(d) Don't know D 
(d) D€pends (Please specify 'below) D 
····················································-·········-·······--····· .. ··-·-···-··---·--·-···--·····-
4. Did you receive an invitation to have a breast x-ray? 
(a) Yes D {b) No D 
If yes, which of the following best describes your feelings when you re::eived 
this invitation? (Please tick one box) 
(a) Not at all worried D 
(b) A little bit worried D 
(c) · Quite worried 
(d} · Very worried 
D 
D 
5. What did you think about the green Breast X-ray programme information 
leaflet in terms of how easy it was to understand? This leaflet may have 
been posted to you with your invitation (Please ticl; one box). · · 
(a) Hard to understand D 
Cb> Just right D 
(c) Too simple D 
(d) Didn't see the leaflet/Don't know D 
6. Was there any information that you wanted to know that wasn't included 
in this leaflet? (Please tick one box) 
(a) Yes D 
(b) No D 
(c} Didn't see the leaflet Q 
If yes, what information should have been included? 







. _,.\ ',( 
















The following questions relate to your experience of having a breast x-ray. 
7. Which of the following best describes your feelings before you came in to 
have your breast x-ray? (Please tick one box) 
(a) Not at all worried D 
(b) A little bit worried D 
(c) Quite worried D 
(d) Very worried D 
8. How long did it take you to travel from home or work, to the screening centre? 
(please tick one box) 
(a) less than 15 minutes D 
between 15 minutes and half an hour D (b) 
(c) 30 minutes to an hour D 
(d) more than an hour (please specify) D-·----.. ·-----·---···------









10. Was the waiting area large enough? 
(a} Yes D (b) No - overcrowded D 
11. Was the changing room warm enough? 
(a) too hot D 
(b) comfortable temperature D 
(c) too cold D 
12. Was there enough privacy for changing? 







13. Did you have any concerns about the way staff treated you, or anyone 
else who came with you, at the breast x-ray centre? 
(a) Yes D (b) No D 
If yes, please comment 
............................................................................................ _ ... _ .................. _ ............... _. __ 
14. Did you feel that the way of taking the breast x-ray was explained to you so 
that you could understand? 
(a) Yes D (b) No D 
If no, please comment 
15. What time was your appointrnent? ......... -·-·-···· .. ··" .. --·-·-·····-·-
What time were you screened? _ ............................ ·---·····-
16. How would you describe your experience of having the breast x-ray? 
(Please tick one box) 
(a) A little uncomfortable D 
(b) Very uncomfortable D 
(c) Painful D 
(d) Very painful D 
17. Did you have any bruising after your x-ray? (Please tick one box) 
(a) None D 
(b) A little D 
(c) Moderate D 
(d) Severe D 
18. How long did you spend at the breast x-ray centre from the time of your 
appointment to the end of having the breast x-ray? (Pl.ease tick one box). 
ca> 1ess than 15 minutes D 
(b) Between 15 minutes and half an ~ D 
(c) 30 ntinutes to an hour D 










19. What do you think is an acceptable time to wait for a breast x-ray? 
(Please tick one box). 
(a) Less than 15 minutes D 
(b) Between 15 minutes and half an hour D 
(c) 30 minutes to an hour D 
20. Did any other people come with you to the breast x-ray centre? 
(a) Yes D (b) No D 
If yes, why did they come? (Please tick any answers that apply). 
(a) For company/support D 
(b) To transport me to the centre D 
{c) To have a breast x-ray also D 
(d) Other (Please describe below) D 
------···· .. ·-······················--·-.. ·····-·--... --------.... ... ----· .. -----
' l ,.·----···-·-················-·-.. ···-····---···--·-·------·----·-·-·-· ... --···-·----
The next questions refer to how you felt while waiting for your results, and 
your overall opinion of the Breast X-ray Programme. 
21. How many days after being x-rayed did you get your result? 
(Please fill in the space below). 
Number of days -··-··--··--··---·-·· .. ···--------.. ------
22. Which of the following best describes how you felt while waiting for your 
results? (Please tick one box). 
(a} Not at all worried D 
(b) A little bit worried D 
(c) Quite wonied D > 
(d} Very worried D 
23. Would you have another breast x-ray in two years lime if you NCe1ved an invitation? 












If yes, would you prefer to be notified through the Breast X-ray Programme 
or make your own arrangements? (Please tick one box}. 
(a) Breast X-ray Programme D 
(b) Arranged privately D 
(c) Arranged through some other organization D 
{e.g. Maori based clinic) 









(This information will help us to make the breast x-ray service as acceptable 
as possible). 
·-··························································-··-···-···--·---····-···-··--·····-·---·--·--···-
--· .. ······--······················---·---·-·-----·...._ _______________________ 
--········--···················--··-··-........... ---·-·---------·---.. ---------
We also need to find out about the hidden costs of this programme, so the 
following questions a.re about how much it cost you to be x-rayed . 
Could you estimate how much it cost you to have a breast x-ray? 
Petrol, bus or taxi $. •••••••••••••••• 
Parking fee $. •••••••••••••••• 
Income lost because of x-ray app:>intment - $. •••••••••••••••• 
Any other cost (Please specify below) 


















I ~ '.i I , 
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26. If others came with you, could you please estimate how much it cost them? 
Petrol, bus or taxi $. •••••••••••••••• 
Parking fee $ ................. 
Income lost because of x-ray appointment $ •••••.•....•.•••• 
Any other cost {Please specify below) 
$. • t ,I• I• t • t ti <It e I e • 
.............................................................................. _._.,._ 
27. How easy or difficult was it for you to fit the breast x-ray appointment into 
your day? (Please tick one box). 
(a) Very easy 8 (b) A little bit difficult 
(c) Quite difficult D 
(d) Very difficult D 
28. What would you have been doing at the time if you had not come to have 
a breast x-ray? (Please tick one box). 
(a) Working in paid employment D 
(b) Voluntary work D 
(c) Leisure activity D 
(d) Caring for a child or other relative D 
(e) Other (Please describe) D 
........................................................................................................ 
···································································-················-··············· 
29. This screening programme is free. If the saeening programme could not continue 
as a free service, how much would you be prepared to pay for a breast x-ray? 
(Please tick one box) 
(a) I would not ta.lee part in the programme if there were a chaJge D 
(b) under $20 
(cl $20-$50 



















The following questions will help us to see if there are any differences among women 
in terms of how they found the breast x-ray programme. 
30. What is your age? (Please fill in the space below). 
Age in yea.rs ...........•............... : ..•. 
31. To which ethnic group or groups do you belong? 
(You may tick more than one answer) 
(a) European D 
(b) NZ Maori D 
(c) Pacific Island Polynesian D 
(d) Asian D 
(f) Other (Please specify below) D 
32. Which of the following best describes you at the moment? (Please tick one answer) 
(a) Working for salaiy/wages D 
Cb> Self-employed D 
(c) Not working in paid employment D 
cd> Retired D 
1f you are working in paid employment, please describe your occupation, please 
be specific, e.g. "Secondary School Teacher" rather than -"reacher" 
(If retired, pleased describe your previous occupation). 
-·····-····-·····-··-·····--· .. ···--·--···----------·----------
-···--·······--···········-··-·-··----·--------------------------
33. What is your yearly household income before tax? (Please tick one answer) 
ca> 1ess than $15,COO D 
Cb> s1s,oco - $30,COO D 
(c) More than $30,()X) D 
34. What is the highest level of education you have reached? (Please tick one answer) 
(a) Primary School D > 
(b) Secondaiy School D 
(c) University Education D 
(d) Trade or Vocational Qnaliflcatk)n. e.g. Polyteclmic D 
For Office 
Use Only 
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Where do you live? (Please tick one box) 
(a) In the Dunedin city area D 
(b) In the Invercargill city area n -(c) In a rural town D 
(d} In the country D 
How would you rate your risk of getting breast cancer compared with other 
women your age? (Please tick one box) 
(a) I think I would be more at risk D 
(b) I think I would be less at risk D 
(c) I think I would have the same risk D 
(d} Don't know D 
Has anyone in your family or close to you had breast cancer? 
(a) Yes D (b) No D 
If yes, please tick any of the following that apply. 
(a) Cose friend 
(b) Mother 
(c) Sister 





(e) Other relative (Please specify below) D 
39. Did you require any help completing this questionnaire? 
(a) Yes D (b) No D 
40. Please fill in today's date ···-----·----·------------ I I I 
., 99 
Thank you for taking time to fill out this questlomwre, which will help u to 
assess the Breut X-ray Programme. 
Please post the completed questionnaire In the post-pakf enftlope proYided. 











' ) < 
-\ 
"' 









ASSESSMENT CLINIC QUESTIONNAIRE 
Thank you for completing this questionnaire about the assessment clinic. 
1. Did you receive an invitation to have a breast x-ray? 
(a) Yes D 
(b) No D 
If yes, which of the following best descn"bes your feelings when you received 
this invitation? (Please tick one of the following) 
(a) Not at all worried D 
(b) A little bit worried D 
(c) Quite worried D 
(d} Very worried D 
2. How worried did you fffi about being screened? 
(Please tick one of the following) 
(a) Not at all worried D 
(b) A little bit worried D 
(c) Quite worried D 
{d) Very worried D 
3. How worried did getting the appointment for the assessment clinic · 
make you feel? (Please tick one of the following) 
(a) Not at all worried D 
(b) A little bit worried D 
(c) Quite worried D 
(d) Very worried D 
4. What did you think about the information that was given to you when you were 
phoned about your appointment? (Please tick one of the following) 
(a) too little information D 
(b) exactly the right amount of information D 









5. How long did it take you to travel from home to the assessment clinic? 
(please tick one answer) 
less than 15 minutes D 
between 15 minutes and half an hour D 




(d) more than an hour D (please specify) ................................................................ .. 
6. How did you travel to the assessment clinic? (please tick one answer) 
(a) walked D 
(b) car D 
(c) bus D 
(d) taxi D 
(e) other D (please descn'be) ........... : ......................................................... .. 
······································································································································· 
................................................................................................. -.................................... . 
7. Did anyone come with you to the assessment clinic? (please tick one answer) 
(a) Yes D 
(b) No D 
If~ why did they come? 
(i) for company D 
(ii) to transport me to the centre D 
(iii) to be screened D 
(iv) other D (please describe) ......................................................... : ..................... .. 
••••~•• H••••••-•••••••••••••••••••••••••-•••••••••••••••••••••••••••••••••••••o••••••••••••••••••••••••••••••a•••••••••••••••••••••••&•••••••••-• 
8. Could you please estimate how much it co!>t ~ to go to the assessment clinic? 
Petrol, bus or taxi $ ••••••••••••••••• 
Parking fee $ ••••••••••••••••• 
Income lost because of x-ray appointment $ ••••••••••••••• ~ ·• 














9. If someone came with you could you please estimate how much it cost them? 
Petrol, bus or taxi $ •.••••••••••••••• 
Parking fe€ $ .•.•••••••••..••• 
Income lost because of x-ray appointment $ ..••••••••••••••• 
Any other cost (Please specify below) 
$ .•••..•••• : .••..• 
10. What would you have been doing if you hadn't had an appointment at the 
assessment clinic? (please tick one answer) · 
(a) working in paid employment D 
(b) voluntary work B (c) leisure activity 
(d) caring for a child or other relative D 
D (please describe) ................................................ : ....................... (e) other 
.......................................................................................................................................... 
11. What time was your appointment? ........................................................ . 
What time were you seen? ..................................................................... .. 
12. How long did you spend at the assessment clinic altogether? 
(please tick one answer) 
(a) less than 15 minutes D 
·(b) between 15 minutes and half an hour D 
(c) 30 minutes to an hour D 
(d) more than an hour D (please specify) ........................................... .. 
13. Was the waiting area large enough? 
Yes D 
No - Overcrowded D 
14. Was the changing room warm enough? (please tick one answer) 
(a) too hot · D 
(b) comfortable temperature D 






'JI 38 39 
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15. Was there enough privacy for changing? 







16. How worried did you feel during the assessment? (Please tick one answer) 
(a) Not at all worried D 
(b) A little bit worried D 
(c) Quite worried D 
(d) Very worried D 
17. How did you find the staff at the assessment clinic? 










(Please tick one answer) 
18. When did you get the result of the assessment? (Please tick one answer) 
(a) straight away (at the assessment clinic) D 
(b) within a week D 
(c) between 1 and 2 weeks after the assessment D 
(d) more than 2 weeks after the assessment D 
19. How worried did you feel while waiting for the result? 





Not at all worried 




























20. How do you think the assessment clinic could be improved? (This information 






21. If you receive another invitation to have a breast x-ray (in 2 years time) do 
you think you will attend? (please tick one answer) 
(a) Yes D 
(b) No D 
vVhy? ·······"························································································ ............................ . 
............... ,. ....................................................................................................................... . 
...................................................................................................................................... 
....................................................................................................................................... 
22. This screening programme is free. If the screening programme could not 
continue as a free service, how much would you be prepared to pay for a 
breast x-ray? (Please tick one answer) 
























24. To which ethnic group or groups do you feel you belong? 
(please tic.1< those which apply) 
(a) EUiopean D 
(b) NZ Maori D 
(c) Pacific Island Polynesian D 
(d) Asian D 
(e) Other D (please specify) ...................................................................... . 
.......................................................................................................................................... 
......................... ,. .............................................................................................................. . 
25. Which of the following best descnoes your working situation? 







Working for salary/wages 
Sell-employed D 
D 
Not working in paid employment 
Retired D 
D 
1f you are working in paid employment please descn'be your 
occupation. (If retired please descn'be your previous occupation) 
.................................................................................................................................... 
......................................................................................................................... _ ..... 
What is your yearly household income before tax? (Please tick one) 
(a) Less than $15,000 D 
(b) $15,000 -$30,000 D 
(c) More than $30,000 D 
What is the highest level of education you have reached? 
(please tic.1< one answer) 
(a) Primary school D 
(b) Secondary school D 
(c) University education D 
(d) Trade or Vocational Qual!!ication D 
THANKYOUFORYOURHELP 
PLEASE POST nns IN THE POST-PAID ENVELOPE PROVIDED 
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TELEPHONE INTERVIEW FOR WOMEN WHO 
DID NOT ATTEND SCREENING 
ID Number ________ _ 
1 2 3 4 5 6 7 




Introduction: (Information for interviewers is given in bold print) 
Hello, my name is Margaret Bahr. I work in the Medical School at Otago University 
with the evaluation of the Otago-Southland Breast Screening Programme. It would 
be a great help to us if you could answer some confidential questions about the 
programme. Is it convenient for me to talk to you now? 







2. Could you please tell me how or where you heard about the screening programme? 
(Tick all replies) Prompt if necessary. 
(i) when I received an invitation to have a breast x-ray D 
(ii) newspaper or magazine D 
(iii) radio or TV D 
(iv) friend or relative D 
(v) speaker at a group to which you belong D 
(vi) family doctor D 
(vii) iwi authority D 
(viii) other (please describe) D 
1 










Ask questions 3-6 if the woman received an invitation. If not please go to question 7. 
>-' 3. (For women who received the invitation) 
> "' Could you please tell me what made you decide not to be screened? (Prompt) 
,,,._. D D24 (i) recent mammogram 
" (ii) already being followed up for a breast problem D D2s 
'~ .. , D D26 (iii) no transport 
J (iv) too far to the screening centre D 021 
(v) inconvenientappointinenttiine D D28 
-4.-, 
(vi) negative reports from other women who had attended D D29 
> (vii) fear of the procedure D D30 
(viii) fear of the possible outcome D D31 
·'\~ (ix) other (record below) D32 t-¥ 
"" 
\ 
4. How worried did you feel when you got the appointment to be screened? 
(a) Not at all worried D 
(b) A little bit worried D 
( c) Quite worried D 
( d) Very worried D 
'\ 
,, 5. Could you please tell me what you thought about the information that was posted to you with 
your invitation? (Prompt) 
(i) hard to understand D 
(ii) just right D D34 
(iii) too simple D 







Was there any information that you wanted to know that wasn't included in the leaflet? 
(please tick one answer) 
(i) Yes D 
(ii) No D 
If~ what information should have been included? ............................................................... .. 
Could you please tell me which screening centre you were invited to? 
(i) Dunedin hospital screening centre D 
(ii) Mobile screening centre D 
(iii) Kew hospital screening centre D 
How would you have travelled to the screening centre? 
(i) walked D 
(ii) car D 
(iii) bus D 
(iv) taxi D 
(v) other (please describe) 
8. How long would it have taken you to travel to the screening centre? 
(for women who did not receive an invitation, interviewer 





less than 15 minutes 
between 15 minutes and half an hour 













Your screening appointment was on (date) at (x) O'clock ---------
9. Can you please recall what you were doing at the time which was set for your appointment? (Prompt) 
(i) working in paid employment D 
(ii) voluntary work D 
(iii) leisure activity D 
(iv) caring for a child or other relative D 
(v) other (please describe) ................................................................. . 
10. How easy would it have been for you to fit the screening appointment 
into your usual routine? (Prompt) 
(a) Very easy D 
(b) Quit.eeasy D 
(c) A little bit difficult D 
< d) Quit.e difficult D 
( e) Very difficult D 
11. Could you please tell me how you would rat.e your risk of getting breast cancer compared with 
other women your age? (Prompt) 
12. 
(i) I think I would be more at risk D 
(ii) I think I would be less at risk D 
(iii) I think I would have the same risk D 
(iv) Don't know D 







If m, please specify: 
























(i) Yes D 
(ii) No D 
Why 
We now need some personal details so we can see if there is any difference between different groups of 
women and how they feel about the screening programme. 
Could you please tell me your age? ........................................................ . 
We need to know your ethnic group. Could you please tell me which ethnic group or groups 
you feel you belong to? (Prompt) 
European D 
NZMaori D 






(v) Other (please specify) ..................................................................... . 
Could you please tell me about your employment? (Prompt) 
Are you: 
(i) Working for salary/wages D 
(ii) Self-employed D 
(iii) Not working in paid employment D 
(iv) · Retired D 
If you are working in paid employment please describe your 





17. Could you please tell me your yearly household income before tax? (Prompt) 
(a) Less than $15,000 D 
(b) $15,000 - $30,000 D 
;, -- D Ds9 (c) More than $30,000 
(d) Refused D 
• i ., 
18. Could you please tell me the highest level of education you have reached? (Prompt) 
(i) Primary school D D60 
r (ii) Secondary school D ' ~" D ,. (iii) University education 
l 
.'>- (iv) Trade or Vocational Qualification D 
(eg: Polytechnic) 
I 


























TELEPHONE INTERVIEW FOR WOMEN WHO 
ATTENDED SCREENING 
ID Number --------
1 2 3 4 5 6 7 
Date ---------
8 9 10 11 12 13 
Participant D14 
Introduction: (Information for interviewers is given in bold print) 
'. 
Hello, my name is Margaret Bahr. I work in the Medical School at Otago 
University with the evaluation of the Otago-Southland Breast Screening 
Programme. It would be a great help to us if you could answer some confidential 
questions about the programme. Is it convenient for me to talk to you now? 





2. Could you please tell me how or where you heard about the screening programme? (Tick all 
replies) Prompt if necessary 
(i) when I received an invitation to have a breast x-ray D D16 
D D17 (ii) newspaper or magazine 
D D1s (iii) radio or TV 
(iv) friend or relative D D19 
(v) speaker at a group to which you belong D D20 
( 
(vi) family doctor D 021 
(vii) iwi authority D D22 
(viii) other (please describe) D D23 
......................................................................................................... 
Ask questions 3-6 if the woman received an invitation. If not please go to question 
7. 
I>- 3. Could you please tell me why you decided to take part in the Breast X-ray programme. 

























To detect breast cancer early D 
Because it was recommended by my family doctor D 
Because I have a breast symptom D 
Becaus_e it is a pilot programme D 
Because it is a free service D 
Because I have a family history of breast cancer D 
Forreassurance D 
Positive reports from other women who had attended D 











4. How worried did you feel when you got the appointment to be screened? 
(a) Not at all worried D 
(b) A little bit worried D 
(c) Quite worried D 
(d) Very worried D D33 
5. Could you please tell me what you thought about the information that was posted to you 
with your invitation? (Prompt) 
(i) hard to understand D 
(ii) just right D D34 
(iii) too simple D 
(iv) didn't see the leaflet/don't know D 
Was there any information that you wanted to know that wasn't included in the leaflet? 
(please tick one answer) 
(i) Yes D 
(ii) No D 
If~ what information should have been included? 
6. Could you please tell me which screening centre you were invited to? 
(i) Dunedin hospital screening centre D 
(ii) Mobile screening centre D 







7. How did you travel to the screening centre? 
(i) walked D 
(ii) car D 
(iii) bus D 
(iv) taxi D 
(v) other (please describe) 
................................................................................................... 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
, 8. How long did it take you to travel to the screening centre? 
(i) less than 15 minutes D 
(ii) between 15 minutes and half an hour D 
(iii) 30 minutes to an hour D 
(iv) more than an hour (please specify) ................................... .. 
Your screening appointment was on (date) at (x)O'clock _______ _ 
9. Could you please tell me what you would have been doing at the time if you had not come 





working in paid employment 
voluntary work 
leisure activity 



























How easy was it for you to fit the screening appointment 
into your usual routine? (Prompt) 
(a) Very easy D 
(b) Quite easy D 
(c) A little bit difficult D 
(d) Quite difficult D 
(e) Very difficult D D4o 
Could you please tell me how you would rate your risk of getting breast cancer compared 
with other women your age? (Prompt) 
(i) I think I would oe more at risk D 
(ii) I think I would be less at risk D D41 
(iii) I think I would have the same risk D 
(iv) Don't know D 
Could you please tell me if anyone in your family or close to you has had breast cancer? 
(i) Yes D 
(ii) No D 































We now need some personal details so we can see if there is any differ~nce between different groups 
of women and how they felt about the screening programme . 
. . . ~ 
14. Could you please tell me your age? 
50·~51 
15. We need to know your ethnic group. Could you please tell me which ethnic group or 
groups you feel you belong to? (Prompt) 
(i) European D D52 
(ii) NZ Maori D D53 
(iii) Pacific Island Polynesian D D54 
(iv) Asian D Dss 
















16. Could you please tell me about your employment? (Prompt) 
Are you: 
(i) Working for salary/wages D 
(ii) Self-employed D 
(iii) Not working in paid employment D 
(iv) Retired D 
If you are working in paid employment please describe your 
occupation. (If retired please describe your previous occupation) 
17. Could you please tell me your yearly household income before tax? (Prompt) 
(a) Less than $15,000 D 
(b) $15,ooo - $30,000 D 
Os1 
(c) More than $30,000 D D 59 
(d) Refused D 
18. Could you please tell me the highest level of education you have reached? (Prompt) 
(i) Primary school 
(ii) .secondary school 
(iii) University education 
(iv) Trade or Vocational Qualification 
(eg: Polytechnic) 
(v) Refused 
THANK YOU FOR YOUR HELP 
D 
D 
D 
D 
D 
7 
D6o 
